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Mucositis is a common side effect of cancer treatment with a major impact on the quality 
of life of patients and occurring during all types of cancer treatment: chemotherapy, 
radiotherapy and targeted therapy (Sonis 2009, Al-Dasooqi et al. 2013, Lalla et al. 2014, Villa 
and Sonis 2015). It is an inflammation and ulceration of the mucosal surfaces and can occur 
in all types of mucosa. Oral and gastrointestinal mucositis (including esophagus, stomach, 
small and large intestine) are the most prominent, but also the respiratory and genitourinary 
tract can be affected by cytotoxic drugs (Peterson et al. 2012, Al-Dasooqi et al. 2013). The 
general term ‘alimentary mucositis’ is often used to describe mucositis in the entire alimentary 
tract (mouth to anus) (Keefe et al. 2007). 
1.1 Oral mucositis 
Oral mucositis is defined as injuries in the oral cavity following cancer treatment and is 
one of the best-studied side effects of cancer treatment (Al-Dasooqi et al. 2013). The major 
symptoms are oral pain, erythema, edema and ulcerations causing a higher infection risk which 
can lead to bacteremia, fungemia and sepsis (Sonis 2004, Potting et al. 2006, Peterson et al. 
2012). Oral mucositis also majorly impact the quality of life of the patients i.e. problems with 
speaking and intake of food and medications which may lead to a dose reduction of the cancer 
treatment and relapse of the cancer (Sonis 2004, Barasch and Epstein 2011). In order to 
estimate the severity of oral mucositis, different scales are used. The widely used World Health 
Organization (WHO) scale combines functional (ability to eat) and objective (erythema, 
ulceration) measurements of oral mucositis (Villa and Sonis 2015) (Table 1.1).  
Table 1.1 - World Health Organization (WHO) grading scale for oral mucositis (WHO 1979) 
Grade Clinical measurements 
0 No symptoms 
1 Pain, erythema 
2 Erythema, ulcers, able to eat solids 
3 Confluent ulcers, unable to eat solids, liquid diet possible 
4 Severe ulceration, bleeding, oral alimentation not possible 
 




The incidence of oral mucositis is high but varies depending on the type of treatment and 
is often underreported. The reported frequency of oral mucositis is around 20 to 40 % in 
conventional chemotherapy for solid tumors, around 80 % for high-dose chemotherapy prior 
to hematopoietic stem cell transplantation (HSCT), but reaching 100 % for radiotherapy for 
head and neck cancer (Sonis 2007, Lalla et al. 2008, Villa and Sonis 2015). Next to the type 
of cancer treatment also the type of cancer drugs, dosage, delivery schedule and 
chemotherapy cycle are important therapy-related risk factors (Villa and Sonis 2015).  
Despite the large number of people suffering from mucositis and the major impact on 
their quality of life, only limited treatment options are available so far. Only palifermin 
(keratinocyte growth factor-1 (KGF-1)) is approved by the US Food and Drug Administration 
and the European Medicines Agency for treatment of oral mucositis in patients receiving 
high-dose chemotherapy and total body irradiation, followed by HSCT for hematological 
malignancies (Sonis 2007). The Multinational Association for Supportive Care in Cancer and 
International Society of Oral Oncology (MASCC/ISOO) formulated guidelines for the 
prevention and treatment of oral mucositis, including the use of palifermin to prevent oral 
mucositis induced by conditioning regimens for HSCT. Recommendations to prevent oral 
mucositis in specific groups of patients include the use of cryotherapy, low-level laser therapy 
(LLLT) and benzydamine mouthwash (Lalla et al. 2014). The use of good oral care protocols 
(typically including brushing, flossing, rinsing and moisturizing) may also reduce the risk, length 
and severity of oral mucositis and lower the risk of infection by reducing the bacterial load 
(McGuire et al. 2013, Villa and Sonis 2015). An interdisciplinary and educational approach is 
important to assure the application of these good oral practices (Keefe et al. 2007). To treat 
the pain, the use of different mouthwashes based on morphine and doxepin is suggested for 
specific groups of patients (Lalla et al. 2014). 
1.2 Gastrointestinal mucositis 
Gastrointestinal mucositis includes inflammation and/or ulceration of the gastrointestinal 
mucosa along the entire alimentary tract (except the oral cavity), but is most prominent in the 
small intestine (Sonis et al. 2004a). Symptoms can include abdominal pain, diarrhea, 
constipation, bleeding, abdominal bloating, malnutrition, dehydration, electrolyte imbalance 
and infections (Gibson and Keefe 2006, Touchefeu et al. 2014). All these symptoms impact 
patient’s quality of life and can lead to a reduction or delay in cancer treatment, increased costs 
due to longer hospitalization and symptom management and even lower survival rates (Elting 
et al. 2003, Gibson et al. 2013, Lalla et al. 2014). In contrast to oral mucositis, only limited 
scales are available to assess the severity of gastrointestinal mucositis. Due to the 
inaccessibility of the small and large intestine, these scales typically measure indirect 
outcomes of mucosal injury, including diarrhea (Peterson et al. 2011). One commonly used 
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scale is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) scale which can be used for diarrhea and abdominal pain (Peterson et al. 2015) 
(Table 1.2). 
Table 1.2 - National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) scale 
for diarrhea (defined as a disorder characterized by frequent and watery bowel movements) and abdominal 
pain (National Cancer Institute 2009).  
Grade Clinical measurements 
Diarrhea  
0 No symptoms 
1 Increase of < 4 stools per day over baseline; mild increase in ostomy output 
compared with baseline 
2 Increase of 4–6 stools per day over baseline; moderate increase in ostomy 
output compared with baseline 
3 Increase of ≥ 7 stools per day over baseline; incontinence; hospitalization 
indicated; severe increase in ostomy output compared with baseline; limiting 
self-care activities of daily living (ADL) 
4 Life-threatening consequences; urgent intervention indicated 
5 Death 
Abdominal pain  
0 No symptoms 
1 Mild pain 
2 Moderate pain; limiting instrumental activities of daily living (ADL) 
3 Severe pain; limiting self care activities of daily living (ADL) 
 
Gastrointestinal mucositis is associated with many commonly used chemotherapy 
regimens (Sonis et al. 2004a), but the incidence is highly dependent on the type of treatment 
regimen and chemotherapeutic agent. Cancer treatments containing fluoropyrimidines (such 
as 5-fluorouracil (5-FU)) and/or irinotecan have an incidence of chemotherapy-induced 
diarrhea as high as 50 - 80 % (Benson et al. 2004, Gibson and Stringer 2009). Similar to oral 
mucositis, only limited options are available to prevent or treat gastrointestinal mucositis. As a 
first line, loperamide is used to treat chemotherapy-induced diarrhea (Benson et al. 2004). 
Moreover, the MASCC/ISOO guidelines recommend and/or suggest the use of amifostine, 
sulfasalazine and probiotics containing Lactobacillus for prevention and octreotide, sucralflate 
and hyperbaric oxygen for treatment in specific groups of patients (Lalla et al. 2014). Glutamine 
and antibiotics have not been shown to be effective (Lalla et al. 2014, Touchefeu et al. 2014).  
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1.3 Pathobiology of mucositis 
Historically, mucositis was thought to be solely an epithelial injury. As cancer therapy 
targets rapidly dividing cancer cells, also rapidly dividing normal cells will get damaged, such 
as the basal epithelial cells in the gastrointestinal and oral mucosa (Sonis 2004, Sonis 2007). 
In 2004, however, Sonis described mucositis as a more complex process, existing of 5 phases 
and comprising not only the epithelium but also other compartments of the mucosa (Sonis 
2004, Sonis 2007, Sonis 2009). This model is applicable to the entire alimentary tract, so to 
both oral and gastrointestinal mucositis (Sonis 2004). 
In the initiation phase chemotherapy will cause DNA damage and strand breaks, which 
may lead to cell death in the epithelium and the submucosa, and the generation of reactive 
oxygen species (ROS). Chemotherapy, radiation and ROS will further activate different 
pathways during the primary response phase (Sonis 2004, Sonis 2009). One of the most 
significant and best-studied activated transcription factors is nuclear factor-kappa B (NF-κB). 
It regulates the expression of more than 200 genes and will for example stimulate the 
production of pro-inflammatory cytokines such as Tumor Necrosis Factor (TNF), Interleukin-1β 
(IL-1β) and IL-6. Moreover, NF-κB impacts genes of the BCL2 family, controlling apoptosis 
(Sonis 2002, Sonis 2007, Logan et al. 2008b). Cell membranes can also be disrupted by 
activation of sphingomyelinase or ceramide synthase, leading to apoptosis (Hwang et al. 
2005). Moreover, stimulation of secretion of matrix metalloproteinases (MMPs) will cause 
break down of the extracellular matrix in the submucosa (Sonis 2007). More recently the 
production of Damage-Associated Molecular Patterns (DAMPs) by damaged cells due to 
chemotherapy and radiotherapy was also proposed to be crucial in the early stages of 
mucositis. These DAMPS will bind to Pattern Recognition Receptors (PRR) which in turn will 
promote the activation of the NF-κB pathway (Sonis 2010). 
In the signal amplification phase, the proteins produced during the primary damage, 
particularly pro-inflammatory cytokines, will stimulate additional damage by positive feedback 
loops. For example, TNF stimulates NF-κB and activates mitogen-activated protein kinase 
(MAPK) signaling, which can ultimately result in cell death (Sonis 2002, Sonis 2004). Again, 
TNF can repeatedly activate sphingomyelinases (Andrieu-Abadie et al. 2001) and MMPs 
leading to accumulated damage (Sasaki et al. 2000). Although many biological processes are 
activated during the early stage of oral mucositis, the epithelium is still intact and only few 
symptoms are visual, generally only erythema (Sonis 2004). In contrast, the ulceration phase 
is the most significant phase both at a symptomatic as at a clinical level. The loss of mucosal 
integrity leads to the formation of ulcerative lesions covered with a pseudomembrane. Bacteria 
will colonize these lesions and penetrate the submucosa which can lead to bacteremia or 
sepsis, mostly in neutropenic patients. In addition, bacterial cell-wall products penetrated into 
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the submucosa, will stimulate production of pro-inflammatory cytokines by macrophages 
(Sonis 2004, Sonis 2007). Last, the healing phase is probably still the least understood. 
Healing occurs spontaneously and is regulated by signals from the extracellular matrix leading 
to migration, proliferation and differentiation of epithelial cells (Sonis 2004, Sonis 2007). Also 
cyclo-oxygenase-2 (COX-2) may play a role as it stimulates angiogenesis (Sonis et al. 2004b, 
Logan et al. 2007). However, the structure of the submucosa will never return to the initial state 
(Denham and Hauer-Jensen 2002, Sonis 2007). 
2. Chemotherapy 
Chemotherapy mostly leads to an acute form of mucositis (in comparison with 
radiotherapy which causes chronic mucositis), developing within 3-4 days after initiation of 
chemotherapy and peaking within 2 weeks (Raber-Durlacher et al. 2010). High risk for 
development of oral mucositis exists for 5-FU, methotrexate, doxorubicin, cytarabine, cisplatin, 
cyclophosphamide and etoposide (Naidu et al. 2004, Napenas et al. 2007, Qutob et al. 2013, 
Villa and Sonis 2015). Gastrointestinal mucositis and its associated diarrhea are mostly 
associated with drugs like fluoropyrimidines (5-FU or capecitabine) and irinotecan but it also 
occurs in treatment regimens based on other chemotherapeutic agents (Wadler et al. 1998, 
Benson et al. 2004). Although the focus in this dissertation is concentrated on the effects of 
5-FU and irinotecan, also other chemotherapeutic agents causing mucositis are shortly 
reviewed here.  
2.1 5-Fluorouracil 
5-FU is one of the oldest chemotherapeutic agents and is used to combat a wide range 
of cancer types, including colorectal and breast cancer. This pyrimidine derivate is an analogue 
of uracil with a fluorine atom on the C-5 position (Longley et al. 2003). After entering the cell 
via facilitated transport, three active metabolites are produced: fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP) which all lead to DNA and RNA damage via misincorporation into DNA 
and RNA and inhibition of thymidylate synthase (TS) (Grem 2000, Longley et al. 2003). In the 
liver, however, 80 % of the 5-FU dose is catabolized into the inactive metabolite 
dihydrofluorouracil (DHFU) by dihydropyrimidine dehydrogenase (DPD) (Diasio and Harris 
1989, Longley et al. 2003), contributing to the short half-life time of 5-FU (6-22 min) (Bocci et 
al. 2000). To increase the efficacy, 5-FU is mostly combined with leucoverin (folinic acid), which 
increases intracellular levels of reduced folate. The active metabolite fluorodeoxyuridine 
monophosphate (FdUMP) needs this reduced folate as a cofactor to inhibit TS (Johnston and 
Kaye 2001, Longley et al. 2003). Another approach is to the use oral 5-FU prodrugs 
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capecitabine, to avoid DPD deactivation in the liver. These prodrugs will be absorbed in the 
gastrointestinal tract and will be preferentially converted to 5-FU in the tumor, resulting in an 
improved efficacy (Johnston and Kaye 2001, Longley et al. 2003). 
Next to leukopenia and thrombocytopenia, 5-FU causes both oral and gastrointestinal 
mucositis (Stringer et al. 2009b). The incidence is about 40 % for oral mucositis and 10 – 15 % 
for grade 3 or 4 oral mucositis (Rubenstein et al. 2004, Sonis et al. 2004a). However, in specific 
regimens the incidence of grade 3 or 4 oral mucositis can reach 66 % for 5-FU in combination 
with other chemotherapeutics (Sonis et al. 2004a). In colorectal cancer the incidence for grade 
3 or 4 diarrhea is 10 % for treatment with FOLFOX (Folinic acid, 5-FU and Oxaliplatin) or 
FOLFIRI (Folinic acid, 5-FU and irinotecan) (Jones et al. 2006). However, other studies show 
incidences reaching 38 % for grade 3 and 4 diarrhea for regimens including 5-FU (Sonis et al. 
2004a). It has been shown that several factors can modulate the mucositis risk. First, DPD 
deficiency will increase 5-FU plasma concentration, leading to higher toxicity rates (Diasio et 
al. 1988, Harris et al. 1991), whereas tumor-selective activation of prodrugs as capecitabine 
will lead to lower toxicity profiles (Johnston and Kaye 2001, Longley et al. 2003). Although 
continuous infusion of 5-FU is better tolerated than bolus in general, both oral and 
gastrointestinal mucositis occur with high incidences in both regimens (Johnston and Kaye 
2001). After an intravenous bolus injection with 5-FU, plasma concentrations in cancer patients 
can reach some hundreds µM, but the plasma levels drop to 15-30 µM after 30 minutes and 
to 0 µM after 2 h (Casale et al. 2004, Kosovec et al. 2008), due to the short half life time of 5-
FU (Bocci et al. 2000). In case of continuous infusion with 5-FU, the plasma concentrations 
are much lower, ranging from 3 to 10 µM and kept for a longer time period (24 h) (Joulia et al. 
1999, Takimoto et al. 1999). Levels in saliva during this continuous infusion range between 
0.08 and 0.8 µM (Joulia et al. 1999). 
2.2 Irinotecan 
Irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, CPT-11) 
is primarily used for treatment of colorectal cancer in combination with 5-FU or oxaliplatin 
(Jones et al. 2006, Smith et al. 2006). DNA topoisomerase is the target of this campothecin 
derivative (Hsiang et al. 1985). Irinotecan will bind to the DNA-topoisomerase I complex, 
preventing religation of the single strand breaks made by this enzyme. This will lead to 
irreversible double strand breaks and cell death (Smith et al. 2006). SN-38 (7-ethyl-10-
hydroxycamptothecin) has been shown to be more than 100 times more active, compared to 
irinotecan (Kawato et al. 1991). This active metabolite is produced in the liver but can be 
de-activated by uridine 5'-diphospho-glucuronosyltransferase 1A1 to SN-38G (Kehrer et al. 
2001). However, this SN-38G can be re-activated again to SN-38 by β-glucoronidase produced 
by microbiota in the colon and cause diarrhea (Takasuna et al. 1996). On average 1.2 % of 
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the dose is excreted as SN-38 in the feces within 24 h (Sparreboom et al. 1998, Slatter et al. 
2000) and based on these data, an average colon concentration of 1-2 µM SN-38 could be 
estimated. Diarrhea is one of most important side effects of treatment with irinotecan, with 
incidences of grade 3 or 4 diarrhea of 10 % for FOLFIRI (Folinic acid, 5-FU and irinotecan) 
and 24 % for IROX (irinotecan and oxaliplatin) regimens for colorectal cancer (Jones et al. 
2006). Other studies with irinotecan showed incidences ranging between 6 and 38 % for grade 
3 or 4 diarrhea depending on the regimen (Sonis et al. 2004a).  
2.3 Other chemotherapeutic agents 
Methotrexate (MTX, 4-amino-4-deoxy-N10-methyl pteroyl-glutamic acid), is an analog 
of folic acid used in the treatment of leukemia, non-Hodgkin lymphoma’s and some solid 
tumors (Deeming et al. 2005). MTX will interfere in the folate pathway, ultimately leading to 
blockage in synthesis of DNA, RNA, thymidylates and proteins (Rajagopalan et al. 2002, 
Vanhoecke et al. 2015a). A risk for grade 3 and 4 oral mucositis of 16-30 % is reported in 
pediatric patients (Sonis et al. 2004a). Salivary concentrations for MTX range between 0.01 
and 0.1 µM during the first 48 h after administration (Steele et al. 1979, Schroder et al. 1987). 
Doxorubicin and daunorubicin are anthracyclines and natural products extracted from 
Streptomyces peucetiusor or Streptomyces galilaeus (Nussbaumer et al. 2011). Different 
mechanisms are proposed for both chemotherapeutic agents of which the most important one 
is the interference with the uncoiling of DNA by inhibition of the topoisomerase II (Gewirtz 1999, 
Tacar et al. 2013, Yang et al. 2014). Doxorubicin is widely used for treatment of solid tumors 
and acute leukemia (Yang et al. 2014). Daunorubicin is an important agent in the treatment of 
acute lymphoblastic and myeloid leukemia (Nussbaumer et al. 2011). Regimens including 
doxorubicin have varying incidence of grade 3 and 4 oral mucositis (0-27 %) and grade 3 and 
4 diarrhea (0.3-9 %) (Sonis et al. 2004a, Jones et al. 2006, Keefe et al. 2007). Maximal salivary 
concentrations of doxorubicin range between 0.01 and 0.15 µM (Bressolle et al. 1992). 
Etoposide was the first agent targeting topoisomerase II, approved by the FDA in 1983 
(Hande 1998). It is a semisynthetic glucoside of epipodophyllotoxin which will inhibit the 
enzyme responsible for the unwinding and cutting of the double-stranded DNA, hereby 
inducing cell death (Hande 1998, Nussbaumer et al. 2011). Etoposide is frequently used for 
treatment of small-cell bronchial carcinoma, testicular cancer and some lymphomas 
(Nussbaumer et al. 2011). Incidences of grade 3 and 4 oral mucositis vary from 4 to 31 % for 
regimens including etoposide (Sonis et al. 2004a, Jones et al. 2006, Keefe et al. 2007). 
Salivary concentrations of etoposide range between 0.1 and 1.5 µM during the first 12 h after 
administration (Holthuis et al. 1986). 
Cytarabine, also known as cytosine arabinoside, is a pyrimidine analogue. Its active 
form cytarabine-5′-triphosphate can be misincorporated into DNA and is also a weak inhibitor 
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of DNA polymerase, finally leading to apoptosis (Shelton et al. 2016). It is mostly used in 
combination with a topoisomerase II inhibitor in treatment of leukemia and non-Hodgkin 
lymphoma (Bolwell et al. 1988, Shelton et al. 2016). Some regimens for hematological 
malignancies including cytarabine can cause oral mucositis (all grades) in 50-75 % of the cases 
(Niscola et al. 2007). Etoposide is excreted in saliva (0.5-4 µM) only at the short term (15 min) 
after high-dose administration (Mori et al. 2006). 
Vincristine is isolated from Madagascar periwinkle (Vinca rosea) and used to treat solid 
tumors (mainly lung and breast), lymphomas and acute leukemia (Nussbaumer et al. 2011). 
Vincristine blocks mitosis by suppression of polymerization dynamics of microtubules, crucial 
in the process of chromosomal division to form new cells (Jordan 2002). Incidences of grade 
3 and 4 oral mucositis vary from 4 to 10 % for regimens including vincristine for non-Hodgkin 
lymphoma (Jones et al. 2006, Keefe et al. 2007).  
Cyclophosphamide is a nitrogen mustard with a broad treatment spectrum in solid 
tumors, lymphoma and leukemia (Nussbaumer et al. 2011). It is an alkylating agents able to 
covalently bind an alkyl group to DNA and to form inter- and intra-strand crosslinks, leading to 
cell apoptosis (Hall and Tilby 1992). Depending on the regimen, a risk of 0-27 % has been 
reported for grade 3 and 4 oral mucositis following treatment including cyclophosphamide 
(Sonis et al. 2004a). Salivary concentrations of cyclophosphamide range between 15-30 µM 
during the first 12 h after administration (Juma et al. 1979). 
3. The role of the microbiota in mucositis 
There is more and more interest in the role and/or the effect of the microbiome in 
mucositis. Current research recognizes and emphasizes their importance both for oral 
(Stringer and Logan 2015, Vanhoecke et al. 2015b, Vasconcelos et al. 2016) and 
gastrointestinal (van Vliet et al. 2010, Stringer 2013, Touchefeu et al. 2014) mucositis. Starting 
with the characteristics of the normal mucosa and its microbiome, we will further describe the 
microbial shifts upon chemotherapeutic treatment observed during observational studies of 
oral and gastrointestinal mucositis. A similar pathobiological model and underlying molecular 
pathways are used to describe both types of mucositis (section 1.3). Therefore, the interactions 
between the host and the microbiome and the mechanisms involved, will be described for 
alimentary mucositis in general in a last section. 
3.1 Observational studies - Oral mucositis 
3.1.1 Characteristics of the normal oral mucosa and its microbiome 
The human oral mucosa consists of a stratified squamous epithelium on top of a 
connective tissue, or lamina propria (Squier and Kremer 2000, Vanhoecke et al. 2015b). Based 
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on its function and histology, there are three types of epithelium (Squier and Kremer 2000). 
The floor of the mouth and the buccal regions are covered with a non-keratinized epithelium. 
Together with the flexible connective tissue underneath, this forms the lining mucosa. In 
contrast, the masticatory mucosa consists of keratinized epithelium on top of a collagenous 
connective tissue and is therefore more resistant to mechanical forces associated with 
mastication on the gingiva and hard palate. The third type is the specialized epithelium, which 
covers the dorsum of the tongue and is a combination of keratinized and non-keratinized 
epithelium (Squier and Kremer 2000). All types of epithelium are covered with a 70-100 µm 
thick layer of salivary fluid consisting of water, mucins, salts, lipids, and proteins (Collins and 
Dawes 1987, Vanhoecke et al. 2015b). Next to the type of epithelium, saliva is a key factor 
influencing microbial composition as it provides buffering capacity and nutrient availability 
(Segata et al. 2012). Salivary mucins are high molecular weight glycoproteins and not only act 
as a primary food source for oral microbiota, but are also important as a host defense 
mechanism via formation of a physical-chemical barrier and for agglutination of microbiota 
removing them from the mouth by swallowing (Marsh and Martin 1999). Also other host factors 
can have an impact on the microbial composition, activity and stability, such as temperature, 
pH, redox potential, host genetics, and host defense molecules (lysozyme, lactoferrin, 
antimicrobial peptides, immunoglobulins, etc.) (Marsh and Martin 1999, Marsh and Devine 
2011).  
All these factors will contribute to a distinct microbial community in each region of the 
oral cavity: teeth, gingiva, tongue, cheek, lip, hard palate and soft palate (Aas et al. 2005, 
Dewhirst et al. 2010). In total, more than 700 species have already been described for the oral 
cavity (Aas et al. 2005, Zarco et al. 2012) and each individual is colonized by a unique 
microbiome (Wade 2013). The Human Microbiome Project characterized the oral communities 
from more than 200 healthy adults (Segata et al. 2012). Samples from different regions of the 
oral cavity were divided in three groups based on microbial community type: Group 1 contained 
buccal mucosa, keratinized gingiva, and hard palate; Group 2 contained saliva and tongue; 
and Group 3 contained sub- and supragingival plaque. At phylum level, Group 1 was 
dominated by Firmicutes (> 55 %), followed in decreasing order of relative abundance by 
Proteobacteria, Bacteroidetes and either Actinobacteria or Fusobacteria. Compared to Group 
1, Group 2 had a lower abundance in Firmicutes and increased levels for Bacteroidetes, 
Fusobacteria, Actinobacteria and TM7 (Candidatus Saccharibacteria). The dental plaque 
samples in Group 3 consisted of an even lower level of Firmicutes and an increased level of 
Actinobacteria. On genus level, Group 1 was dominated by Streptococcus, whereas Group 2 
and 3 had a more even distribution of Streptococcus, Veillonella, Prevotella, Neisseria, 
Fusobacterium, Actinomyces and Leptotrichia (> 2 % in Group 2 and 3) and Corynebacterium, 
Capnocytophaga, Rothia and Porphyromonas (> 2 % in Group 3). Group 1 showed a lower 
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diversity (measured by the inverse Simpson index), probably due to the high abundance of 
Streptococcus (Segata et al. 2012).  
Oral microbiota are present as planktonic cells in saliva or as biofilms on both dental and 
mucosal surfaces (Avila et al. 2009, Vanhoecke et al. 2015b). The early colonizers of the 
biofilms are Streptococcus and Actinomyces as they can adhere to the oral surfaces. The 
immature biofilm consist of 80 % Streptococcus spp., which forms the basis for a multi-layered 
multi-species biofilm (Kolenbrander et al. 2010). One of the key species in biofilm formation is 
Fusobacterium as it creates anaerobic microenvironments and makes physical bridges 
(Kolenbrander et al. 2010). This ‘bridging’ capacity is established by special cell surface 
proteins (adhesins) providing inter-species adherence (Kaplan et al. 2009). In contrast to 
multilayer dental plaques, mucosal biofilms are less characterized. The high turnover rate of 
the epithelial cells makes it more difficult to adhere which leads to the formation of one single 
biofilm layer and a wash-out of non-adhered microbiota by saliva (Vanhoecke et al. 2015b).  
Certain genera, such as Porphyromonas, Treponema, and Tannerella, are characterized 
by pathogenic members and therefore associated with disease. However, it has been shown 
that also in the healthy oral cavity, these genera are present at low abundance (Segata et al. 
2012). Moreover, also commensal species can become pathogenic in response to certain 
triggers in the oral cavity such as changes in oral hygiene (Avila et al. 2009). However, oral 
infections are most likely caused by consortia of biofilm microbiota rather than a single 
pathogenic species (Jenkinson and Lamont 2005). 
3.1.2 Oral microbial shifts upon chemotherapeutic treatment  
Although the role of the oral microbiota in chemotherapy-induced mucositis is still 
unclear, there is growing interest in this topic (Stringer and Logan 2015, Vanhoecke et al. 
2015b, Vasconcelos et al. 2016). In 2007, a first review stated that changes in the oral 
microbiome are inconsistent during chemotherapy, due to the great variability in patient 
populations, sample types, and sample collection methods (Napenas et al. 2007). 
Nevertheless, both this and later studies most frequently isolated Enterobacteriaceae spp., 
Pseudomonas spp., Klebsiella pneumonia and E. coli as Gram-negative species in blood and 
oral swabs during chemotherapy/HSCT (Napenas et al. 2007, Panghal et al. 2012). Similarly, 
the most commonly isolated Gram-positive species were Staphylococcus spp. and 
Streptococcus spp. (Napenas et al. 2007, Napenas et al. 2010, Olczak-Kowalczyk et al. 2012, 
Panghal et al. 2012). Pediatric studies showed that the Streptococcus oralis group of viridans 
streptococci is persistent following chemotherapy and total body irradiation (Lucas et al. 1997) 
and that the presence of Staphylococcus spp. and Enterococcus spp. is correlated with oral 
lesions (Olczak-Kowalczyk et al. 2012). Also other microorganisms have been shown to be 
associated with mucositis or oral ulcerations. In HSCT patients, Porphyromonas gingivalis in 
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particular, but also Parvimonas micra, Treponema denticola and Fusobacterium nucleatum 
were associated with oral ulcerations (Laheij et al. 2012). Fungal species, such as Candida, 
(de Mendonca et al. 2012, Laheij et al. 2012, Olczak-Kowalczyk et al. 2012) and viruses, such 
as Herpes simplex virus (HSV)-1, (de Mendonca et al. 2012, de Mendonca et al. 2015) are 
also associated with mucositis and/or oral lesions.  
In the past, Gram-negative bacteria were the main cause of infections in neutropenic 
cancer patients. However, a shift towards Gram-positive infections has been shown in the 
1990s (Zinner 1999) and also more recent studies have indicated Gram-positive bacteria as 
major pathogens causing infections (Panghal et al. 2012). This can be explained by the 
prophylactic use of fluoroquinolones, the use of high-dose chemotherapy causing oral mucosal 
barrier disruption and the use of central venous lines increasing the risk of infections with skin 
bacteria (Zinner 1999, Panghal et al. 2012). Viridans streptococci are one of the main Gram-
positive pathogens causing infections. Factors that predispose to the development of viridans 
streptococci sepsis are neutropenia, oral mucositis, high-dose cytarabine and antimicrobial 
prophylaxis with trimethoprim-sulphamethoxazole or quinolone (Shenep 2000, Tunkel and 
Sepkowitz 2002). 
Most of the previous mentioned studies used cultivation techniques to identify and 
quantify the oral microbiota. Recently, molecular techniques are being used to study the 
microbiome, leading to new in-depth insights. The use of 16S rRNA clone libraries of oral 
buccal samples of 9 breast cancer patients before and after chemotherapy resulted in species 
previously unidentified in patients. Moreover, a shift to a more complex microbial community 
after chemotherapy was observed with 60 % of the species only present after the treatment 
(Napenas et al. 2010). In pediatric patients, 454-sequencing of oral mucosal bacterial samples 
showed a lower diversity and higher inter-individual variability for patients compared to 
reference individuals. Furthermore, they found a higher microbial diversity before the start of 
chemotherapy and a more significant modification of the bacterial community by chemotherapy 
(before the occurrence of mucositis) in patients who later developed oral mucositis (Ye et al. 
2013). In a recent study with pediatric patients with acute myeloid leukemia (AML), amplicon 
sequencing of oral and stool microbiota showed a correlation between increased variability of 
the microbial diversity over time with higher risk of infection, respectively during an after 
chemotherapy (Galloway-Pena et al. 2017).  
In conclusion, only limited studies dealing with the effect of chemotherapy on the oral 
microbiome were conducted so far and most of them used cultivation techniques. Moreover, 
research on the composition of the microbiota and/or relative abundance of different species 
before and after chemotherapy is limited, making it difficult to clearly indicate the shifts 
occurring after chemotherapy or linked with mucositis (Vanhoecke et al. 2015b). These shifts 
also widely vary depending on the chemotherapy regimen, sampling- and patient-related 
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variables (Vanhoecke and Stringer 2015). More longitudinal clinical investigations are needed 
to fully understand the interactions between the host, oral mucositis and the oral microbiome 
(Vasconcelos et al. 2016).  
3.2 Observational studies - Gastrointestinal mucositis 
3.2.1 Characteristics of the normal gastrointestinal mucosa and its microbiome 
The human digestive tract is partitioned in different sections, each with its own mucosa 
and microbiome. In this dissertation the focus will be on the large intestine, as our research is 
investigating the effect of chemotherapy on the colon microbiome. The mucosa of the large 
intestine has a single layered epithelium which is covered with a protectant mucus-layer. 
Goblet cells in the epithelium will produce mucins, which are the main building blocks of the 
mucus-layer. In contrast with the small intestine, the colon has a two-layered mucus system, 
both built by mucin 2 (MUC2). The inner dense layer is attached to the epithelial cells, whereas 
the outer layer is loose and unattached (Johansson et al. 2011, Johansson et al. 2013). The 
major functions of the mucosa are the absorption of nutrients and barrier formation (Van der 
Flier and Clevers 2009). Together with the mucus layer, tight junctions and the innate and 
adaptive immune system will establish this mucosal barrier protecting against gut microbial 
invasion (Van den Abbeele et al. 2011). 
Not only the mucosa, but also the microbiota differ in each part of the gastrointestinal 
tract, depending on the pH, retention time, exposure to oxygen, substrate availability and host 
secretions (Macfarlane and Macfarlane 1997, Flint et al. 2012). The colon harbors the most 
dense and complex microbial community (Walter and Ley 2011) containing hundreds of 
different species, mostly member of the five most abundant bacterial phyla (Firmicutes, 
Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia) (Walter and Ley 2011). 
Next to longitudinal variation, axial variation occurs in the gastrointestinal tract, with different 
microbiota in the lumen compared to the mucus layer. A gradient in increasing microbial 
diversity and density is observed from the mucosa to the lumen (Van den Abbeele et al. 2011). 
A clear difference in mucus-associated microbiota was seen with higher levels of Firmicutes 
and more specifically Lachnospiraceae and Ruminococcaceae (Nava et al. 2011). 
Within one individual, the intestinal microbial community is relatively stable over time, 
although several factors can cause significant changes, such as antibiotics and diet, but also 
chemotherapy. In contrast, large inter-individual differences exist in abundance and 
composition of the stool microbiome, whereas functional profiles remain more stable over 
different individuals (Huttenhower et al. 2012). Both adverse and beneficial functions are 
exerted by the human gut microbiome. Adverse functions include infection and production of 
toxins (Louis et al. 2014), whereas beneficial functions can be protective, structural or 
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metabolic, comprising for example short-chain fatty acid (SCFA) production, vitamin 
production, immune system development and mucosal barrier fortification (O'Hara and 
Shanahan 2006). The major metabolic pathways that drive the growth of colon microbiota are 
carbohydrate fermentation (with production of SCFA and gases) (Falony and De Vuyst 2009), 
protein fermentation (with production of toxic and carcinogenic products) (Louis et al. 2014) 
and mucus fermentation (with production of SCFA and oligosaccharides) (Belzer and De Vos 
2012). 
3.2.2 Gastrointestinal microbial shifts upon chemotherapeutic treatment  
A lot of research on gastrointestinal mucositis was conducted using laboratory animals. 
Although there are differences between inflammatory diseases in humans and animals and 
their respective microbiome, these models are important to provide insights in the pathobiology 
of mucositis (Ley et al. 2005, Touchefeu et al. 2014). Tests with germ-free mice treated with 
irinotecan have confirmed that microbiota modify the mucositis process, as conventional mice 
had higher inflammatory markers, more lesions and higher intestinal permeability in 
comparison with germ-free mice (Pedroso et al. 2015). Multiple studies have shown shifts in 
the microbiome following treatment with 5-FU, irinotecan and MTX. In a rat study, 5-FU caused 
a shift in composition from predominantly Gram-positive to Gram-negative bacteria, as shown 
by microbiological culture techniques (von Bultzingslowen et al. 2003). A later study with 5-FU 
showed a decrease in Enterococcus spp., Lactobacillus spp. and Streptococcus spp. in the 
colon using standard microbiological culture techniques and an increase in Clostridium spp. 
and Staphylococcus spp. in fecal samples at 24 h using q-PCR (Stringer et al. 2009c). Similar 
rat studies have been done with irinotecan, which reported an increase in E. coli and a 
decrease in Bifidobacterium spp. and Lactobacillus spp. (Stringer et al. 2007, Stringer et al. 
2008, Stringer et al. 2009a). An increase in Clostridium cluster XI and Enterobacteriaceae was 
seen for both irinotecan and irinotecan/5-FU treatment regimens in rats (Lin et al. 2012). Also 
MTX impacts the microbiota in rats, decreasing the number and diversity of microbiota (Fijlstra 
et al. 2015). In general, a shift from commensal microbiota (Bifidobacterium spp. and 
Lactobacillus spp.) to Escherichia spp., Clostridium spp. and Enterococcus spp. has been 
observed after chemotherapeutic treatment in animal studies (Touchefeu et al. 2014). These 
microbiota are also frequently isolated in the blood of cancer patients, causing bacteremia 
(Montassier et al. 2013).  
Human studies have also reported changes in the fecal microbiota following 
chemotherapeutic treatment. In pediatric patients, a decrease in total number and diversity of 
microbiota was reported during chemotherapy regimens. Fluorescent In Situ Hybridization 
(FISH) showed a decrease in anaerobic bacteria (Bacteroides spp., Clostridium cluster XIVa, 
Faecalibacterium prausnitzii, and Bifidobacterium spp.) combined with an increase in 
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potentially pathogenic aerobic Enterococcus spp. The authors concluded that the disturbed 
balance could increase the risk for Gram-positive aerobic infections among immune-
compromised patients with cancer (van Vliet et al. 2009). Another study showed a decrease in 
the Clostridium cluster IV and XIXa, Bifidobacterium, Lactobacillus, Veillonella, and 
Faecalibacterium prausnitzii in patients receiving different chemotherapy regimens. This 
disturbed balance favored colonization with Clostridium difficile and Enterococcus faecium 
(Zwielehner et al. 2011). After conditioning chemotherapy for bone marrow transplantation, a 
sharp reduction in alpha diversity of the fecal microbiota and a drastic drop in Faecalibacterium 
accompanied by an increase of Escherichia was observed (Montassier et al. 2014). A similar 
study showed a decrease in abundances of Firmicutes and Actinobacteria and an increase in 
Proteobacteria in fecal samples of patients following chemotherapy (Montassier et al. 2015). 
Some changes can also be associated with chemotherapy-induced diarrhea. Stringer et al. 
(2013) reported decreases in Lactobacillus spp., Bifidobacterium spp., Bacteroides spp., 
Enterococcus spp. and methanogenic archaea and an increase in Escherichia coli and 
Staphylococcus spp. in fecal samples of patients with chemotherapy-induced diarrhea. In 
general, the most frequent changes in patients receiving chemotherapy are a decrease in 
Bifidobacterium, Clostridium cluster XIVa, Faecalibacterium prausnitzii and an increase in 
Enterobacteriaceae and Bacteroides (Touchefeu et al. 2014). 
In conclusion, both animal and clinical studies indicate that chemotherapeutic treatment 
causes major modifications to the gut microbiome and can lead to a disturbed balance. This 
imbalance will possibly also contribute to the mucositis process (Touchefeu et al. 2014). 
3.3 Interactions between the microbiome and the mucosa in the context of 
mucositis 
The interactions between the microbiome and the host mucosa are similar in oral and 
gastrointestinal mucositis, as they are both described by the same pathobiological model and 
as similar processes occur in both regions (Sonis 2004). Therefore, the mechanisms 
underlying host-microbe cross talk during mucositis will be relevant for both types of mucositis.  
3.3.1 Mucosal barrier function 
A healthy gut is characterized by an intestinal homeostasis and the commensal 
microbiota can help the intestinal mucosa in maintaining this balance via different mechanisms 
(Figure 1.1) (van Vliet et al. 2010, Touchefeu et al. 2014). The integrity of the mucosal barrier 
is crucial in this homeostasis and is ensured by both the mucus layer and the tight junction 
formation in the epithelial barrier. Dysregulation of these interactions can lead to inflammatory 
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bowel disease (Medzhitov 2007) or to mucositis after dysregulation of the mucosal barrier by 
chemo- or radiotherapy (Touchefeu et al. 2014). 
 
Figure 1.1 - Protective actions of intestinal microbiota on the intestinal mucosa (Touchefeu et al. 2014). 
 
The first crucial step in maintaining the mucosal barrier is reducing epithelial 
permeability. However, both human and rat studies have shown that chemotherapy increases 
epithelial permeability (Keefe et al. 1997, Carneiro-Filho et al. 2004, Russo et al. 2013). 
Epithelial integrity and tight junctions are the main key factors to assure low permeability and 
chemotherapy can impact both of them. In the third phase of the pathobiology of mucositis, 
epithelial cell loss will aggravate the permeability in the alimentary tract due to activation of 
apoptosis via different pathways (Sonis 2007). Moreover, chemotherapy has also been shown 
to disrupt tight junctions, both in the oral and gastrointestinal mucosa (Hamada et al. 2010, 
Wardill et al. 2016). In contrast, commensal gut microbiota can enhance barrier function by 
influencing expression and distribution of tight junctions (Ulluwishewa et al. 2011). 
Furthermore, microbiota can induce the production of heat shock proteins which preserve the 
viability of epithelial cells in stress conditions and maintain the epithelial integrity (Arvans et al. 
2005, Matsuo et al. 2009). Also microbial metabolites can attenuate epithelial permeability. 
Butyrate, a short chain fatty acid produced by gut microbiota, has shown to reduce intestinal 
permeability in 5-FU induced mucositis in mice (Ferreira et al. 2012). This indicates that shifts 
in microbiota could play a role in epithelial permeability, influencing the severity of mucositis in 
the ulcerative phase (van Vliet et al. 2010). 
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Next to epithelial integrity, the mucosal barrier is maintained by the mucus layer. Both 
the composition of the mucus layer and the mucus secretion are affected by chemotherapy in 
rat studies (Stringer et al. 2009a, Stringer et al. 2009b, Stringer et al. 2009c). Goblet cells 
(specialized epithelial cells in production of mucin) decreased in the colon following irinotecan 
treatment, whereas mucin secretion increased. This is linked with higher abundance of 
cavitated goblet cells (cells which have released mucins by exocytosis) (Stringer et al. 2009a, 
Stringer et al. 2009b). Similar trends were seen following treatment with 5-FU. Total goblet cell 
numbers and abundance of cavitated goblet cells increased in the jejunum (Stringer et al. 
2009c). Similarly, jejunal mucin content was reduced on day 1 and 3, but increased again at 
day 7 after 5-FU treatment (Saegusa et al. 2008). However, in methotrexate-induced 
mucositis, goblet cells were only decreased in the small intestinal crypts and not in the villi 
(Verburg et al. 2000). Not only chemotherapy, but also gut microbiota can affect goblet cells 
and the mucus layer. Directly, via the local release of bioactive factors or indirectly, via 
activation of host immune cells (Deplancke and Gaskins 2001). Germfree mice are shown to 
have less and smaller goblet cells and a different mucus composition in comparison with 
conventional mice (Kandori et al. 1996, Deplancke and Gaskins 2001). The enhancement of 
mucus secretion in the presence of microbiota is explained by the advantages it offers for the 
gut microbiota, as it serves as an energy source and protects the microbiota against rapid 
luminal expulsion by offering a surface to adhere (Deplancke and Gaskins 2001). Microbiota 
also steer the composition of the mucins by regulating genes encoding mucins, such as the 
upregulation of muc-2 and muc-3 genes by certain Lactobacillus strains (van Vliet et al. 2010). 
Last, also host-derived inflammatory mediators, such as IL-1, IL-4, IL-6, IL-9, and TNF-α have 
been shown to increase mucus secretion (Deplancke and Gaskins 2001). In conclusion, 
multiple key factors in the mucositis process such as chemotherapy, microbiota and 
inflammatory proteins, can impact the mucus layer improving or attenuating the strength of the 
mucosal barrier. 
3.3.2 Host-microbe communication 
Normal host-microbe communication 
Epithelial cells are key players in the communication between the host and its microbiota. 
Their pattern recognition receptors (PRRs) are able to recognize and bind microbe 
associated molecular patterns (MAMPs). These are microbial macromolecular ligands, such 
as lipopolysaccharide, flagellin, peptidoglycans or formylated peptides (Medzhitov 2007, Neish 
2009). These MAMPs are produced by both pathogenic and commensal microbiota, however, 
PRR do not themselves distinguish between pathogens and commensals (Rakoff-Nahoum et 
al. 2004, Medzhitov 2007). PRR can be transmembranic, like Toll-like receptors (TLRs), 
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intracellular, like Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), or 
secreted, like collectins and are present in all multicellular organisms (Medzhitov 2007, Neish 
2009). TLR activation by binding of a MAMP, triggers a cascade of cellular signals, activating 
the NF-κB pathway and ultimately developing an inflammatory response with the upregulation 
of pro-inflammatory cytokines and chemokines (Doyle and O’Neill 2006, van Vliet et al. 2010, 
Vanhoecke et al. 2015b). These chemoattractant cytokines can further attract immune cells 
and also have antimicrobial properties (Durr and Peschel 2002, Kagnoff 2006). This entire 
process forms the basis of the innate immune response, which establishes an intestinal 
homeostasis leading to a low grade inflammation, barrier formation, wound repair and tissue 
regeneration (Medzhitov 2007, Cario 2008, Touchefeu et al. 2014) (Figure 1.1). 
Interference of chemotherapy and microbiota with host-microbe communication 
A highly important pathway in mucositis and in innate immunity is the TLR/NF-κB 
signaling. Cancer therapy will induce cell death which will lead to the release of DAMPs. By 
binding to TLRs, these will activate an inflammatory response (Vasconcelos et al. 2016). 
However, when mucosal injury starts and permeability increases, the abundance of MAMPs 
will increase, further stimulating the overall immune status of the tissue (Vanhoecke and 
Stringer 2015, Vasconcelos et al. 2016). MAMPs known for oral diseases are, for example, 
Treponema denticola flagellin (Beklen et al. 2009) and Porphyromonas gingivalis LPS 
(Kocgozlu et al. 2009). Interestingly, both species were also associated with oral ulcerations 
after high-dose chemotherapy (Laheij et al. 2012).  
Both DAMPs and MAMPs will bind to TLRs, which have been shown to be crucial in 
host-microbe cross talk and epithelial homeostasis (Rakoff-Nahoum et al. 2004). The 
disturbance of the host-microbe interactions by chemotherapy is (partially) mediated by TLR 
signaling (Vanhoecke and Stringer 2015). In particular TLR4, which binds to 
lipopolysaccharides (LPS), is linked with chemotherapy-induced gut toxicity (Wardill et al. 
2014). MTX-treated rats showed an increase in TLR4 protein in the small intestine during gut 
toxicity (Hamada et al. 2013). In contrast, irinotecan caused a decrease in both TLR4 and 
TLR5 in rats and the absence of both is correlated with a better wound healing capacity 
(Gibson et al. 2016). Moreover, the shifts in microbiota following chemotherapy (see above) 
will lead to changes in available ligands to bind to TLRs and ultimately cause an altered TLR 
activity (Stringer and Logan 2015).  
A cascade of signals will further lead to the activation of NF-κB, which is a key molecule 
in the pathobiology of mucositis (Sonis 2004, Sonis 2007, Vanhoecke and Stringer 2015). 
NF-κB is not only activated by TLRs, but also by chemotherapy directly or indirectly via ROS 
(Sonis 2004). Rat studies showed increased tissue and serum levels of NF-κB following 
chemotherapy (Logan et al. 2008a, Logan et al. 2008b). Also in vivo, increased levels of NF-
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κB are shown following cytotoxic chemotherapy in oral mucosa biopsies (Logan et al. 2007). 
Commensal microbiota, such as Bacteroides thetaiotaomicron, Bifidobacterium infantis and 
Lactobacillus salivarius are able to decrease NF-κB levels (Kelly et al. 2004, O'hara et al. 
2006). Therefore, regulation of the microbiota following chemotherapy can reduce NF-κB 
production and further inflammatory processes (Stringer 2013). 
Next to TLR-NF-κB signaling, MAPK signaling is a major pathway in mucositis and can 
also be activated by bacterial ligands (Figure 1.2) (Sonis 2007, Stringer and Logan 2015). 
MAPK signaling is involved in the regulation of multiple eukaryotic cell activities including 
activation of transcription factors, stress response, differentiation, and growth (Handfield et al. 
2008). Activation of MAPK signaling by bacterial ligands will lead to production of 
pro-inflammatory cytokines and apoptosis (Stringer and Logan 2015). Moreover, rat studies 
showed that MAPK signaling was upregulated in the intestinal tract following irinotecan 
treatment (Bowen et al. 2007a, Bowen et al. 2007b).  
Also the inflammasome is involved in host-microbe communication. These protein 
complexes are formed in the cytosol after sensing MAMPs or DAMPs and are mostly formed 
of NLRs. They regulate the activation of caspase-1, leading to cleavage of IL-1 to their 
bioactive forms IL-1β and IL-18, which are pro-inflammatory cytokines (Guo 2015). It has been 
shown in mice that inflammasomes can mediate gastrointestinal mucositis via IL-1β and IL-18 
and that they are ROS dependent (Arifa 2014).  
 
Figure 1.2 - Microbiota can influence mucositis by interfering with TLR/NF-κB pathway, MAPK signaling 




Both NF-κB, MAPK signaling and the inflammasome will lead to the activation of 
pro-inflammatory cytokines such as TNF, IL-1β and IL-6, which are all important in the 
pathobiology of mucositis (Sonis 2004, Stringer and Logan 2015). These pro-inflammatory 
cytokines have all been shown to be upregulated following irinotecan, 5-FU and MTX treatment 
in rats (Logan et al. 2008a, Logan et al. 2009). 
All these processes will lead to an inflammatory status and immune activation in the 
tissue (van Vliet et al. 2010). Commensal microbiota provide a continuous exposure to 
bacterial ligands, which can bind to TLR and lead to a low grade inflammatory status (Rakoff-
Nahoum et al. 2004). This homeostasis is also regulated by immune effector molecules, such 
as Immunoglobulin A (van Vliet et al. 2010). Immunoglobulin A is the most abundant antibody 
in all mucosal secretions and is produced by B-cells in the gut-associated lymphoid tissue 
(GALT) (Fagarasan and Honjo 2003). By regulating this immune effector molecules, both 
microbiota and their products are able to maintain homeostasis (van Vliet et al. 2010). 
3.3.3 Mucosal repair and wound healing 
The pathobiological model of mucositis shows that wound healing is crucial in the 
recovery from mucositis (Sonis 2004). The epithelial wound healing process exists of two 
mechanisms: migration and proliferation. Migration is the most important process at the edge 
of the wound, whereas proliferation is taking place at more distinct places (Zahm et al. 1997). 
Next to epithelial cells also fibroblasts are important in the wound healing process as they 
produce the extracellular matrix (Ryu et al. 2009). Fibroblasts and vascular endothelium 
produce cyclooxygenase-2 (COX-2), which stimulates angiogenesis leading to submucosal 
restructuring (Sonis 2007). Moreover, epithelial migration, proliferation and differentiation will 
be steered from the submucosa during the healing phase of mucositis (Sonis 2004, Sonis 
2007). Although a spontaneous healing is occurring after cessation of the cancer treatment, 
the structure of the submucosa will never be identical to its initial state, even after complete 
epithelial closure (Sonis 2007) (Denham and Hauer-Jensen 2002). 
Radiotherapy may disturb the normal wound healing process by interfering with the 
vascular system, fibroblasts and growth factor levels (Tibbs 1997). However, the use of 
recombinant human epidermal growth factor has been shown to increase proliferation of 
fibroblasts and epithelial cells leading to faster wound healing capacity in radiotherapy-induced 
oral mucositis in rodents (Lee et al. 2007, Ryu et al. 2009). Although studies are limited, there 
are some indications that also chemotherapy may impact wound healing capacity (Bland et al. 
1984).  
More importantly, the microbiome has been shown to majorly impact wound repair and 
tissue regeneration (Cario 2008, Touchefeu et al. 2014) (Figure 1.1) and protect the gut against 
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injuries (Rakoff-Nahoum et al. 2004). The positive effect of microbiota on wound healing was 
confirmed by tests with germ-free animals. In the absence of microbiota, lower rates of 
epithelial cell migration and cell turnover were observed (Rolls et al. 1978). Moreover, the 
migration of the cells to the top of the villi was retarded (Savage et al. 1981). Not only intestinal 
wound healing, but also repair of skin incisions has been shown to be enhanced in the 
presence of normal intestinal microbiota in comparison to germ-free mice (Okada 1994). 
However, microbiota can also negatively affect wound healing. Edwards and Harding 
(2004) showed that low bacterial levels improve wound healing in chronic wounds, whereas 
infection with a high bacterial load are detrimental for the wound healing process. The 
importance of microbial concentration in the wound healing process was also confirmed in vitro 
(De Ryck et al. 2015). Next to microbial load, also the composition of the microbiome is 
important, as infection with certain species may delay wound healing and others may even 
have a beneficial impact on wound healing (Laheij et al. 2013, De Ryck et al. 2015). De Ryck 
et al. (2015) showed that S. mitis and S. oralis significantly improved wound healing capacity, 
whereas Klebsiella oxytoca and Lactobacillus salivarius reduced healing of oral epithelial cells 
in an in vitro model. Also Porphyromonas gingivalis has been shown to reduce wound healing 
and is linked with oral ulcerations during mucositis (Laheij et al. 2013). In contrast, 
Akkermansia muciniphila is a wound-mucosa-associated species of the human gut which can 
stimulate both migration and proliferation of enterocytes (Alam et al. 2016). Not only microbial 
cells itself, but also bacterial metabolites may impact wound healing. For example, the 
supernatant of Lactobacillus cultures has been shown to reduce wound closure (Halper et al. 
2003). The effect of bacterial LPS on wound healing depends on its concentration, with low 
concentrations causing an improvement in wound healing by activation of epidermal growth 
factor receptor, whereas high concentrations cause a reduction in healing capacity (Koff et al. 
2006). Butyrate has been shown to stimulate migration of cells in vitro, leading to a better repair 
of mucosal damage (Wilson and Gibson 1997, Hamer et al. 2008). So far it is not clear which 
mechanisms are steering the impact of microbiota on wound healing. However, quorum 
sensing molecules are thought to play a role in signaling during wound healing (De Ryck et al. 
2015).  
Next to microbiota and their metabolites, also host-derived products can impact wound 
healing capacity. In saliva, histatin 1 and histatin 2 are identified as the most important 
molecules stimulating wound closure in the oral cavity (Oudhoff et al. 2008). Also MMPs, 
zinc-dependent endopeptidases crucial in maintaining homeostasis in the extracellular matrix, 
may be important in both wound healing and mucositis. MMPs are shown to be increased 
following chemotherapeutic treatment both in animal studies (Al-Dasooqi et al. 2010) and 
clinical studies (Stringer et al. 2013). Moreover, in the pathobiology of mucositis they are 
responsible for the degradation of the extracellular matrix (Sonis 2004). With regards to wound 
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healing, MMP-9 is linked with accelerated healing, whereas MMP-2 reduced wound healing 
capacity (de Bentzmann et al. 2000).  
Some of the current treatments for mucositis also focus on stimulating wound healing 
capacity of the epithelium. For example, the use of LLLT, which is recommended for the 
prevention of oral mucositis in patients receiving HSCT conditioning high-dose chemotherapy 
(Lalla et al. 2014). It is hypothesized that the effectiveness of LLLT is based on the fact that 
the laser light is absorbed by chromophores in the mitochondria which will activate ATP 
production, cell proliferation, protein synthesis and stimulate tissue repair (Karu 1988, Simoes 
et al. 2009).  
3.3.4 Conclusion 
In conclusion, both chemotherapy and microbiota interfere with multiple crucial 
processes and signaling pathways during mucositis: the integrity of the components of the 
mucosal barrier, the underlying immune system and signaling mechanisms such as 
TLR-NF-κB and MAPK pathways. This interference will ultimately alter the inflammatory and 
immune status of the epithelium and repair mechanisms. In a healthy individual, interactions 
between all these processes result in a state of homeostasis. However, cancer treatment will 
disturb this balance and the microbiota of the alimentary tract can both help to restore this 
balance or further aggravate the dysbiosis, depending on different factors such as bacterial 




4. Research questions 
Both oral and gastrointestinal mucositis are prevalent side effects of chemotherapeutic 
treatments which majorly affect patient’s quality of life. More and more, mucositis research is 
focusing on the role of microbiota in the development of both oral and gastrointestinal 
mucositis. As chemotherapeutic agents are present in saliva an feces and are theoretically 
able to cause damage to the DNA of the microbiota, chemotherapy might not only damage the 
host cells, but also the host microbiome. In vivo studies have indeed reported microbial shifts 
following chemotherapeutic treatment, both in rats and in humans. This disturbed microbiome 
might further aggravate the mucositis development. However, it is still unclear if the 
chemotherapy disturbs the microbiota directly or if the chemotherapy disturbs the host 
environment and thereby creates a dysbiotic microbiome. 
To further answer this question, two different approaches were used during this PhD 
thesis (Figure 1.3). In the first two chapters, we focused on the direct effect of chemotherapy 
on both oral and gastrointestinal microbiota. In chapter 4 and 5, the addition of a host 
compartment made it possible to investigate interactions between chemotherapy, microbiota 
and the host. 5-FU and irinotecan were chosen as chemotherapeutic agents in this thesis, as 
previous in vivo studies have shown that both 5-FU and irinotecan have an impact on the host 
microbiota (see section 3.2.2). 
5-FU is a commonly used chemotherapeutic agent characterized by high incidences of 
mucositis. To evaluate the direct effect of 5-FU on different oral microorganisms, an in vitro 
study with monocultures was performed in Chapter 2. The effect of physiologically relevant 
concentrations of 5-FU (0.1-50 µM) on growth and viability of 11 oral microorganisms was 
assessed with growth curves and flow cytometry. Moreover, the possible role of DPD, an 
enzyme involved in 5-FU resistance, was investigated.  
Next to 5-FU, irinotecan also highly induces gastrointestinal mucositis. To assess the 
direct impact of 5-FU and SN-38 (the active metabolite of irinotecan) on the gut microbiome, 
an in vitro colon simulation with microbiota from different healthy individuals was performed 
(Chapter 3). Changes in microbial functionality and community composition were monitored 
following multiple treatments in a Mucosal-Simulator of the Human Intestinal Ecosystem 
(M-SHIME®). 
In Chapter 4, an in vitro oral co-culture model was used to study the interactions between 
1) the chemotherapeutic agents 5-FU, 2) an oral microbial biofilm, and 3) an oral epithelial 
monolayer. The impact of different microbial sample types (saliva, buccal or tongue) and donor 
types (healthy individuals or patients suffering from mucositis) on wound healing was reported 
and linked with bacterial count and composition.  
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Finally, a longitudinal observational in vivo study studied the oral microbiota of pediatric 
patients treated for hematological malignancies (Chapter 5). Analysis of the microbiome 
before, during and after chemotherapy was performed, including periods with and without 
mucositis. The microbial shifts were reported and correlated with clinical data such as 
chemotherapy, mucositis, antibiotic treatment, neutropenia, inflammation, use of mouth rinses, 
and pain. 
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5-Fluorouracil (5-FU), a commonly used chemotherapeutic agent, often causes oral 
mucositis, an inflammation and ulceration of the oral mucosa. Microorganisms in the oral cavity 
are thought to play an important role in the aggravation and severity of mucositis, but the 
mechanisms behind this remain unclear. Although 5-FU has been shown to elicit antibacterial 
effects at high concentrations (>100 µM), its antibacterial effect at physiologically relevant 
concentrations in the oral cavity is unknown. This study reports the effect of different 
concentrations of 5-FU (range 0.1-50 µM) on the growth and viability of bacterial monocultures 
that are present in the oral cavity and the possible role in the activity of dihydropyrimidine 
dehydrogenase (DPD), an enzyme involved in 5-FU resistance. Our data showed a differential 
sensitivity among the tested oral species towards physiological concentrations of 5-FU. 
Klebsiella oxytoca, Streptococcus salivarius, Streptococcus mitis, Streptococcus oralis, 
Pseudomonas aeruginosa and Lactobacillus salivarius appeared to be highly resistant to all 
tested concentrations. In contrast, Lactobacillus oris, Lactobacillus plantarum, Streptococcus 
pyogenes, Fusobacterium nucleatum and Neisseria mucosa showed a significant reduction in 
growth and viability already starting from very low concentrations (0.2 - 3.1 µM). We could also 
provide evidence that DPD is not involved in the 5-FU resistance of the selected species. The 
observed variability in response to physiological 5-FU concentrations may explain why certain 
microbiota lead to a community dysbiosis and/or an overgrowth of certain resistant 
microorganisms in the oral cavity following cancer treatment.  
  
2 CHAPTER 2 
5-Fluorouracil sensitivity varies 
among oral microorganisms  
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1. Introduction 
5-FU is a commonly used chemotherapeutic agent for colon and breast cancer. It is an 
anti-metabolite that inhibits human thymidylate synthase and is incorporated in DNA and RNA 
(Grem 2000, Longley et al. 2003). One of the main side effects of 5-FU treatment is oral 
mucositis, an inflammation and ulceration of the mucosa of the oral cavity (Peterson and Sonis 
1982, Carnel et al. 1990). It majorly affects the quality of life of patients, including problems 
with eating, speaking and drinking, and treatment mainly is concentrated on pain relief and 
oral hygiene (Villa and Sonis 2015).  
Along the gastrointestinal tract, microorganisms play an important role in sustaining 
homeostasis and health (Aziz et al. 2013). Evidence is also emerging that microorganisms are 
involved in the development and severity of 5-FU-induced mucositis (Stringer and Logan 2015, 
Vanhoecke et al. 2015b). Changes in the composition of the oral microorganisms have been 
reported for chemotherapy in human studies (Lucas et al. 1997, Napenas et al. 2010) and for 
5-FU specifically in a rat study (von Bultzingslowen et al. 2003), with a shift towards more 
Gram-negative rods and bacterial translocation to cervical and mesenteric lymph nodes 
following treatment with 5-FU. A number of studies have been looking at the antibacterial effect 
of 5-FU on monocultures of mainly pathogenic strains such as Pseudomonas, Klebsiella and 
Staphylococcus (Wright and Matsen 1980, Ueda et al. 1983, Bodet et al. 1985, Takahata et 
al. 1986). Although 5-FU was shown to have substantial antibacterial effects, the tested 
concentrations in these studies were much higher than what is usually present in vivo. 
Notwithstanding the fact that after an intravenous bolus injection with 5-FU, plasma 
concentrations in cancer patients can reach some hundreds µM, the plasma levels eventually 
drop to 15-30 µM after 30 minutes and to 0 µM after 2 h (Casale et al. 2004, Kosovec et al. 
2008), due to the short half life time (6-22 min) of 5-FU (Bocci et al. 2000). In case of continuous 
infusion with 5-FU, the plasma concentrations are much lower, ranging from 3 to 10 µM and 
kept for a longer time period (24 h) (Joulia et al. 1999, Takimoto et al. 1999). Levels in saliva 
during this continuous infusion range between 0.08 and 0.8 µM (Joulia et al. 1999). It is 
therefore of interest to investigate the putative antimicrobial effect of physiologically relevant 
5-FU concentrations on commensal microorganisms in the context of oral mucositis.  
One of the main reasons for the short half life time of 5-FU is the presence of DPD in 
humans which breaks down 80 % of the 5-FU to dihydrofluorouracil in the liver (Diasio and 
Harris 1989). Patients with decreased DPD activity are more sensitive to 5-FU and are more 
likely to develop side effects, like mucositis, neurotoxicity and myelosuppression (Diasio et al. 
1988, Harris et al. 1991, Takimoto et al. 1996). Interestingly, also some microbial species 
possess DPD activity (Hidese et al. 2011), which might play a role in their sensitivity to 5-FU.  
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For this study, several representative species of the oral cavity were selected. 
S. salivarius, S. oralis and S. mitis were included since Streptococcus is the most dominant 
genus present in the oral cavity (Dewhirst et al. 2010). Also less abundant Lactobacillus 
species L. salivarius, L. oris and L. plantarum were included because of their ability to produce 
lactic acid (Marsh and Martin 1999). Fusobacterium nucleatum was included as it is important 
in biofilm formation in the oral cavity (Zijnge et al. 2010). Furthermore, the non-pathogenic 
Neisseria mucosa was included as it can cause bacteremia in neutropenic patients developing 
oral mucositis (Mechergui et al. 2014). As pathogens might play an important role in mucositis, 
we also included Streptococcus pyogenes, Pseudomonas aeruginosa and Klebsiella oxytoca. 
S. pyogenes is a common oral pathogen (Wescombe et al. 2012), whereas P. aeruginosa and 
Klebsiella were recorded in the oral cavity of chemotherapy-treated patients (Panghal et al. 
2012). Furthermore, oral mucositis has been associated with an increase in Klebsiella (Marsh 
and Martin 1999). In this study, the difference in sensitivity of different relevant oral species 
towards various 5-FU concentrations in the context of oral mucositis were studied. Also, the 
putative role of DPD in microbial resistance to 5-FU was evaluated. 
2. Materials and methods 
2.1 Chemicals 
A filter-sterilized stock solution of 100 mM 5-FU (Sigma Aldrich, Diegem, Belgium) was 
prepared in dimethyl sulfoxide (DMSO) and further diluted to 50, 25, 12.5, 6.3, 3.1, 1.6, 0.8, 
0.4, 0.2 and 0.1 mM. A filter-sterilized stock solution of 250 mM uracil (Sigma Aldrich, Diegem, 
Belgium) was prepared in DMSO and further diluted to 125, 100, 50, 32, 16, 12.8 and 6.4 mM. 
Stock solutions were further diluted (1:1000) in culture medium for the experiments. 
2.2 Microorganisms and culture conditions 
All monocultures were obtained from the Belgian Co-ordinated Collection of 
Micro-organisms/ LMG bacteria collection. Streptococcus oralis (LMG 14553), S. salivarius 
(LMG 11489), S. mitis (LMG 14557), S. pyogenes (LMG 15868) and Klebsiella oxytoca 
(LMG 3055) were cultured in Brain Heart Infusion (BHI) medium (Sigma Aldrich, Diegem, 
Belgium) at 37°C. Lactobacillus salivarius (LMG 9477), L. oris (LMG 9848) and L. plantarum 
(LMG 9211) were cultured in Man, Rogosa and Sharpe (MRS) medium (Oxoid, Aalst, Belgium) 
at 37°C. Neisseria mucosa (LMG 5136) was cultured in Heart Infusion medium (Sigma Aldrich, 
Diegem, Belgium) at 33°C. Pseudomonas aeruginosa (LMG 10639) in medium containing 
0.45 g/L KH2PO4 (Carl Roth, Karlsruhe, Germany), 2.39 g/L Na2HPO4.12H2O (Carl Roth, 
Karlsruhe, Germany), 1 g/L Lab-Lemco beef extract (Oxoid, Aalst, Belgium), 2 g/L yeast extract 
(Oxoid, Aalst, Belgium), 5 g/L peptone (Oxoid, Aalst, Belgium) and 5 g/L NaCl (Carl Roth, 
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Karlsruhe, Germany) at 37°C. Fusobacterium nucleatum (ATCC 10953) was cultured in 
anaerobic Brain Heart Infusion (BHI) medium (Sigma Aldrich, Diegem, Belgium) at 37°C. 
Except for Fusobacterium nucleatum, all strains were cultured under aerobic conditions. 
L. plantarum was cultured both aerobically and anaerobically. 
For the assays in anaerobic conditions, all manipulations and measurement of growth 
kinetics were performed in an anaerobic workstation (GP-Campus, Jacomex, TCPS NV, 
Rotselaar, Belgium) under a N2:CO2 (90:10, v/v) atmosphere. The preparation of anaerobic 
medium was done in Balch tubes (Glasgerätebau, Germany). 
Before the start of each experiment, fresh bacteria derived from a -80°C glycerol stock 
were plated onto an agar plate and incubated overnight. Next, one colony of each test species 
was transferred into 9 mL broth and incubated in static conditions overnight at their optimal 
growth temperature. Subsequently, cultures were transferred (10 % v/v) into fresh broth and 
allowed to grow for 20 h. Cultures were then diluted to 104 intact cells/mL in fresh medium, as 
measured by flow cytometry (BD Accuri C6, Becton, Dickinson and Company, Erembodegem, 
Belgium) according to Van Nevel et al. (2013) before the start of the experiment. 
2.3 Growth assays 
Continuous growth curves were generated in 96 well plates (transparent, flat bottom) 
(Cell Star, Greiner Bio One, Wemmel, Belgium). In each well, a microbial suspension of 200 µL 
of each species (104 cells/mL) was treated with different concentrations of 5-FU (0.1-50 µM) 
and allowed to grow in static conditions at the optimal growth temperature for each species. 
Growth was monitored spectrophotometrically (optical density at 620 nm) by means of a Tecan 
Sunrise platereader (Tecan, Männedorf, Switzerland) every 30 or 60 minutes over a period of 
18 to 75 h, depending on the strain. For experiments including uracil, the same experimental 
set-up was used, but growth was monitored by a Tecan Infinite M200 Pro (Tecan, Männedorf, 
Switzerland). By fitting the logistic growth model to the growth data, growth rate (µ) and 
maximal optical density (ODmax) were calculated using Grofit (version 1.1.1-1) in R (version 
3.0.2) (Kahm et al. 2010). The estimation and biological errors were propagated under the 
assumption of normal distributed and independent errors. Each condition was performed in 
triplicate or quadruplicate. 
2.4 Viability assays 
In each well of a 96 well plate, 200 µL of a diluted bacterial suspension (104 cells/mL) 
(see previous section) was treated with different concentrations of 5-FU (0.1-50 µM) for 24 h 
at the optimal growth temperature of each test species. After incubation, the number of intact 
and damaged cells was measured by flow cytometry as described by Van Nevel et al. (2013). 
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For this, the samples were diluted in a filter sterile phosphate buffered solution to obtain cell 
numbers within the detection range (104-106 cells/mL). Next, the samples were stained with 
SYBR Green I (10000x diluted from stock, Invitrogen) and propidium iodide (final concentration 
4 µM, Invitrogen) and incubated for 13 min at 37°C before measurement. SYBR Green 
penetrated all cells and resulted in a green fluorescence whereas propidium iodide penetrated 
only cells with a damaged cell membrane. Fluorescence resonance energy transfer (FRET) 
between propidium iodide and SYBR Green thus only occurred in damaged cells and 
generated a distinct, lower energy fluorescence signal for the damaged cells. The flow 
cytometer (BD Accuri C6 flow cytometer, BD, Erembodegem, Belgium) was equipped with a 
488 nm solid-state laser and Milli-Q was used as sheath fluid. Signals were detected in 
fluorescent channels FL1 (green) and FL3 (red), respectively equipped with a 518-548 nm and 
670 nm bandpass filter. Cell counts were done by measuring the number of particles in a set 
volume after gating on green vs. red fluorescence plots in the BD CSampler software. The 
gating made it possible to quantify both intact and damaged cells in each sample. We used 
the intact cell densities as an indicator for cell viability (Berney et al. 2007). Quality control of 
absolute cell counting was done with standardized beads. Background was monitored by 
measuring a filtered sample, equally diluted as the test samples. Each condition was 
performed in triplicate or quadruplicate. 
 
2.5 Statistical analysis 
Mixed-model regression of growth rate (µ), maximal OD and flow cytometer data (log 
cells/mL) were performed in the R (version 3.0.2) statistical environment with the concentration 
as categorical predictor. A random intercept effect was incorporated for each replicate 
measurement. In order to make correct statistical inference, all models were evaluated for 
normal distributed residuals with homogenous variance, by Shapiro Wilk test (p>0.05) and 
visually by Q-Q plots. Model parameters were estimated by maximum likelihood. When a 
significant concentration effect was present (ANOVA, p < 0.01), the categories were compared 
pair-wise by posthoc analysis using Tukey’s HSD method. All tested concentrations were 
compared with the control condition (0 µM) and differences were considered significant at 
p < 0.05. 
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3. Results 
3.1 Effect of 5-FU on growth of oral monocultures 
To investigate the effect of 5-FU on the growth of different oral monocultures, growth 
curves, based on optical density, were generated (see Supplementary Figure 2.1 and 
Supplementary Figure 2.2) and growth rates (µ) and maximal optical densities (ODmax) were 
calculated in presence or absence of different concentrations of 5-FU (0.1-50 µM). 5-FU had 
no or only a minor inhibitory effect on the growth of Lactobacillus salivarius, Streptococcus 
salivarius, Streptococcus mitis, Streptococcus oralis, Klebsiella oxytoca and Pseudomonas 
aeruginosa (Figure 2.1 and Supplementary Figure 2.1). S. salivarius and P. aeruginosa did not 
show a response in terms of ODmax. For S. salivarius, the growth rate decreased significantly 
at concentrations of 5-FU higher than 6.3 µM (48-81 %). For P. aeruginosa, a significant 
decrease in growth rates could be observed at 3.1 µM 5-FU (15-58 %). S. mitis and S. oralis 
showed only a significant decrease in ODmax (67 and 64 % respectively) at the highest tested 
concentration (50 µM 5-FU) and a decrease in growth rate starting from 6.3 µM (38-75 %) and 
12.5 µM (32-64 %), respectively. K. oxytoca showed a significant decrease in ODmax (30-35 %) 
for 12.5-50 µM; for growth rates only a significant decrease was seen at 6.3 µM (37 %) but not 
at higher concentrations. For L. salivarius there was distinct variability in the data, but a 
significant decrease in growth rate was seen at 6.3 µM 5-FU (75 %) and a decrease of 53-57 % 
(not significant) was seen at 12.5-25 µM 5-FU.  
Lactobacillus oris, Lactobacillus plantarum (aerobic/anaerobic), Streptococcus 
pyogenes, Fusobacterium nucleatum and Neisseria mucosa appeared to be more sensitive to 
5-FU (Figure 2.2 and Supplementary Figure 2.2). For L. oris a significant decrease in ODmax 
(22-32 %) was seen for concentrations ranging from 0.8 to 12.5 µM 5-FU, whereas at 50 µM 
no growth was detected. For L. plantarum (aerobic) only a significant decrease in growth rate 
was seen at concentrations higher than 3.1 µM (57-70 %), although decreases of 19-41 % 
(non-significant) were seen at 0.4 - 1.6 µM. L. plantarum (anaerobic) showed significant 
decrease for all tested concentrations (0.1 - 25 µM) for both growth rate as well as ODmax. No 
growth was detected for concentrations starting from 6.3 µM. S. pyogenes did not show a 
response in terms of ODmax, but a significant decrease in growth rate at concentrations higher 
than 0.4 µM 5-FU (33-72 %) was observed. For F. nucleatum a significant decrease in ODmax 
and growth rate was seen for 0.8 and 0.4 µM respectively and no growth was detected for 
concentrations higher than 1.6 µM 5-FU. For N. mucosa significant decreases in ODmax and 
growth rate were detected for concentrations higher than 0.8 and 0.2 µM respectively and no 





Figure 2.1 - 5-FU has only a minor negative effect on growth of K. oxytoca, S. salivarius, S. mitis, S. oralis, P. aeruginosa and L. salivarius.  
Maximal optical density (ODmax) and growth rate (µ), calculated from growth curves of oral monocultures treated with different concentrations of 5-FU (0.1-50 µM)  





Figure 2.2 - 5-FU has a major negative effect on the growth of L. oris, L. plantarum (aerobic/anaerobic), S. pyogenes, F. nucleatum and N. mucosa.  
Maximal optical density (ODmax) and growth rate (µ), calculated from growth curves of oral monocultures treated with different concentrations of 5-FU (0.1-50 µM)  
(AV ± SD;   = control condition (0 µM)). Significant deviations from the control condition (0 µM) are indicated by the asterisk (p<0.05). 
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3.2 Effect of 5-FU on viability of oral monocultures 
After 24 h of treatment, the monocultures were stained with SYBR Green/propidium 
iodide to evaluate the effect of different physiological concentrations of 5-FU on cell viability. 
This staining made it possible to quantify both intact and damaged cells in each sample. We 
used the intact cell densities as an indicator for cell viability (Berney et al. 2007).  
Since the number of damaged cells of all tested monocultures (except for L. salivarius) 
was lower than the background, these data were not presented in the graphs. Some species 
showed only a minor decrease in the number of viable cells (Figure 2.3). For K. oxytoca, 
S. salivarius, S. oralis and P. aeruginosa the amount of viable cells decreased with less than 
0.65, 1.19, 1.03, 0.65 log units respectively at a concentration range between 12.5-50 µM. 
Despite the high variability in the counts of S. mitis cells, numbers generally did not drop more 
than 2.4 log units or below the background value. The number of intact cells for L. salivarius 
decreased with 0.8 log units at 25 µM, coinciding with an increase of damaged cells with 1.6 
log units starting from 3.1 µM. 
 The most sensitive test species appeared to be F. nucleatum, L. oris, L. plantarum, 
N. mucosa and S. pyogenes (Figure 2.4). For L. oris and N. mucosa there was a decrease in 
viable cells above 1.6 µM and going below the background at 25 and 6.3 µM respectively. 
L. plantarum (aerobic/anaerobic), S. pyogenes, and F. nucleatum were even more sensitive 
and showed a decrease for concentrations higher than 0.2, 0.4, 0.4 and 0.4 µM 5-FU 
respectively and going below the background at 0.4, 0.8, 0.4 and 0.8 µM respectively. 
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Figure 2.3 - 5-FU has a minor effect on viable cell counts above 25 µM for K. oxytoca, S. salivarius, S. oralis, 
S. mitis, P. aeruginosa, whereas L. salivarius had more damaged cells after treatment with 3.1-50 µM 5-FU. 
Flow cytometric analysis of viability of oral monocultures treated with different concentrations of 5-FU     
(AV ± SD). Significant deviations from the control condition (0 µM) are indicated by the asterisks (p<0.05). 





Figure 2.4 - 5-FU causes a major decrease in viable cell counts starting from 0.4-1.6 µM for L. oris, L. 
plantarum (aerobic/anaerobic), S. pyogenes, F. nucleatum and N. mucosa. 
Flow cytometric analysis of viability of oral monocultures treated with different concentrations of 5-FU     
(AV ± SD). Significant deviations from the control condition (0 µM) are indicated by the asterisks (p<0.05). 
The background (dotted line) represents a filtered sample. 
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3.3 Effect of 5-FU on growth of oral monocultures in presence of uracil 
To investigate the role of DPD in the sensitivity response towards 5-FU, growth 
experiments were performed with two resistant species, namely Streptococcus salivarius and 
Pseudomonas aeruginosa in the presence and absence of uracil, an inhibitor of DPD. DPD is 
normally involved in the degradation of 5-FU into the non-toxic dihydrofluorouracil. 
Quantification of 5--FU and dihydrofluorouracil was not possible by HPLC analysis, due to high 
background (data not shown). Hence, we hypothesize that 5-FU resistant microorganisms 
might become more sensitive to 5-FU in the presence of uracil, a competitive substrate of DPD, 
provided that the activity of 5-FU is DPD-mediated. Therefore, growth curves were generated 
for 0 µM, 1.6 µM and 12.5 µM of 5-FU with or without uracil (5-FU:uracil ratio of 1:4) (similar 
results were obtained with a 1:10 ratio; data not shown). At 1.6 µM 5-FU, uracil did not 
modulate the resistance of both test species towards 5-FU (data not shown). Remarkably, at 
12.5 µM, uracil stimulated growth in the presence of 5-FU rejecting our hypothesis that DPD 
was involved in the microbial resistance towards 5-FU (Figure 2.5; p-values see 
Supplementary Table 2.1 and Supplementary Table 2.2). 
 
 
Figure 2.5 - At 12.5 µM, 5-FU had a small negative effect on the growth of P. aeruginosa and S. salivarius 
and by adding uracil, they both became a bit more resistant to 5-FU.  
Maximal optical density (ODmax) and growth rate (µ) calculated from growth curves of P. aeruginosa and S. 
salivarius treated with or without 5-FU (12.5 µM) and with or without uracil (50 µM) (AV ± SD). Relevant 




5-FU is one of the oldest chemotherapeutic agents and causes multiple side effects such 
as oral mucositis. It is known to have an antibacterial effect at high concentrations, but its effect 
at physiologically relevant concentrations is still underexplored. In this study, we show that at 
low concentrations (0.1-50 µM) there is a great variability in 5-FU sensitivity among oral 
microorganisms. The combination of growth and viability test results suggests that oral 
microorganisms can be divided in two sensitivity groups: the resistant microorganisms and the 
sensitive microorganisms. The first group consists of Klebsiella oxytoca, Streptococcus 
salivarius, Streptococcus mitis, Streptococcus oralis and Pseudomonas aeruginosa which only 
experience a minor decrease in growth and viability following exposure to high concentrations 
of 5-FU (12.5-50 µM). The second group comprises Lactobacillus oris, Lactobacillus plantarum 
(aerobic/anaerobic), Lactobacillus salivarius, Streptococcus pyogenes, Neisseria mucosa and 
Fusobacterium nucleatum which appear to be more sensitive to 5-FU with clearly negative 
effects on both growth and viability starting from 0.4-3.1 µM . One of the sensitive species is 
somewhat particular, namely L. salivarius for which there is a distinct increase in damaged 
cells at higher concentrations of 5-FU, measured by flow cytometry.  
Our finding of differential microbial sensitivity to 5-FU correlates with previous in vivo 
observations. In a rat mucositis study, Stringer et al. (2009c) identified Pseudomonas 
aeruginosa and Escherichia coli as 5-FU resistant species. Further, P. aeruginosa and E. coli 
were shown to be able to overgrow the oral community and penetrate into the damaged 
underlying mucosa thereby causing local infections (Stringer et al. 2009c). Another study with 
rats reported similar shifts, with Gram-negative rods becoming more abundant upon treatment 
with 5-FU (von Bultzingslowen et al. 2003). Also other chemotherapeutics have been shown 
to generate differential microbial response leading to infections as demonstrated for 
pathogenic Pseudomonas aeruginosa in leukemic patients (Goldschmidt and Bodey 1972). 
Therefore, microbial 5-FU resistance should be considered as an important risk factor for 
infections especially in the context of oral mucositis.  
Previous studies investigating the antibacterial properties of 5-FU primarily evaluated 
concentrations that are not representative of in vivo 5-FU concentrations during chemotherapy. 
Plasma concentrations after continuous infusion range from 0.1 to 8.8 µM, depending on the 
dose (300 – 2300 mg/m²/day) (Grem 2000). In the mouth, saliva levels during continuous 
infusion range from 0.08 to 0.8 µM (Joulia et al. 1999), hence significantly lower than what can 
be measured in plasma but still high enough to affect the most sensitive microorganisms in the 
mouth. Furthermore, plasma concentrations can reach much higher concentrations in DPD 
deficient patients due to the 10 times longer half life time of 5-FU (Saif et al. 2009).  
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In humans, DPD seems to play an important role in obtaining resistance to 5-FU since it 
can break down 5-FU to the non-toxic dihydrofluorouracil (Aziz et al. 2013). Literature data on 
microbial DPD is scarce, but the presence of DPD activity has previously been shown for 
Pseudomonas aeruginosa (Kim and West 1991) and Escherichia coli (West 1998). In our 
study, K. oxytoca, S. salivarius, S. mitis, S. oralis and P. aeruginosa were shown to be 5-FU 
resistant. However, a search of the NCBI protein database on all tested microorganisms, 
indicated that theoretically only P. aeruginosa and L. oris contain a DPD enzyme. Hence, no 
clear link between microbial DPD and 5-FU sensitivity could be identified. In clinical settings a 
combination of 5-FU and uracil, an inhibitor of DPD, is used to improve the efficiency of 5-FU. 
Uracil competitively binds to DPD, reducing the degradation of 5-FU to dihydrofluorouracil 
(Takechi et al. 1997, Omura 2003). In our study, we applied the same principle to test if 
microbial 5-FU sensitivity is dependent on the presence of DPD in resistant microorganisms, 
Yet our results suggest that DPD is not a key-enzyme. 
Many other enzymes have been reported to be involved in the pharmacokinetics of 5-FU, 
including thymidylate synthase (TS). TS provides the sole de novo production of thymidylate 
and is inhibited by 5-FU (Longley et al. 2003). In cell lines a positive relationship exists between 
the DPD and TS levels and 5-FU sensitivity (Beck et al. 1994). In C. elegans, overexpression 
of TS and DPD leads to a higher survival after treatment with 5-FU (Kim et al. 2008). Also in 
humans, overproduction of TS results in 5-FU resistance (Clark et al. 1987, Johnston et al. 
1995). Interestingly, a search for TS presence in the NCBI protein database in our study 
showed hits for all tested species. Therefore, TS and other enzymes might play a role in 5-FU 
resistance. At least for the treatment of colorectal cancer patients, the analysis of three 
predictive markers (TS, DPD and thymidine phosphorylase (TP)) is used to predict 5-FU 
efficacy (Salonga et al. 2000). 
In conclusion, our study shows that 5-FU sensitivity varies among different oral 
microorganisms and that 2 clear groups can be distinguished: resistant and sensitive 
microorganisms. Some species such as L. oris, L. plantarum, L. salivarius, S. pyogenes, 
N. mucosa and F. nucleatum are sensitive at concentrations as low as 0.4 µM, which can be 
measured in blood and saliva during continuous 5-FU treatment. We also provided evidence 
that the DPD enzyme is probably not responsible for microbial resistance to 5-FU. Our data 
further indicate that oral mucositis patients are likely to develop infections caused by an 
overgrowth of 5-FU resistant strains such as the multi-drug resistant P. aeruginosa and 
dysbiosis of the mucosa. To get a complete picture of the impact of 5-FU on the oral 
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6. Supplementary information 
 
Supplementary Figure 2.1 - Growth curves of Klebsiella oxytoca, Streptococcus salivarius, Streptococcus 
mitis, Streptococcus oralis, Pseudomonas aeruginosa and Lactobacillus salivarius treated with different 
concentrations of 5-FU.  
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Supplementary Figure 2.2 - Growth curves of Lactobacillus oris, Lactobacillus plantarum 
(aerobic/anaerobic), Streptococcus pyogenes, Fusobacterium nucleatum and Neissera mucosa treated 




Supplementary Table 2.1 - P-values of maximal optical density (ODmax) and growth rate (µ) calculated from 
growth curves of P. aeruginosa treated with or without 5-FU (12.5 µM) and with or without uracil (50 µM). 
 
P. aeruginosa - 5-FU + 5-FU 
ODmax µ -uracil + uracil -uracil + uracil 
- 5-FU 
- Uracil / <1e-04 <1e-04 <1e-04 
+ uracil 1 / <1e-04 <1e-04 
+ 5-FU 
- Uracil <0,001 <0,001 / <1e-04 
+ uracil 0,406 0,385 <0,001 / 
 
 
Supplementary Table 2.2 - P-values of maximal optical density (ODmax) and growth rate (µ) calculated from 
growth curves of S. salivarius treated with or without 5-FU (12.5 µM) and with or without uracil (50 µM). 
 
S. salivarius - 5-FU + 5-FU 
ODmax µ -uracil + uracil -uracil + uracil 
- 5-FU 
- Uracil / 0,460 <1e-4 0,974 
+ uracil 0,001 / <1e-4 0,233 
+ 5-FU 
- Uracil <1e-4 <1e-4 / <1e-4 










5-Fluorouracil and irinotecan (SN-38)  
have limited impact on colon microbial 

















This chapter has been redrafted after 
Vanlancker, E., Vanhoecke, B., Stringer, A. and Van de Wiele, T. 5-Fluorouracil and 
irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro. 





Gastrointestinal mucositis is a debilitating side effect of chemotherapy, with currently no 
treatment available. As changes in microbial composition have been reported upon 
chemotherapeutic treatment in vivo, it is thought that gut microbiota contribute to the mucositis 
etiology. Yet, it is not known whether chemotherapeutics directly cause microbial dysbiosis, 
thereby increasing mucositis risk, or whether the chemotherapeutic subjected host 
environment disturbs the microbiome thereby aggravating the disease. To address this 
question, we used the M-SHIME®, an in vitro mucosal simulator of the human intestinal 
microbial ecosystem, as an experimental setup that excludes the host factor. The direct impact 
of two chemotherapeutics, 5-fluorouracil (5-FU) and irinotecan, on the luminal and mucosal 
gut microbiota from several human donors were investigated through monitoring fermentation 
activity and next generation sequencing. At a dose of 10 µM in the mucosal environment, 5-FU 
impacted the functionality and composition of the colon microbiota to a minor extent. Similarly, 
a daily dose of 10 µM SN-38 in the luminal environment did not cause significant changes in 
the functionality or microbiome composition. As our mucosal model does not include a host 
compartment, we conclude that a putative microbial contribution to mucositis is initially 
triggered by an altered host environment upon chemotherapy.  
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1. Introduction 
5-Fluorouracil (5-FU) and irinotecan (SN-38) are two commonly used chemotherapeutic 
agents for cancer treatment. A major side effect of these agents is gastrointestinal mucositis, 
an inflammation and ulceration of the gastrointestinal mucosa and mostly diagnosed based on 
the occurrence of diarrhea (Benson et al. 2004, Peterson et al. 2015). The incidence of 
chemotherapy-induced diarrhea associated with 5-FU or irinotecan treatment varies around 
50-80 % (Benson et al. 2004). Treatment of colon cancer with FOLFOX (5-FU, leucovorin, and 
oxaliplatin) or FOLFIRI (5-FU, leucovorin and irinotecan) or IROX (Irinotecan and oxaliplatin) 
results in a risk for grade 3 or 4 diarrhea (severe diarrhea requiring hospitalization or having 
life-threatening consequences, according to the National Cancer Institute Common 
Terminology Criteria of Adverse Events (NCI CTCAE) classification) of 10 %, 10 % and 24 %, 
respectively (Keefe et al. 2007). While gastrointestinal mucositis often causes cessation of the 
cancer treatment and a lot of discomfort for the patient, no effective treatment is available yet. 
The MASCC/ISOO has put an effort in formulating guidelines and recommendations on how 
to prevent and treat gastrointestinal mucositis, such as by the use of octreotide for the 
treatment of diarrhea associated with HSCT (Lalla et al. 2014). 
In research on the pathobiology of mucositis more and more interest is going to the role 
and/or the effect of the gut microbiota during chemotherapeutic treatment (van Vliet et al. 2010, 
Stringer 2013). Microbiota have an important function in many pathways some of which are 
also involved in the development of gastrointestinal mucositis. For example, microbiota 
influence intestinal permeability and thickness of the mucus layer, both important in barrier 
function during mucositis (van Vliet et al. 2010, Touchefeu et al. 2014). Next, recognition of 
microbial antigens to TLR can activate the NF-κB pathway, resulting in production of 
pro-inflammatory cytokines that are crucial in the mucositis pathobiology (van Vliet et al. 2010, 
Touchefeu et al. 2014, Vanhoecke and Stringer 2015). Under healthy conditions commensal 
microorganisms are thought to live in a homeostatic relationship with the host providing a low 
grade immune activation and stimulating epithelial repair in an NF-κB dependent pathway (van 
Vliet et al. 2010, Touchefeu et al. 2014). But during cancer treatment, changes at the level of 
the host and/or microbiome may disturb this homeostatic relationship and increase the 
inflammatory status.  
Animal and human studies have repeatedly shown that chemotherapeutics can change 
the gut microbiota (Stringer 2013, Touchefeu et al. 2014). In rat models, both 5-FU (von 
Bultzingslowen et al. 2003, Stringer et al. 2009c) and irinotecan (Stringer et al. 2007, Stringer 
et al. 2008, Stringer et al. 2009a, Lin et al. 2012) modified the gut microbiome, with a decrease 
in commensal microbiota and increases in Escherichia spp., Clostridium spp. and 
Enterococcus spp. Clinical studies report on shifts of fecal microbiota upon chemotherapeutic 
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treatment (Touchefeu et al. 2014), with a lower diversity and abundance of microbiota 
observed after chemotherapy. Most frequent changes are decreases in Bifidobacterium, 
Faecalibacterium and Clostridium cluster XIVa and increases in Bacteroides and Escherichia 
(van Vliet et al. 2009, Zwielehner et al. 2011, Stringer et al. 2013, Montassier et al. 2014). Yet, 
besides impacting the microbiota, chemotherapeutics also affect the mucus layer and the 
number of goblet cells which is likely the result of an increase in pro-inflammatory cytokine 
levels and leading to an altered mucosal barrier (Stringer 2013).  
To further unravel the role of microbiota in gastrointestinal mucositis, it is important to 
understand the direct impact of chemotherapeutics on the functionality and composition of the 
gut microbiome. While animal and human studies do not allow to distinguish between host and 
microbiome effects, the goal of the present study was to investigate the direct effect of two 
chemotherapeutics, 5-FU and SN-38, on the gut microbiome. Therefore we used an in vitro 
model that was proven to be representative for the human colon microbiome: the M-SHIME® 
model (Mucosal-Simulator of the Human Intestinal Microbial Ecosystem) (Van den Abbeele et 
al. 2012).  
2. Materials and methods 
2.1 Chemicals 
A filter-sterilized stock solution of 10 mM 5-FU (Sigma Aldrich, Diegem, Belgium) was 
prepared in DMSO. The stock solution was further diluted (1:1000) in the mucus solution to a 
final concentration of 10 µM. 
A filter-sterilized stock solution of 10 mM SN-38 (Sigma Aldrich, Diegem, Belgium) was 
prepared in DMSO. The stock solution was further diluted (1:1000) in the medium to a final 
concentration of 10 µM. 
2.2 M-SHIME 
2.2.1 Experimental set-up 
The M-SHIME® (Mucosal-Simulator of the Human Intestinal Microbial Ecosystem, joint 
registered name from Ghent University and ProDigest) is an in vitro dynamic model for the 
human intestinal tract, incorporating both luminal and mucosal colon environment, resulting in 
distinct luminal and mucosal microbial populations (Van den Abbeele et al. 2012). The set-up 
used in this study consisted of a stomach/small intestine vessel and two proximal colon vessels 
(control and treatment) for six human donors in parallel (Figure 3.1).  
Fecal samples were collected and prepared within 1 h according to standard procedures 
(Molly et al. 1993). In short, aliquots (20 g) of fresh fecal samples were diluted and 
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homogenized with 100 mL 0.1 M phosphate buffer (8.8 g/L K2HPO4. and 6.8 g/L KH2PO4., pH 
6.8) containing 1 g/L sodium thioglycolate as reducing agent. After removal of the particulate 
material by centrifugation (2 min, 500 g), each colon vessel was inoculated with 40 mL of the 
fecal suspension. 
The double-jacketed vessels were kept at 37°C and flushed daily with N2 (5 min) to 
assure anaerobic conditions. All colon compartments (500 mL) were stirred (200 rpm) and 
pH-controlled (pH 5.6-5.9). Mucosal conditions were created as described by Van den Abbeele 
et al. (2012). Briefly, 80 mucin-agar covered microcosms (AnoxKaldnes K1 carrier; 
AnoxKaldnes AB, Lund, Sweden) were brought in a polyethylene netting (Zakkencentrale, 
Rotterdam, the Netherlands) (Van den Abbeele et al. 2012). Half of the microcosms were 
replaced every other day with fresh sterile ones under a flow of N2 to maintain anaerobic 
conditions. After washing the beads twice with phosphate buffered solution (PBS) to discard 
luminal microbiota, samples of the mucin-agar were taken and stored at -20°C. 
After an initial incubation of 16 h, pumps were switched on in order to supply each colon 
compartment with 140 mL nutritional medium and 60 mL pancreatic juice three times a day. 
The nutritional medium contained (in g/L) yeast extract (3.0), special peptone (1.0), mucin 
(2.0), arabinogalactan (0.25), pectin from apple (0.5), xylan (0.25), potato starch (1.0). The 
pancreatic juice was prepared as described earlier by Van den Abbeele et al. (2012). The 
treatment started after two days of stabilization.  
Microbial fermentation activity of the proximal colon (SCFA production) and community 
composition (ratio Firmicutes/Bacteroidetes/Proteobacteria, Supplementary Table 3.1 and 
Supplementary Table 3.2) was shown to be consistent with that of previous SHIME runs (Molly 
et al. 1994, Geirnaert et al. 2015). 
2.2.2 Experimental design M-SHIME with 5-FU 
In this set-up we compared a challenge of the in vitro cultured human microbiota with 
5-FU to a control situation (Figure 3.1A). As 5-FU is intravenously supplemented to the patient 
and reaches the gut through the mucus layer, we chose to dose 5-FU directly in the mucus-
covered microcosms. Taking into account pharmacokinetics during continuous infusion with 
5-FU, a representative serum concentration range of 5-FU in vivo is 3-10 µM. We chose the 
highest concentration to evaluate the effect to mucosal 5-FU towards the gut microbiome. 
DMSO was used as a negative control. On day 0, 2 and 4, half of the mucin-covered 
microcosms were replaced with new treated ones. Therefore, three doses of 5-FU were given 
in total. To cover biological reproducibility, we compared six different donors, all healthy 
volunteers who had no history of antibiotic treatment up to 6 months prior to the study (Ethical 
approval from Ghent University hospital, Belgian Registration number BE 6700201214538). 
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Luminal samples were taken every 24 h and mucosal samples every 48 h (on day 2, 4 and 6). 
For donor 1 and 2, additional luminal samples were taken 6 h after each treatment. 
2.2.3 Experimental design M-SHIME with SN-38 
In this set-up we compared a challenge of the in vitro cultured human microbiota with 
SN-38 to a control situation (Figure 3.1B). As SN-38 enters the small intestine via the bile, the 
treatment was added daily to the luminal environment, just before the feed entered the colon 
compartments. As an average colon concentration was estimated on 1- 2 µM, based of fecal 
concentrations of SN-38, a concentration of 10 µM was used to make sure testing the highest 
physiological relevant concentration. The M-SHIME system was treated with SN-38 for 6 
consecutive days. DMSO without SN-38 was used as a negative control. On day 0, 2 and 4, 
half of the mucin-covered microcosms were replaced with new ones (non-treated). To cover 
biological reproducibility, we compared five different donors (healthy volunteers) who had no 
history of antibiotic treatment up to 6 months prior to the study (Ethical approval from Ghent 
University hospital, Belgian Registration number BE 6700201214538). Both luminal and 
mucosal samples were taken every 48 h.  
2.3 Short chain fatty acids (SCFA) 
Luminal samples were diluted 1:2 to a total volume of 2 mL and the SCFA were extracted 
with diethyl ether and analyzed using a gas chromatograph as described by De Weirdt et al. 
(2010). The concentration of acetate, propionate, butyrate, isobutyrate, valerate, isovalerate, 
caproate and isocaproate was determined in each sample and the total amount of SCFA was 
calculated as the sum of all. The relative concentration of each SCFA was expressed as mol % 
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Figure 3.1 - Experimental set-up of A) M-SHIME with 5-FU and B) M-SHIME with SN-38. Arrows indicate the 
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2.4 DNA extraction 
Total DNA was extracted from the pellet of 1 mL liquid samples or 0.25 g mucin-agar 
according to a protocol adapted from Vilchez-Vargas et al. (2013). Cells were lysed with 1 mL 
lysis buffer (100 mM Tris/HCl pH 8.0, 100 mM EDTA pH 8, 100 mM NaCl, 1 % (m/v) 
polyvinylpyrrolidone and 2 % (m/v) sodium dodecyl sulphate) and 200 mg glass beads 
(0.11 mm, Sartorius) in a FastPrep® 96 instrument (MP Biomedicals, Santa Ana, USA) for two 
times 40 s (1600 rpm). Following removal of glass beads by centrifugation (5 min at maximum 
speed), DNA was extracted from supernatant using a phenol–chloroform extraction. The DNA 
was precipitated at -20°C with 1 volume of ice-cold isopropyl alcohol and 0.1 volume of 3 M 
sodium acetate for at least 1 h. After removal of isopropyl alcohol by centrifugation (30 min, 
maximum speed), the DNA pellet was dried and resuspended in 100 µL 1x TE (10 mM Tris, 
1 mM EDTA) buffer. The DNA samples were immediately stored at −20°C until further analysis. 
The quality of DNA samples was analyzed by gel electrophoresis (1.2 % (w/v) agarose) (Life 
technologies, Madrid, Spain). The DNA samples were diluted (1:10) for further analysis. 
2.5 Microbial community analysis 
2.5.1 Denaturing Gradient Gel Electrophoresis (DGGE) 
The 16S rRNA gene region was amplified by means of PCR using the PRBA 338F-GC 
and 518R primers targeting the V3 region (Muyzer et al. 1993, Ovreas et al. 1997). The PCR 
program consisted of 10 min 95°C; 30 cycles of 1 min 94°C, 1 min of 53°C, 2 min of 72°C; and 
a final elongation for 10 min at 72°C. Amplification products were analyzed by gel 
electrophoresis (1.2 % (w/v) agarose). The DGGE was performed using the INGENY phorU 
System (Ingeny International BV, The Netherlands), based on the protocol of Muyzer et al. 
(1993). The PCR fragments were mixed with loading buffer (5:1) before loading onto 8 % (w/v) 
polyacrylamide gels with denaturing gradients ranging from 45 % to 60 % (where 100 % 
denaturant contains 7 M urea and 40 % formamide). The electrophoresis was run for 16 hours 
at 60°C and 120 V. Staining and analysis of the gels was performed as described previously 
(Boon et al. 2000). To process and compare the different gels, a homemade marker of different 
PCR fragments was loaded on each gel (Boon et al. 2002). The normalization and analysis of 
the DGGE gel patterns was carried out with the BioNumerics software 5.10 (Applied Maths, 
Sint-Martens-Latem, Belgium). The calculation of the similarity matrix was based on the 
Pearson correlation coefficient, and clustering was performed with the unweighted pair-group 
average method algorithm (UPMA). 
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2.5.2 16S rRNA gene Illumina MiSeq sequencing 
Illumina amplicon sequencing was performed by LGC Genomics (Berlin, Germany) on 
the MiSeq platform. The V3-V4 region of the 16S rRNA gene was amplified using primers 
derived from Klindworth et al. (2013): 341F (NNNNNNNNNTCCTACGGGNGGCWGCAG) and 
785R (NNNNNNNNNNTGACTACHVGGGTATCTAAKCC). The PCR mix included 1 µl of DNA 
extract, 15 pmol of both the forward and reverse primer in 20 µL of MyTaq buffer containing 
1.5 units MyTaq DNA polymerase (Bioline) and 2 µl of BioStabII PCR Enhancer (Sigma). For 
each sample, the forward and reverse primers had the same unique 10-nt barcode sequence. 
The PCR program consisted of 2 min 96°C predenaturation and 20 cycli of 96°C for 15 s, 50°C 
for 30 s, 70°C for 90 s. Next, ∼20 ng amplicon DNA of each sample was pooled for up to 48 
samples carrying different barcodes. The amplicon pools were purified with one volume 
AMPure XP beads (Agencourt) to remove primer dimer and other small mispriming products, 
followed by an additional purification on MinElute columns (Qiagen). Finally, about 100 ng of 
each purified amplicon pool DNA was used to construct Illumina libraries by means of adaptor 
ligation using the Ovation Rapid DR Multiplex System 1-96 (NuGEN). Illumina libraries were 
pooled and size selected by preparative gel electrophoresis. Sequencing was done on an 
Illumina MiSeq using v3 Chemistry (Illumina). To assess the sequencing quality a mock 
community was included in triplicate in the sequencing run (error rate = 0.183 %).  
The Mothur software package (v.1.33.3), and guidelines developed by Schloss et al. 
(2011) were used to process Illumina data. Forward and reverse reads were assembled into 
contigs and ambiguous contigs or contigs with divergent lengths were removed. The number 
of unique sequences was determined and these were aligned to the Mothur-reconstructed 
SILVA Seed alignment (v123). Sequences not aligning within the region targeted by the primer 
set or sequences with homopolymer stretches with a length higher than 12 were removed. 
Sequences were pre-clustered together within a distance of 1 nucleotide per 100 nucleotides. 
These cleaned-up and preclustered sequences were checked for Chimera's (with 
Uchime)(Edgar et al. 2011). The sequences were classified using RDP (Ribosomal Database 
Project) release 14 and a naive Bayesian classifier (Wang's algorithm). All sequences that 
were classified as Eukaryota, Archaea, Chloroplasts and Mitochondria were removed. If 
sequences could not be classified at all (even not at (super)Kingdom level) they were removed. 
The operational taxonomic units (OTUs) were clustered with an average linkage and at the 
97 % sequence identity. Samples with less than 1000 reads per sample were not used for 
further analysis. 
The sequences reported in this paper have been deposited in the European Nucleotide 





Studying the microbial community composition  
Multiple diversity parameters can be used to describe a microbial community. These 
parameters can be calculated based on DGGE or Illumina amplicon sequencing data. Two 
main levels of diversity can be considered: α-diversity and β-diversity  (Whittaker 1972).  
α-diversity  
The α-diversity is a measure for the diversity within one sample and multiple 
parameters can be used to quantify this α-diversity (Marzorati et al. 2008). Richness is a 
measure for the number of species present in a sample. For DGGE, the species richness 
corresponds with the number of bands. For amplicon sequencing, the species richness 
corresponds with the number of OTUs. Evenness is a measure for community organization. It 
is based on the difference in relative abundance of different species. Perfect evenness is 
defined as a community for which all species are present at the same abundance. Evenness 
can be quantified by the Gini coefficient, which is the surface between the Lorenz curve and 
the perfect evenness line (Box Figure 1) and can have values between 0 and 1. High Gini 
coefficients correspond to uneven communities and low Gini coefficients to even communities. 
 
Box Figure 1: The Gini coefficient is a measure for the evenness of a community. The higher the Gini 
coefficient, the lower the evenness.  
A more uniform way to describe diversity, is by using the Hill numbers (Hill 1973). Each 
Hill number represents a different level of diversity. Hill number order 0 (H0) is the richness of 
a sample, i.e. the number of OTUs in a sample. Hill number order 1 (H1) is the exponential of 
the Shannon index and takes not only into account richness, but also evenness. Hill number 
order 2 (H2) is the inverse of the Simpson index and takes into account evenness to an even 
higher degree.  
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β-diversity  
The β-diversity is a measure for the diversity between different samples. Different 
distance matrices can be used to assess the β-diversity, such as Pearson correlation 
coefficient and Bray-Curtis dissimilarities. Based on these distance matrices, clustering of the 
samples can be done to check which samples are more similar to each other, for example via 
unweighted pair-group average method algorithm (UPMA) for DGGE data. Ordination plots 
can be used to visualize the similarities between samples in a 2D plot, based on the distance 
matrix. Non-metric Multidimensional Scaling (NMDS) is a non-parametric ordination method 
for which the visualization is optimized by reducing the ‘stress’, which represents the difference 
between the visualization and the actual distance matrix. However, statistical significance of 
differences between two groups is based on the complete distance matrix and can be 
determined by for example by Permutational ANOVA (PERMANOVA). To quantify the 
community variation, the distance to the centroid (= mean of a group) can be calculated for 
each sample based on the distance matrix. This is a measure for the within-group dispersion 
i.e. how variable samples are within a certain group. 
2.6 Statistical analysis 
All statistical analyses were performed in R (version 3.3.2).  
Statistical inference on the 5-FU and SN-38 treatment effect on the SCFA concentration 
was performed by spline regression. Natural splines were fitted for each group (control and 
treatment) to the scaled and centered temporal data because these provide more stable 
estimates at the boundary time points (James et al. 2014). Knots were fixed at the 33.3 % and 
66.6 % quantiles. Model parameter estimation was performed by the ordinary least squares 
method, resulting in model residuals that were normal distributed and did not exhibit temporal 
autocorrelation. Due to the presence of moderate heteroscedasticity in the model residuals, 
robust White heteroscedasticity-consistent standard errors (vcovHC function, sandwich v2.3-4 
package) were used in the statistical inference on the treatment effect (type II ANOVA).  
The packages phyloseq (McMurdie and Holmes 2013) and vegan (Oksanen 2016) were 
used for microbial community analysis. Heatmaps were generated with the pheatmap package 
and order-based Hill’s numbers (Hill 1973) were calculated. If the data were normally 
distributed (tested with Shapiro-Wilk test) and homoscedastic (tested with Levene test), 
differences in Hill’s numbers were defined via ANOVA and Tukey as post-hoc test; if not, 
Kruskall Wallis test with Tukey post-hoc testing was used. Non-metric multidimensional scaling 
(NMDS) plots of the bacterial community data were created based on the Bray-Curtis distance 
measures. Significant differences were identified by means of Permutational ANOVA 




3.1 Effect of 5-FU on the metabolic activity in the gut 
The effect of 5-FU (at 10 µM in the mucosal environment) on the gut microbiome of 
6 healthy donors was investigated using a M-SHIME® harboring both luminal and mucosal 
microbiota (Figure 3.1A). SCFA analysis showed interindividual differences and the total 
luminal SCFA concentration before the first treatment ranged from 25.5 µM to 39.5 µM 
between the six donors. Overall, there is no significant difference between treatment with 5-FU 
and control behavior through time (p=0.18). Although, for donor 1 and donor 2, total SCFA 
concentrations started increasing after the second 5-FU treatment, compared with the control, 
with a final increase of 113 % and 76 % respectively at day 6 (Figure 3.2). The same trends 
(i.e., an increase for donor 1 and 2 and no effect for all other donors), were observed for the 
total mucosal SCFA concentration (Supplementary Figure 3.1). Further, 5-FU did not have any 
effect on the relative proportions of acetate, propionate, butyrate or branched SCFA 
(Supplementary Figure 3.2). For donor 1 and 2, the experimental set-up also allowed the 
inclusion of a distal colon region (pH 6.6-6.9). However, we observed no effect of 5-FU on the 
SCFA production (Supplementary Figure 3.3) 
3.2 Effect of 5-FU on the gut microbial profile 
To investigate the effect of 5-FU on the composition of both luminal and mucosal 
microbiota, both DGGE and Illumina sequencing of the 16S rRNA gene were performed for all 
samples at day 0 and day 6.  
Clustering analysis of DGGE profiles showed prominent interindividual variability, but no 
significant impact of 5-FU treatment. Even after 6 days of treatment, profiles still clustered 
together for each donor with similarities between control and treatment ranging from 79-98 % 
for luminal samples and 93 % to 99 % for mucosal samples, except for donor 2 who had only 
70 % similarities. Hence, there was no clear shift in the microbial profile for all donors, only 
minor differences between control and 5-FU treated samples could be observed 
(Supplementary Figure 3.4). 
Illumina sequencing showed that all samples were dominated by Proteobacteria, 
Bacteroidetes and Firmicutes. At the genus level, Escherichia/Shigella, Bacteroides, 
Veillonella and Clostridium cluster XIVa were most abundant (Figure 3.3 and Supplementary 
Figure 3.5). Also NMDS plots showed no significant difference between control and 5-FU 
treatment (p=0.75) and treatment condition only explained 2.7 % of the variation of the 
microbiome after treatment (based on Bray–Curtis dissimilarities on OTU level) (Figure 3.4A). 
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For all samples, donor individuals and sampling time point explained most of the variation, 
respectively 38.9 % and 14.8 % (p=0.0001 and p=0.0001) (Table 3.1). 
At the genus level, the 5-FU treatment showed a trend in increased relative abundance 
of Bacteroides from 24.4 ± 13.2 % to 41.1 ± 11.6 % (p=0.065) and decreased abundance of 
Escherichia/Shigella from 19.7 ± 17.1 % to 8.9 ± 7.2 % (p= 0.23) in the lumen for 5 out of 6 
donors. In the mucus fraction, these shifts could not be observed. In contrast, 5-FU did not 
influence the diversity in the lumen at the end of treatment, but did increase the diversity (first 
and second order Hill numbers) in the mucus (p=0.010 and p=0.055 respectively), indicating 
a higher evenness and diversity (Supplementary Figure 3.6). In general, mucus samples had 
a higher diversity than luminal samples (p-values for Hill numbers: p=0.058, p=0.0032 and 
p=0.0039) (Supplementary Figure 3.6). Only for donor 2, a changed mucus bacterial profile 
was observed, with increases in Anaeroglobus, Roseburia and Parabacteroides (Figure 3.3 
and Supplementary Figure 3.5).  
 
Figure 3.2 - At 10 µM in the mucosal environment of the M-SHIME, 5-FU increases luminal total short chain 





Figure 3.3 - Heatmap representing the most abundant genera (at least 0.1 % on average) showed no clear 
effect of treatment with 5-FU on the gut microbial composition of 6 healthy donors (D1-D6). 
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Figure 3.4 - NMDS plots based on Bray Curtis dissimilarities of Illumina sequencing data at day 6 (after 
treatment) showed large interindividual variability, but no clear effect of the treatment with A) 5-FU or B) 
SN-38. 
 
Table 3.1 - p-values and R² for different confounding factors based on Bray Curtis dissimilarities of the 
Illumina sequencing data (significant values are indicated in italic). 





p-value 0.0001 0.0001 0.0071 0.90 
R² 38.9 % 14.8 % 5.2 % 1.2 % 
Day 0 
p-value 0.0001 NA 0.033 0.96 
R² 63.8 % NA 8.7 % 1.8 % 
Day 6 
p-value 0.0001 NA 0.16 0.75 
R² 70.1 % NA 6.5 % 2.7 % 






p-value 0.0097 0.0001 0.0014 0.72 
R² 17.7 % 30.3 % 9.0 % 1.4 % 
Day 0 
 
p-value 0.0001 NA 0.0028 0.77 
R² 54.2 % NA 13.7 % 2.7 % 
Day 6 
 
p-value 0.0001 NA 0.0001 0.31 
R² 44.3 % NA 24.0 % 5.1 % 
 
3.3 Effect of SN-38 on the metabolic activity in the gut 
The effect of SN-38 (the active metabolite of irinotecan) (at 10 µM in the luminal 
environment) on the gut microbiome of 5 healthy donors was investigated using a M-SHIME 
with proximal colon vessels (Figure 3.1B). Interindividual differences in the total luminal SCFA 
concentration before the first treatment ranged from 18.3 µM to 45.9 µM between the five 
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donors. Overall, there is no significant difference between treatment with SN-38 and control 
behavior through time (p=0.85) (Figure 3.5). A similar trend (no effect of SN-38) was observed 
for the total mucosal SCFA concentrations (Supplementary Figure 3.8). Also for the relative 
luminal concentrations of acetate, propionate, butyrate and branched SCFA, no impact of 
SN-38 was detected (Supplementary Figure 3.9). For donor 1 (in duplicate), the experimental 
set-up allowed the inclusion of a distal colon region (pH 6.6-6.9). However, we observed no 
effect of SN-38 had on the SCFA levels of the distal colon microbiota (Supplementary Figure 
3.10). Similarly, the experimental set-up also allowed running a luminal-SHIME system 
(without mucus compartment). However, again no effect on SCFA production was observed, 
excluding the fact that the mucus layer protects the microbiota against the SN-38 
(Supplementary Figure 3.11). 
 
 
Figure 3.5 - At 10 µM in the luminal part of the M-SHIME, irinotecan (SN-38) has no effect on luminal total 
short chain fatty acid concentrations. Arrows indicate the time of dosing. 
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3.4 Effect of SN-38 on the gut microbial profile 
To investigate the effect of SN-38 on the composition of both luminal and mucosal 
microbiota, DGGE and Illumina sequencing of the 16S rRNA gene were performed for all 
samples at day 0 and day 6.  
Clustering analysis of DGGE profiles showed large interindividual variability, but no effect 
of SN-38 treatment was observed. After 6 days of treatment microbial profiles still clustered 
together for each donor with similarities ranging from 94 to 98 % for luminal samples (even 
higher than at the start) and 68 to 92 % for mucosal samples. There were no clear shifts in the 
microbial profile of all 5 donors and only minor differences between control and SN-38 treated 
samples could be observed (Supplementary Figure 3.12).  
Illumina sequencing showed that all samples were dominated by Proteobacteria, 
Bacteroidetes and Firmicutes. At the genus level, Escherichia/Shigella, Bacteroides, 
Veillonella and Clostridium cluster XIVa were most abundant (Figure 3.6 and Supplementary 
Figure 3.13). The NMDS plots demonstrated no significant difference between control and 
SN-38 treatment (p=0.31) and the treatment condition only explained 5.1 % of the variation of 
the microbiome after treatment (based on Bray-Curtis dissimilarities on OTU level) (Figure 
3.4B). For all samples, donor individuals and sampling time point explained most of the 
variation, respectively 17.7 % and 30.3 % (p= 0.0097 and p=0.0001) (Table 3.1). 
No effect of SN-38 on specific genera or diversity indices were noticed for all donors, but 
some donor-specific changes of relative abundances of some genera could be observed. For 
donor 2 and 3, an increase in Cloacibacillus was observed (from respectively 1.4 to 14.6 % 
and 0 to 22.4 %) in presence of SN-38 in the lumen, compared with the control. For donor 3 
and donor 5, Alistipes increased in the lumen in presence of SN-38 compared with the control 
(from 0.4 to 9.4 % and 0.09 to 7.8 % respectively). In the mucus, an increase in Roseburia for 
donor 1 (in duplicate) and donor 2 was observed in presence of SN-38 compared with the 
control (from 9.9 to 24.9 %, 2.4 to 25.1 % and 2.1 to 18.5 % respectively) (Figure 3.6 and 
Supplementary Figure 3.13). Similar to 5-FU, mucosal samples showed a higher evenness 




Figure 3.6 - Heatmap representing the most abundant genera (at least 0.1 % on average) showed no clear 
effect of treatment with SN-38 on the gut microbial composition of 5 healthy donors (D1-D5). 
4. Discussion 
Patients often have to deal with several side effects from cancer treatment, of which 
gastrointestinal mucositis is one of the most debilitating. The major symptoms are inflammation 
and ulceration of the gastrointestinal tract accompanied with diarrhea. Gut microbiota are more 
and more believed to play a role in the etiology and severity of mucositis, but the direct effect 
of chemotherapy on gut microbiota is not yet clear. In this study, we show that 5-FU and SN-38 
only have a limited impact on colon microbial functionality and composition in an in vitro model 
mimicking both the luminal and mucosal gut microbiota.  
5-FU was added solely to the mucosal part of the M-SHIME® as it reaches the gut mainly 
via the blood and gut mucosa. Plasma concentrations of 5-FU can reach some hundreds of 
µM in cancer patients, for example with a bolus injection with 5-FU, but they rapidly drop to 
15-30 µM after 30 minutes and to 0 µM after 2 h (Casale et al. 2004, Kosovec et al. 2008), due 
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to the short half life time (6-22 min) of 5-FU (Bocci et al. 2000). In contrast, for a continuous 
infusion with 5-FU, the plasma concentrations will be much lower, ranging from 3 to 10 µM, 
but are steady for a longer time period (24 h) (Joulia et al. 1999, Takimoto et al. 1999). As we 
wanted to investigate a long term dosing, we chose to dose at 10 µM 5-FU in the mucus layer, 
which is in close contact with the blood circulation.  
The active metabolite of irinotecan, SN-38, was added to the luminal part of an 
M-SHIME® as it reaches the colon via the small intestine and through microbial synthesis, 
hydrolyzing biliary secreted, non-toxic SN-38G to the active compound SN-38 by 
β-glucuronidase activity (Takasuna et al. 1996). This also explains why feces levels of SN-38 
are much higher than plasma levels. Considering that on average 1.2 % of the dose is excreted 
as SN-38 in the feces within 24 h (Sparreboom et al. 1998, Slatter et al. 2000), (an estimated 
average colon concentration of ∼1-2 µM), and assuming a homogeneous distribution along 
the colon, a dose of 10 µM SN-38 was used in the luminal part of the M-SHIME.  
Neither 5-FU nor SN-38 had a significant impact on the functionality or the composition 
of the M-SHIME community. Only some donor-specific changes could be observed: increases 
in Bacteroides, Cloacibacillus, Alistipes and Roseburia and a decrease in Escherichia/Shigella 
after chemotherapeutic treatment. Our observations are in contrast with what was found in 
human trials analyzing stool samples after chemotherapy, namely an increase in Escherichia 
and a decrease in Roseburia and varying trends for Bacteroides (van Vliet et al. 2009, 
Zwielehner et al. 2011, Stringer et al. 2013, Montassier et al. 2014, Montassier et al. 2015) 
However, these studies used different chemotherapeutic agents and the use of antibiotics was 
not excluded. With regards to animal studies, an increase in Escherichia was shown in fecal 
samples of rats treated with 5-FU (Stringer et al. 2009c).  
No shifts in the M-SHIME microbiome could be observed after 5-FU treatment, although 
our previous research on single species clearly showed a differential sensitivity effect amongst 
oral species towards the drug (Vanlancker et al. 2016) and the same trend was observed for 
gastrointestinal microbiota (Stringer et al. 2009c, Florez et al. 2016). For example, Escherichia 
coli and Pseudomonas aeruginosa were highly resistant to 5-FU whereas Bifidobacteria were 
much more sensitive (Stringer et al. 2009c, Florez et al. 2016, Vanlancker et al. 2016). 
Apparently, when present in a well-balanced ecosystem as the M-SHIME system, the impact 
of 5-FU is very low. For irinotecan on the other hand, 34 gut species are shown to be resistant 
till 330 µM irinotecan (Florez et al. 2016), although in vivo transformation of irinotecan to more 
toxic compounds as SN-38 had not been taken into account in this study. For both 5-FU and 
SN-38, however, we could not evaluate what the effect of chemotherapeutics would be on an 
unbalanced ecosystem, as in our study, stool samples from healthy donors (non-antibiotic 
exposed) were used as inoculum. Therefore, it may be interesting to investigate the effect of 
chemotherapeutic agents on an unbalanced gut microbial ecosystem, such as after antibiotic 
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treatment. As many patients will also receive antibiotics during their treatment, 
chemotherapeutics may therefore have a bigger impact on this unbalanced, less diverse 
microbiome. 
Although we did not see a major direct impact of chemotherapeutic treatment (5-FU and 
SN-38) on the colon microbiota in vitro, both clinical and animal studies show that these 
chemotherapeutic treatments can have an impact on the gut microbiota. Rat studies with 5-FU 
and SN-38 have shown that there are clear shifts in the microbial composition after 
chemotherapy (Stringer et al. 2007, Touchefeu et al. 2014). We hypothesize, that host-microbe 
interactions or the presence of the host are needed to induce these changes in vivo and that 
there is only a minor direct effect of chemotherapy on the gut microbial ecosystem as such. 
This also suggests that the host is a major contributing element in the drug toxicity towards the 
gut microbiome. The stressed host environment can induce or aggravate microbial dysbiosis 
and indirectly increase gastrointestinal mucositis severity. Targeting the microbiome with 
probiotics could still be a good strategy to treat mucositis by supporting a homeostatic gut 
microbial ecosystem. Gut microbiota can protect the intestinal mucosa by regulating important 
pathways in mucositis such as TLR-NF-κB pathway, mucus layer, intestinal permeability, 
mucosal repair etc (Touchefeu et al. 2014). 
In conclusion, 5-FU and SN-38 displayed a limited impact on microbial composition and 
functionality of a healthy in vitro M-SHIME® colon ecosystem. We know from clinical and animal 
studies that the microbiome changes upon treatment with chemotoxic agents and therefore we 
assume that these changes are primarily induced in presence of host cells. These modulation 
of the host cells and tissue can have a major impact on the gut microbiome resulting in 
dysbiosis that can further aggravate the mucositis process. This mechanism where disrupted 
host-microbe interactions under chemotherapeutic stress contribute to the process of 
mucositis, needs to be further investigated.  
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6. Supplementary information 
Supplementary Table 3.1 - Abundance of major phyla (%), based on Illumina MiSeq sequencing of the 16S 
rRNA gene, for different types of samples in the M-SHIME runs with 5-FU (AV ±SD) 
   Firmicutes Bacteroidetes Proteobacteria 
Lumen Day 0 Control 39,1 ± 31,9 23,6 ± 12,4 29,6 ± 22,0 
  5-FU 41,8 ± 23,3 26,9 ± 14,1 26,4 ± 19,0 
 Day 6 Control 28,5 ± 23,7 31,2 ± 15,3 30,3 ± 17,3 
  5-FU 27,7 ± 19,6 46,1 ± 12,3 17,6 ± 9,9 
Mucus Day 0 Control 67,0 ± 20,8 11,3 ± 9,5 15,2 ± 15,4 
  5-FU 71,3 ± 13,2 11,1 ± 6,3 12,6 ± 7,9 
 Day 6 Control 48,1 ± 16,8 16,5 ± 11,3 18,9 ± 11,5 
  5-FU 47,9 ± 12,8 21,7 ± 8,8 16,7± 9,3 
 
Supplementary Table 3.2 - Abundance of major phyla (%), based on Illumina MiSeq sequencing of the 16S 
rRNA gene, for different types of samples in the M-SHIME runs with SN-38 (AV ±SD) 
   Firmicutes Bacteroidetes Proteobacteria 
Lumen Day 0 Control 46,9 ± 15,7 23,2 ± 14,7 27,0 ± 16,4 
  SN-38 36,5 ± 18,2 33,2 ± 9,3 27,0 ± 11,9 
 Day 6 Control 23,1 ± 9,0 53,3 ± 7,6 23,2 ± 10,9 
  SN-38 17,8 ± 8,1 51,2 ± 5,9 24,6 ± 9,6 
Mucus Day 0 Control 75,4 ± 19,9 10,7 ± 8,2 11,3 ± 16,8 
  SN-38 73,0 ± 17,8 14,3 ± 7,8 10,1 ± 12,6 
 Day 6 Control 44,8 ± 15,8 19,3 ± 2,9 23,5 ± 9,1 





Supplementary Figure 3.1 - At 10 µM in the luminal part of the M-SHIME, 5-FU has limited effect on mucosal 
total short chain fatty acid concentrations (arrows indicate the time of dosing). 
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Supplementary Figure 3.2 - At 10 µM in the luminal environment of the M-SHIME, 5-FU has no effect on 
luminal relative short chain fatty acid concentrations. 
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Supplementary Figure 3.3 - At 10 µM in the luminal environment of the distal part of the M-SHIME, 5-FU has 





Supplementary Figure 3.4 - At 10 µM in the mucosal part of the M-SHIME, 5-FU has no clear effect on both the luminal and the mucosal microbial composition as 






Supplementary Figure 3.5 - Relative abundances of the 20 most abundant genera of the microbial community of the M-SHIME run with 5-FU based on Illumina Miseq 
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Supplementary Figure 3.6 - Hill numbers based on Illumina sequencing of the 16S rRNA gene as a measure 
for diversity. Order 0 displays species richness, order 1 the exponential of Shannon’s entropy index and 
order 2 the inverse of Simpson’s concentration index. 
 
 
Supplementary Figure 3.7 - NMDS plots based on Bray Curtis dissimilarities of Illumina data on day 0 





Supplementary Figure 3.8 - At 10 µM in the luminal part of the M-SHIME, irinotecan (SN-38) has no effect on 
mucosal total short chain fatty acid concentrations (arrows indicate the time of dosing). 
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Supplementary Figure 3.9 - At 10 µM in the luminal part of the M-SHIME, irinotecan (SN-38) has no effect on 
luminal relative short chain fatty acid concentrations. 
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Supplementary Figure 3.10 - At 10 µM in the luminal part of the distal environment of the M-SHIME, 







Supplementary Figure 3.11 - At 10 µM in the luminal part of the proximal environment of the L-SHIME, 






Supplementary Figure 3.12 - At 10 µM in the luminal part of the SHIME, SN-38 has no clear effect on both the luminal and the mucosal microbial composition as 





Supplementary Figure 3.13 - Relative abundances of the 20 most abundant genera of the microbial community of the M-SHIME run with SN-38 based on Illumina 
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Oral microbiota reduce wound healing capacity  
of epithelial monolayers,  
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Oral mucositis is still one of the most painful side effects of chemotherapeutic treatment 
with a major impact on quality of life for cancer patients. A mounting body of evidence suggests 
a role for the oral microbiome in mucositis. However, the underlying mechanisms remain 
elusive. In this work, we have investigated the interactions between the host, the microbiome 
and chemotherapeutic treatments in more detail. To this end, the effect of 5-fluorouracil (5-FU), 
commonly inducing mucositis, was assessed on a co-culture model that consists of an 
epithelial cell layer and a biofilm derived from oral microbiota from different types of samples 
(saliva, buccal swabs and tongue swabs) and donors (healthy individuals and patients 
suffering from mucositis). After 24 h of co-incubation, all oral microbial samples were found to 
reduce wound healing capacity with 26 ± 15 % as compared with untreated condition. 
Compared with saliva and tongue samples, buccal samples were characterized by lower 
bacterial cell counts and hence higher wound healing capacity. For samples from healthy 
individuals, an inverse correlation was observed between bacterial cell counts and wound 
healing capacity, whereas for patients suffering from mucositis no correlation was observed. 
Moreover, patient-derived samples had a less diverse microbial community and higher 
abundances of pathogenic genera. No major impact of 5-FU on wound healing capacity or the 
composition of the microbiome was seen at physiologically relevant concentrations in the 
mouth. In conclusion, bacterial cell count is inversely correlated with wound healing capacity, 
which emphases the importance of oral hygiene during oral wound healing in healthy 
individuals. However, future research on extra measures besides oral hygiene is needed to 
assure a good wound healing during mucositis, as for patients the bacterial composition seems 
also crucial. The direct effect of 5-FU on both the microbiome and wound healing is minimal, 
pointing to the importance of the host and its immune system in chemotherapy-induced 
microbial shifts. 
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1. Introduction 
Oral mucositis is a painful and debilitating complication of cancer treatment with a major 
impact on the quality of life of the patient. Its frequency is high but varies depending on the 
type of treatment with around 20-40 % incidence in conventional chemotherapeutic treatment 
of solid tumors, to almost 100 % for high-dose chemotherapy prior to HSCT or radiotherapy 
for head and neck cancer (Sonis 2007, Lalla et al. 2008, Villa and Sonis 2015). Although it is 
one of the most studied toxicities of cancer treatment, only few therapeutic agents are available 
for oral mucositis (Villa and Sonis 2016). One of the chemotherapeutic agents with high risk of 
developing mucositis is 5-FU (Villa and Sonis 2015), an antimetabolite that inhibits thymidylate 
synthase (TS) and is incorporated in DNA and RNA (Grem 2000, Longley et al. 2003). The 
incidence of developing grade 3-4 oral mucositis (i.e. confluent ulcers and unable to eat solids) 
in case of 5-FU treatment is more than 15 % (Sonis et al. 2004a). During continuous infusion 
(22 h), plasma levels of 5-FU range from 3 to 10 µM and saliva levels from 0.08 to 0.8 µM 
(Joulia et al. 1999, Takimoto et al. 1999). Previous research has indicated that some oral 
species are sensitive to 5-FU starting from 0.4 µM (Vanlancker et al. 2016). 
The pathogenesis of mucositis is described by the 5-stage model of Sonis (2007). 
Shortly, ROS are generated in the initiation phase, followed by the activation of transcription 
factors, such as NF-κB. These induce the production of pro-inflammatory cytokines and 
activate other signaling pathways. Feedback-loops induce more inflammation and apoptosis 
which lead to the ulceration phase, in which bacteria colonise the ulcers and can penetrate to 
the submucosa. In most cases, spontaneous healing takes place within two to three weeks 
after completion of the treatment. Although this last phase is of great importance in terms of 
recovery and further continuation of the cancer treatment, it is also the least understood (Sonis 
2007).  
More and more evidence is emerging on the role of the oral microbiome in the 
pathogenesis of oral mucositis (Stringer and Logan 2015, Vanhoecke et al. 2015b, 
Vasconcelos et al. 2016). Microbiota can play a negative role in mucositis and induce infection 
of the ulcers which encourages the use of antimicrobial agents. However, no clinical guidelines 
have been formulated regarding the use of antimicrobial agents due to insufficient and 
conflicting scientific data (Saunders et al. 2013, Vanhoecke et al. 2015b). Microbiota may also 
be involved in phases other than the ulceration phase, and this role can be both positive and 
negative (van Vliet et al. 2010). Microbiota are for example able to influence the activation of 
TLR, NF-κB and MAPK, which are all proteins involved in important signaling pathways 
regulating mucositis. This way, microbiota might contribute to a higher tissue inflammation 
level and therefore increase apoptosis rate (Stringer and Logan 2015).  
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Clinical studies have shown shifts in the oral microbial profile of patients, both after 
chemo- and radiotherapy. However, the great variability in patient population, sample 
collection and technical methods to analyze the microbiota makes it difficult to generalize 
conclusions (Vanhoecke et al. 2015b). It seems that for blood cultures and oral swabs taken 
during chemotherapy, the most frequently isolated Gram-negative species are 
Enterobacteriaceae spp., Pseudomonas spp., and E. coli, whereas Staphylococcus spp. and 
Streptococcus spp. are the most frequently isolated Gram-positive species (Napenas et al. 
2007, Vanhoecke et al. 2015b). Not only microbial composition, but also functional factors such 
as the mucus layer and microbial adhesion can be affected by the cancer treatment (Stringer 
et al. 2009c, Vanhoecke et al. 2015b). Moreover, oral microbiota may regulate wound 
recovery, with positive or negative effects depending on the species and the bacterial density 
(Edwards and Harding 2004, Laheij et al. 2013, De Ryck et al. 2015). These factors will depend 
on both the donor and on the specific site in the oral cavity, as they each have their own 
microbial community (Segata et al. 2012). For example, the saliva microbiome resembles the 
tongue microbiome but is distinct from the buccal mucosal microbiome (Segata et al. 2012). 
In this study, we further investigated the role of oral microbiota on wound healing capacity 
and the effect of chemotherapy on both the microbiota and wound healing in an in vitro 
co-culture model that was previously optimized (De Ryck et al. 2014). First, the toxicity of 5-FU 
towards oral epithelial cells was determined using the MTT/SRB cytotoxicity tests. Next, the 
impact of oral microbiota and 5-FU, and the combination thereof, on epithelial wound healing 
were studied in the co-culture model for 24 h, with a special focus on the potential impact of 
the type of oral sample and donor variability.  
2. Materials and methods 
2.1 Cell culture 
The TR146 cell line, obtained from the Laboratory of Experimental Cancer Research 
(Ghent University Hospital), is an oral squamous cell carcinoma cell line isolated from a local 
lymph node metastasis (Rupniak et al. 1985). Cells were cultured at 37°C, 10 % CO2 and 90 % 
relative humidity in Dulbecco’s modified Eagle’s Medium (DMEM) (Gibco) with 10 % heat 
inactivated fetal bovine serum (Greiner Bio-one), 100 IU/mL penicillin (Gibco), 100 μg/mL 
streptomycin (Gibco) and 2.5 μg/mL amphotericin B (Gibco).  
2.2 Oral samples 
Oral samples were obtained from healthy children or patients suffering from oral 
mucositis (Ethical approval from Ghent University hospital, Belgian Registration number 
B670201112526), all aged 6-14 years. All patients were treated for hematological 
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malignancies. Three types of samples were collected: saliva, buccal swab and tongue swab. 
All samples were collected at least 2 h after eating or brushing teeth and before sampling the 
oral cavity of the individuals was flushed with drinking water. For the buccal and tongue 
samples, a sterile cotton swab was gently wiped ten times along the inner cheek or on the 
dorsal side of the tongue and subsequently dissolved in 1 mL of PBS.  
2.3 Chemicals 
A filter-sterilized stock solution of 100 mM 5-FU (Sigma Aldrich) was prepared in DMSO 
and further diluted to 75, 50, 20, 10, 5, 1, 0.1, 0.01 mM in DMSO. Stock solutions were further 
diluted (1:1000) in culture medium for the experiments. 
2.4 MTT/SRB test 
To test the cytotoxicity of 5-FU, an MTT/SRB test was performed. The MTT assay 
(Mosmann 1983) was used to measure the mitochondrial activity and the SRB assay (Vichai 
and Kirtikara 2006) to measure cellular protein content. TR146 cells were seeded in 96 well 
plates at a density of 40 000 cells/well (100 µL DMEM with serum/well). After 24 h, medium 
was discarded and 100 µL serum-free, antibiotic-free DMEM was added together with different 
5-FU concentrations (0.01-100 µM). DMSO (1:1000) was used as a control. All plates were 
incubated at 37°C and 5 % CO2. After 24 h, 48 h and 5 days an MTT and SRB test was 
performed. Six biological replicates were included for each 5-FU concentration and for each 
time point. For the MTT-assay, 20 µL MTT (3-(4,5-demethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (5 mg/mL in PBS) was added and incubated for 2 h at 37°C. All 
medium was removed and formazan crystals were resuspended in 100 µL DMSO. The 
absorbance was measured at 570 nm. For the SRB (sulforhodamine B) assay, cells were 
fixated by adding 25 µL 50 % trichloroacetic acid (TCA) and incubated for 1 h at 4°C. After 
removal of the TCA, the plate was rinsed with water and dried. Next, 75 µL SRB solution (0.4 % 
in 1 % glacial acetic acid) was added and the plate was incubated for 30 minutes at 4°C. The 
plate was then rinsed with 1 % glacial acetic acid and dried. The stained cells were 
resuspended in 200 µL 10 mM Tris buffer and the absorbance was measured at 490 nm.  
2.5 Co-culture model 
To investigate the interactions of oral microbiota and oral epithelial cells without direct 
contact, we used an oral in vitro model described by De Ryck et al. (2014) (Figure 4.1). Briefly, 
the model consists of a 24-well Transwell® plate with removable inserts with a polycarbonate 
membrane of pore size 0.4 µm (Corning Incorporated). In the apical part, 20 µL of the bacterial 
suspension was brought on top of a solidified agar/mucin solution (75 µL, 5 % porcin mucin 
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Type II, 0.8 % agar). PBS was used as a control. In the basolateral side, epithelial cells were 
seeded at a density of 250 000 cells/well and at confluency a wound healing assay was 
performed (see below). During co-culture, the inserts with the microbiota were transferred to 
the wells containing the epithelial cells and incubated at 37°C, 10 % CO2 in serum-free, 
antibiotic-free DMEM (Gibco) with 5-FU (10 µM) or DMSO as a control (1:1000). After 24 h of 
co-culture, inserts were removed and 100 µL PBS was added to collect the bacteria for further 
analysis. For each of the seven donors (4 healthy individuals and 3 patients suffering from 
mucositis), a buccal sample, a saliva sample and a tongue sample as well as a blank (without 
microbiota) was tested in this co-culture model, each with and without 10 µM 5-FU (Figure 
4.1). Each condition was tested in triplicate or quadruplicate.  
2.6 Wound healing assay 
During co-incubation, a wound healing assay was performed based on the protocol by 
De Ryck et al. (2014) (Figure 4.1). TR146 cells were stained with Vybrant DiI cell labelling 
solution (Life Technologies) before seeding in 24 well Transwell® plates at 250 000 cells/well. 
At the start of the experiment, two scratches were made in the confluent monolayer using a 
sterile 100 µL pipette tip. Cell medium was discarded to remove cellular debris and 1 mL of 
new serum-free, antibiotic-free DMEM was added to the cells. At four selected fields per well 
and at each time point, images of the wound were acquired using a fully automated widefield 
fluorescent microscope (Nikon Ti, Nikon Instruments), equipped with a 4x/0.15 Plan Achromat 
objective and EM-CCD camera (Andor Ixon+, Andor Instruments). The surface area of the 
wound was calculated for each time point using a home-written script for FIJI freeware 
(http://fiji.sc) that is available upon reasonable request (www.uantwerpen.be/Cell-
group/scripts). In brief, the DiI counterstained time-lapse images are first pre-processed by 
background subtraction and local contrast enhancement, after which the non-damaged part of 
the cell monolayer is detected by a combination of variance, maximum and Gaussian blur 
filtering, and segmented using a user-defined or automatic threshold. The inverse of this mask 
is selected as wounded area. The relative wound size was calculated by normalizing to the 
wound area at 0 h.  
At the end of the wound healing experiment, metabolic activity and viability of the 
epithelial cells was evaluated with an MTT-assay. To each well, 1 mL of serum-free, 
antibiotic-free DMEM and 200 µL MTT (5 mg/mL in PBS) was added and incubated for 2 h at 
37°C. After removal of the medium, the formazan crystals were dissolved in 1 mL DMSO. 
Absorbance at was measured at 540 nm (200 µL) (Infinite F50 Tecan). Percentage of viability, 
compared to the control, was calculated.  
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Figure 4.1 - Experimental set-up of the co-culture model with 1) oral epithelial TR146 cells stained with DiI, 
2) agar/mucin layer, 3) microbial biofilm or PBS as a control, 4) polycarbonate membrane with 0.4 µm pores, 
5) DMEM with 0 µM or 10 µM 5-FU. Fluorescent images show examples of wounds (red line) at 0 h and 24 h 
(based on De Ryck et al. (2014)). 
2.7 Colony-forming units (CFU) 
To measure the number of viable cells present in the insert, the oral samples (saliva, oral 
swab, tongue swab) were plated using Brain Heart Infusion (BHI)-agar plates. A dilution series 
was made and 10 µL of bacterial suspension was plated in triplicate.  
2.8 Flow cytometry 
The number of intact and damaged bacterial cells in the insert after 24 h was measured 
by flow cytometry as described in Chapter 2, section 2.4 based on Van Nevel et al. (2013).  
2.9 Microbial community analysis 
Total DNA was extracted from the pellet of the bacterial suspension on the filter at 
t = 24 h or the pellet of 100 µL of the sample at t = 0 h as described in Chapter 3, section 2.4. 
On all samples, DGGE was performed using the 338F-GC and 518R primers targeting the V3 
region of the 16S rRNA gene as described in Chapter 3, section 2.5.1. Richness and Gini 
coefficient were calculated based on the DGGE profiles. The number of bands that were 
detected is a measure for richness. The Gini coefficient, based on the Pareto-Lorenz curves, 
is a measure for evenness of the community (Marzorati et al. 2008). Higher Gini coefficients 
represent a lower evenness, indicating the dominance of a small fraction of species in the 
community. Illumina sequencing of the V3-V4 region of the 16S rRNA gene was performed on 
one replicate of each condition for the saliva samples of all individuals by LGC Genomics 
(Berlin, Germany) on the MiSeq platform as described in Chapter 3, section 2.5.2. The Illumina 
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sequencing data were deposited to the European Nucleotide Archive (SRA) with study number 
PRJEB20819.  
2.10 Statistical analysis 
All statistical analyses were performed in R (version 3.3.2). Mixed-model regression of 
MTT and SRB data was performed for each time point with the concentration as categorical 
predictor. A random intercept effect was incorporated for each replicate measurement. In order 
to make correct statistical inference, all models were evaluated for normal distributed residuals 
with homogenous variance, by Shapiro Wilk tests (p>0.05) and visually by Q-Q plots. Model 
parameters were estimated by maximum likelihood. When a significant concentration effect 
was present (ANOVA, p < 0.01), the categories were compared pair-wise by posthoc analysis 
using Tukey’s Honestly Significant Difference (HSD) method. All tested concentrations were 
compared with the control condition (0 µM) and differences were considered significant at 
p<0.05. 
For all other basic statistics, linear models were build using forward selection of 
parameters (fixed factors and interactions) on the scaled and centered data. All models were 
evaluated for normal distributed residuals with homogenous variance. When a significant effect 
was present, the posthoc analysis was performed using multiple comparisons with Benjamini 
Hochberg correction. When interactions were present, data were split in subgroups to define 
significant differences. Differences were considered significant at p<0.05. 
The packages phyloseq (McMurdie and Holmes 2013) and vegan (Oksanen 2016) were 
used for microbial community analysis. Heatmaps were generated with the pheatmap package 
and order-based Hill’s numbers (Hill 1973) were calculated. NMDS plots of the bacterial 
community data were created based on the Bray-Curtis distance measures. Significant 
differences were identified by means of Permutational ANOVA (PERMANOVA) using the 
adonis function (vegan).  
3. Results 
3.1 5-FU toxicity to oral epithelial TR146 cells  
To assess the direct toxicity of 5-FU towards TR146 oral epithelial cells, an MTT/SRB 
test was performed after 24 h, 48 h and 5 days of treatment (Figure 4.2). The SRB test showed 
a significant decrease (p<0.05) in protein content starting from 10 µM for all time points. These 
decreases ranged from a drop with 10 % for 10 µM after 24 h to 63.6 % for 100 µM after 5 
days. The MTT test showed a small but significant (p<0.05) increase in mitochondrial activity 
for some time points at low concentrations of 5-FU (0.01-1 µM). At higher concentrations 
(starting from 10 µM), small decreases were observed after 24 h and 48 h. Viability dropped 
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to less than 50 % after 5 days of treatment with 5-FU at levels higher than 20 µM (p<0.05). 
Together these data show that 5-FU was toxic for TR146 cells starting from 20 µM after 24 h 
and starting from 10 µM after 48 h or 5 days. 
 
 
Figure 4.2 - MTT and SRB toxicity test of 5-FU (0.01-100 µM) on oral epithelial TR146 cells (AV±SD, n=6). 
Significant deviations from the control condition (0 µM) are indicated by the asterisks (p<0.05). 
3.2 Bacterial cell counts are determined by sample and donor type 
For seven donors (4 healthy individuals and 3 patients suffering from mucositis), three 
types of samples (saliva, buccal swabs and tongue swabs) were investigated in a co-culture 
model (Figure 4.1). In this model, the microbial sample was incubated for 24 h on an 
agar/mucin layer in indirect contact with oral epithelial cells. Each sample was tested in 
absence of presence of 10 µM 5-FU in the basolateral compartment. Both the initial (directly 
after taking the sample, t = 0 h) and final (after 24 h of co-culture, t = 24 h) bacterial cell counts 
were evaluated (Figure 4.3A). Depending on the type of sample and the type of donor, the 
initial bacterial concentration ranged between 1 and 5 log CFU. With regards to the different 
oral sample types, a clear distinction was observed between buccal swabs on the one hand 
and saliva and tongue swabs on the other. The initial (t = 0 h) bacterial concentration in buccal 
swabs (1.9 ± 1.3 log CFU) was significantly lower compared to saliva (3.7 ± 1.8 log CFU, 
p<0.001) and tongue swabs (3.6 ± 1.0 log CFU, p<0.001). Despite this variation in initial 
number, all samples were able to grow up to a concentration of 7-8 log CFU after 24 h of 
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co-culture in the in vitro model. The difference in concentration, depending of the sample type, 
was still present after 24 h, with slightly lower bacterial cell counts for the buccal swab 
amended wells (7.4 ± 0.4 log cells) compared to saliva (7.9 ± 0.4 log cells, p<0.001) and tongue 
swab amended wells (7.8 ± 0.4 log cells, p<0.001). Also the type of donor affected the bacterial 
cell counts. While patient samples displayed a 2-3 log lower initial bacterial concentration 
compared to healthy individuals (p<0.001), no significant differences were noted after 24 h in 
the co-culture model (p=0.12). Surprisingly, treatment with 5-FU did not alter bacterial cell 
counts at 24 h (p=0.60). Thus, bacterial cell counts are determined by both sample type and 
donor type, but are not affected by 5-FU. 
3.3 Buccal-derived samples have lower microbial diversity, compared to 
saliva and tongue amended samples 
DGGE analysis (Figure 4.3B and Supplementary Figure 4.1) showed that differences in 
microbial diversity between sample types was dependent on the type of donor, as an significant 
interaction between donor type and sample type was seen. For healthy individuals, the 
microbial community of the buccal swab amended wells was lower in richness and evenness, 
compared to saliva (for both p<0.001) and tongue swab amended wells (for both p<0.001) at 
24 h. For patients, only a significant increase in Gini coefficient was seen for buccal amended 
wells, compared to saliva (p=0.0055). For each donor, Bray-Curtis analysis of DGGE profiles 
also showed significant differences between the different sample types (Supplementary Table 
4.1).  
3.4 Patient-derived samples are less diverse and enriched in pathogenic 
genera as compared to healthy donor samples 
With regards to donor type, DGGE analysis showed different responses depending on 
the type of sample. For saliva and tongue swab amended wells, a lower richness (p<0.001 for 
both) and evenness (p=0.0084 and p<0.001) was observed for patient-derived samples at 
24 h, compared to wells with samples from healthy individuals (Figure 4.3B). However, no 
differences were seen for buccal swab amended wells (richness p=0.91 and evenness 
p=0.77). The high cell density in saliva samples allowed for performing Illumina sequencing 
(guaranteeing high-quality data acquisition). As could be expected, the results showed clear 
differences between donor types (Figure 4.4 and Supplementary Figure 4.2). In 
correspondence with DGGE results, diversity parameters based on amplicon sequencing were 
lower for patient-derived samples, compared to samples from healthy individuals (Hill number 
order 0, p=0.0067; order 1, p=0.028; order 2, p=0.026) (Figure 4.4C). Bray-Curtis analysis at 
OTU level revealed that 16.0 % of the variation in the composition of the saliva samples could 
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be attributed to the type of donor (p=0.0016). Visualization by NMDS plots confirmed the major 
impact of donor type as all patient-derived samples cluster to one side of the plot (Figure 4.4B). 
At 24 h, patient-derived saliva samples were more dominated by Lactobacillales (containing 
Streptococcus, Abiotrophia and Enterococcus) (95.3 ± 6.9 %) compared to samples derived 
from healthy individuals (45.3 ± 23.0 %) (p<0.001). In contrast, Veillonella is more abundant in 
samples derived from healthy individuals at 24 h (50.8 ± 24.3 %) in comparison with patient-
derived samples (3.8 ±6.4) (p<0.0023). The initial (t = 0 h) samples from patients contained 
also more pathogenic genera, for example 25.5 % of Porphyromonas for patient 1, 2.8 % of 
Enterococcus and 3.3 % of Staphylococcus for patient 2 and 40.8 % of Porphyromonas and 
12.7 % of Mycoplasma for patient 3. These genera were not (Enterococcus and Mycoplasma) 
or at much lower abundances (Staphylococcus 0-0.04 %, Porphyromonas 0.2-2.3 %) detected 
in the samples derived from healthy individuals. Interestingly, the initial microbial composition 
of the saliva samples of healthy individuals 1 and 2 on the one hand, and 3 and 4 on the other 
hand were very similar. This can be explained by the fact that these were samples from 
siblings, living in the same environment and having similar eating habits. In brief, patient 
samples had lower microbial diversity and higher abundance of pathogenic genera. 
3.5 5-FU have no major impact on bacterial composition 
DGGE showed that 5-FU did not affect richness (p=0.83) nor evenness (p=0.069) of the 
bacteria. Bray-Curtis analysis showed that only for patient 2, a significant effect of 5-FU on the 
microbial profile could be detected based on the DGGE profile (p=0.0014) (Supplementary 
Table 4.1). For all sample types of this patient, two dominant bands clearly disappeared 
following 5-FU treatment (Supplementary Figure 4.1). Similar to DGGE, Illumina sequencing 
showed that 5-FU treatment did not significantly affect the bacterial diversity (Figure 4.4C). 
However, following 5-FU treatment, a general trend in increased Streptococcus abundance 
(from 40.6 ± 26.7 % to 68.1 ± 25.5 % ; p=0.099) and of decreased Veillonella abundance (from 
44.7 ± 34.8 % to 26.8 ± 23.4 % ; p=0.32) was observed (Figure 4.4A). In contrast to the other 
individuals, wells derived from patient 3 were dominated by Abiotrophia after 24 h of co-culture 
both with and without 5-FU. More specifically, Prevotella abundance increased following 5-FU 
treatment for samples derived from healthy individual 3 and 4 (0.4 % to 3.8 % and 0.4 % to 
2.2 % respectively). For patient 2, Enterococcus and Streptococcus were the most abundant 
genera in the untreated wells (70.4 % and 29.2 % respectively), whereas in presence of 5-FU 
Streptococcus dominated with 98.9 %. This result confirmed the changed DGGE profiles of 
patient 2 following 5-FU treatment (Supplementary Figure 4.1). Altogether, these results 
indicate small yet non-significant changes in the composition of the biofilm following 5-FU 




Figure 4.3 - Bacterial cell counts and composition of microbiota derived from different sample and donor 
types cultured in the oral co-culture model in presence or absence of 5-FU. A) Bacterial cell counts at t = 0 h 
and t = 24 h (AV±SD); B) Richness and Gini coefficient as measure for bacterial diversity by DGGE (AV±SD). 
Significant differences between groups are indicated by the asterisks (p<0.05). 
3.6 Bacterial composition changes after 24 h of co-culture 
Finally, a significant change in bacterial composition was observed with Illumina 
sequencing attributed to sampling time points (t = 0 h vs. t = 24 h) (p=0.01), which explained 
13.3 % of the variation in all samples (based on Bray-Curtis dissimilarities on OTU level). This 
difference was also visible in the NMDS plot (Figure 4.4B). Moreover, all Hill numbers showed 
a decrease in diversity at 24 h compared to the initial samples (Hill number order 0, p<0.001; 
order 1, p<0.001; order 2, p<0.001) (Figure 4.4C). Streptococcus and Veillonella were the 
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dominating genera in the saliva samples after 24 h in the in vitro model (together 95.6 ± 4.2 %), 
apart from the control sample derived from patient 2, which was dominated by Enterococcus 
and the samples derived from patient 3, which were dominated by Abiotrophia (Figure 4.4A). 
Next to Streptococcus and Veillonella, the initial saliva samples were also populated by 
Prevotella, Neisseria, Granulicatella, Haemophilus, Actinomyces, Porphyromonas, 
Fusobacterium, and Megasphaera, of which levels depended on the donor. A lot of this 
diversity was lost during the 24 h incubation in the co-culture model. For some donors, most 
genera were still present albeit at relatively low abundances.  
 
 
Figure 4.4 - Illumina sequencing of the 16S rRNA gene of the microbiota in the saliva samples. A) Barplot 
representing the 14 most abundant genera; B) NMDS plot with 95 % confidence ellipsoids of the mean, 
p-values and R² for different confounding factors based on Bray-Curtis dissimilarities; C) Hill numbers 
order 0, 1 and 2 representing richness, evenness and diversity respectively (AV±SD). Significant differences 
between groups are indicated by the asterisks (p<0.05). 
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3.7 Epithelial wound healing is reduced by oral microbiota, irrespective of 
the presence of 5-FU 
To investigate the closure of artificially induced wounds in an epithelial monolayer over 
time, we followed wound healing in a separate set-up with and without microbiota derived from 
a buccal swab from a healthy individual in presence or absence of 5-FU (Figure 4.1). 
Compared to the (unchallenged) control wells, epithelial cell wound healing slowed down in 
presence of microbiota starting from 16 h, eventually resulting in a 16 % lower wound healing 
after 25 h (Figure 4.5A). The presence of 5-FU had no effect on the wound healing capacity 
and this was independent of microbial presence.  
This experiment showed that co-culture with microbiota reduces wound healing of oral 
epithelial cells. This effect might, however, be caused by different bacterial cell counts and 
composition, which have been shown to depend on the type of donor and the sample type. 
Indeed, although a general reduction (25.9 ± 15.1 %) of wound healing capacity was observed 
by the addition of oral microbiota, differences could be noticed between the sample and donor 
types (Figure 4.5). 
First, addition of microbiota derived from saliva and tongue swabs had a more 
detrimental effect on wound healing in comparison with buccal-derived microbiota (p=0.0051 
for saliva; p=0.041 for tongue) (Figure 4.5B). Regarding the type of donor, no difference in 
wound healing capacity was noticed (p=0.95). However, plotting the wound opening at 24 h as 
a function of the bacterial cell counts revealed two different trends between healthy and patient 
samples (Figure 4.5C). Microbial samples from healthy individuals displayed a linear 
relationship with each additional log CFU of bacterial cells resulting in a 15.2 % increase in 
wound opening (p=0.00082). Independent of microbiome composition, this is indicative 
(adjusted R² = 0.17) of a higher wound healing capacity at lower bacterial loads. However, no 
such trend could be observed for patient samples (p=0.13). Again, no modulating effect of 
5-FU on wound healing was observed after 24 h in the presence (p=0.49) and absence 
(p=0.21) of microbiota. An MTT assay performed after 24 h of co-culture showed no effect of 
sample type (p=0.26) or type of donor (p=0.23) on the cell viability of TR146 cells. A small but 
significant increase in epithelial cell viability was observed following 5-FU treatment in 
presence of microbiota (89.5 ± 11.0 % to 95.3 ± 11.4 %, p=0.004), whereas no effect was 
observed in absence of microbiota (p=0.94). Together these data indicate that wound healing 
potential is determined by both bacterial cell count and bacterial composition. 
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Figure 4.5 - A) Oral microbiota derived from a buccal swab reduce wound healing capacity of oral epithelial 
cells in an in vitro mucosa model, irrespective of the treatment with 5-FU (10 µM) (AV±SE); B) Sample type 
affect wound healing capacity, whereas donor type and presence of 5-FU do not (AV±SD); C) For healthy 
individuals, a positive correlation between the opening of the wound and bacterial cell count at 24 h was 
observed, but for patients no such trend was noticed. 
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Oral mucositis is a debilitating side effect of chemotherapeutic treatment in which 
microbiota are more and more shown to play an important role. In this study, we investigated 
the interactions between the oral microbiome, oral epithelial cells and a chemotherapeutic 
(5-FU) using an in vitro co-culture model. As wound healing is crucial in recovering from 
mucositis, this was one of the functional endpoints in the model apart from microbial numbers 
and composition.  
Our data showed that oral microbiota reduced wound healing capacity for all seven 
donors with 25.9 ± 15.1 %. Previous research using the same in vitro model, showed that oral 
microbiota had similar negative effects on wound healing (De Ryck et al. 2014). However, this 
reduction appeared to be species- and concentration-dependent (Edwards and Harding 2004, 
De Ryck et al. 2015). Not only in the oral cavity, but also in other body sites wound healing 
capacity can be concentration dependent. In chronic skin wounds, low amounts of microbiota 
can improve wound healing, whereas in infectious conditions with high bacterial loads wound 
healing capacity is significantly reduced (Edwards and Harding 2004). Our data for healthy 
individuals confirmed previous research, as lower bacterial cell counts correlated with higher 
wound healing capacity. This encourages the use of good oral hygiene during mucositis, 
shown previously to be of high importance in oral mucositis, as colonization of the ulcers by 
microbiota may prolong the healing phase (Keefe et al. 2007, Villa and Sonis 2016). However, 
for patients that are in the acute mucositis phase, more measures might be needed, as we 
have shown that for such patients wound healing capacity was independent of the bacterial 
cell counts. This indicates that also bacterial composition might be important in acute mucositis 
patients. De Ryck et al. (2015) indeed showed that wound healing capacity seems to be 
species-dependent with Klebsiella oxytoca having a deleterious effect on wound healing, 
whereas Streptococcus mitis and S. oralis stimulated wound healing. 
Further, we observed differences in the composition and diversity of oral microbiota 
derived from patients suffering from mucositis compared to healthy individuals. The abundance 
of Lactobacillales was higher in patient samples in comparison with healthy individuals and the 
diversity of samples derived from patients was lower. Our results are in accordance with a 
prospective study with 454-sequencing of mucosal samples also showing a lower diversity in 
patient samples compared to reference individuals (Ye et al. 2013). Moreover, the Illumina 
data from our study revealed the presence of larger numbers of genera containing pathogenic 
species, like Porphyromonas, Enterococcus and Staphylococcus, in the patient-derived 
samples, which could lead to a higher infection risk. Porphyromonas gingivalis was shown 
previously to be predictive for the development of oral ulcerations in HSCT patients (Laheij et 
al. 2012). 
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Different sites in the oral cavity are colonized with distinct microbial communities (Segata 
et al. 2012). In our study, buccal swabs had lower bacterial cell counts, compared to saliva 
and tongue swabs, leading to a higher wound healing capacity, which is in line with the 
previous results. DGGE also indicated lower richness and evenness in the buccal samples. 
This lower diversity of buccal microbiome compared to saliva and tongue samples has already 
been explained by extensive data derived from The Human Microbiome Project by the 
dominance of Streptococcus in buccal samples (Segata et al. 2012). 
We also investigated the effect of 5-FU on different endpoints in the co-culture model. 
We chose to work with a dose of 10 µM, as this was the highest non-toxic concentration for 
TR146 cells after 24 h. Similar toxicity profiles have been recorded for other cell lines such as 
for Caco-2 cells (Fang et al. 2014). In vivo concentrations range from 3 to 10 µM in plasma 
and 0.08-0.8 µM in saliva following continuous treatment (Joulia et al. 1999, Takimoto et al. 
1999), but significantly increase in case of DPD deficiency (Saif et al. 2009). Previous research 
showed a variable sensitivity among oral species towards 5-FU (Vanlancker et al. 2016). 
However, in our system which comprises a plethora of oral species cultured in a biofilm, we 
did not see an impact of 5-FU on both bacterial cell counts or wound healing. Further, 5-FU 
had only a minor impact on bacterial composition with an increasing trend in Streptococcus 
and a decreasing trend in Veillonella. Streptococcus oralis, S. mitis and S. salivarius have been 
shown in a previous study to be resistant to 5-FU at 10 µM, (Vanlancker et al. 2016) which 
might explain their ability to increase in abundance. No data are available on the sensitivity of 
5-FU to Veillonella, however our data suggest that Veillonella is sensitive towards 5-FU. The 
results for patient 2 indicated high sensitivity of Enterococcus towards 5-FU, confirming 
previous research (Stringer et al. 2009c). Moreover, patient 2 was the only donor for which a 
significant effect of 5-FU on the microbial composition was shown. This indicates a donor-
specific effect of 5-FU which encourages the use of a personalized approach. 
At 24 h, the biofilm formed in the model was mainly dominated by Streptococcus and 
Veillonella for the saliva samples. Although this indicates a loss of diversity of the original saliva 
sample when cultured in the in vitro model, this loss might be due to biofilm formation. In vivo 
growth of an oral biofilm on enamel-dentin slabs in the mouth of healthy volunteers also 
showed a dominance of Streptococcus (62 %) and Veillonella (27 %) after 48 h (Klug et al. 
2016). Although we used saliva samples, the high abundance of Streptococcus is more similar 
to buccal samples (Segata et al. 2012). We hypothesize that the use of an agar/mucin layer 
as a substrate promotes biofilm formation of a buccal community, despite the use of a saliva 
sample as a microbial source. This immature biofilm is formed by streptococci, known to be 
initial colonizers of the oral biofilm (Kolenbrander et al. 2010). With respect to Veillonella, 
dependency on the lactic acid produced by streptococci has been shown (Kolenbrander 2000) 
and therefore these species are likely to co-occur.  
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In conclusion, oral microbiota reduce wound healing capacity of epithelial cells with 
higher bacterial cell counts linked to lower wound healing capacity in healthy individuals. 
However, for patients suffering from mucositis the mechanism of wound healing is more related 
to microbial composition, rather than microbial load as their oral samples are characterized by 
a disturbed microbial community with higher abundances of pathogenic genera. More research 
on the link between oral microbial composition and wound healing capacity is needed to fully 
understand their role in the wound healing process in patients suffering from mucositis. 
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6. Supplementary information 
Supplementary Table 4.1 - p-values and R² for different confounding factors based on Bray-Curtis 
dissimilarities of the DGGE data (significant values are indicated in italic) 
 
5-FU Sample types  
p-value R² p-value R² 
Healthy 1 0.42 11.1 % 0.0009 58.3 % 
Healthy 2 0.38 12.1 % 0.0012 80.5 % 
Healthy 3 0.24 8.5 % 0.0001 59.3 % 
Healthy 4 0.50 4.6 % 0.0001 57.7 % 
Patient 1 0.72 7.7 % 0.0013 48.0 % 






Supplementary Figure 4.1 – DGGE profiles of oral samples from healthy individuals and patients, in absence and presence of 5-FU at 24h . 
Healthy 1 Healthy 2 
r.._ CoOOol Buccal 5-FU r.._ CoOOol Buccal 5-FU 
lluo<al 5-FU Buc::célll Controt 
lluo<al 5-FU Buccal Cont<ol 
lluo<al Comol Salt"a 5-FU 
lluo<al Cooool SaiNa 5-FU 
Saliva 5-FU Saliva Control 
Saliva 5-FU Saliva Contrd 
SaWa Cooool Tongue Cont<ol 
SaWa CoOOol Tongue Controt 
Healthy 3 Healthy 4 
TI 
Saliva Coolrot Salrva Control 
Saliva Coolrot SaiiVa Conlrol 
Saliva Coolrot Sahva Control 
Saliva 5-FU Salrva 5-FU 
Saliva 5-FU Sahva 5-FU 
Saliva 5-FU SaiiVa 5-FU 
lluo<al Conooi Bucoal Control 
lluo<al Control Bucoal Cooltol 
lluo<at Control Bucoal Control 










T ong.Je 5-fU Tongue 5-FU 
r..".,. 5-FU Tongue 5-FU 
r..".,. 5-FU Tongi.Jê 5-FU 
Patient 1 Patient 2 
Tongue Control 1 Saliva Control 






Bucoal Control 1 
Salîva 5-FU 
Bucoal Control 2 Buccal Control 
SaWa 5-FU Buccal Control 
Saiva 5-FU Buccal Control 
Saliva Control 1 Buccal 5-FU 











Supplementary Figure 4.2 - Heatmap representing the square root transformed relative abundance of genera present for at least 0.1 % based on Illumina sequencing 
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The oral microbiome of cancer patients is subjected to several modulatory factors 
throughout cancer therapy. To what extent modulation of the oral microbiota contributes to the 
etiology or severity of oral mucositis is thus far not known. To this end, we performed a 
longitudinal study of the oral microbiota from five pediatric patients, treated with chemotherapy 
for hematological malignancies and suffering from oral mucositis. Saliva, buccal and mucositis 
lesions were sampled before and during chemotherapy over a 2-2.5 month period and after 
therapy as follow-up. Microbial community composition was determined with 16S rRNA gene 
based Illumina sequencing and correlations with clinical data were made. The oral microbial 
community displayed large dynamics throughout therapy in all patients, with patient-specific 
shifts. While Streptococcus was the predominant genus for 3 out of 5 patients, the other 2 
patients showed a large variability in dominant genera over time, indicating a highly 
unbalanced microbiome. While the overall community composition seemed to return to its 
initial composition at least 1 month after therapy, a sustained impact towards lower diversity 
values was noted. Surprisingly, chemotherapy and mucositis had only a minor effect on 
microbial community composition, whereas one of the major confounding factors of our study 
was the use of systemic antibiotics as it majorly affected both microbial composition and 
diversity. Other confounding factors were sample type and sampling period, but also the use 
of antibacterial mouth rinse with chlorhexidine, neutropenia and inflammation. Mucositis 
lesions were highly dominated by streptococci, but also by more pathogenic genera as 
Aggregatibacter, Enterococcus and Fusobacterium. In conclusion, chemotherapy, antibiotic 
treatment and/or antibacterial mouth rinse will lower microbial diversity and create dysbiosis, 
which may increase the risk of infection and bacterial sepsis in neutropenic patients. 
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1. Introduction 
Oral mucositis is one of the multiple disorders from which development and severity is 
suspected to be influenced by microbiota (Stringer and Logan 2015, Vanhoecke et al. 2015b, 
Vasconcelos et al. 2016). The exact role of the oral microbiota in mucositis is however still 
unclear and multiple factors can impact the oral microbial community of cancer patients during 
and after chemotherapy. 
Shifts in the oral microbial community of cancer patients following chemotherapy have 
been shown in multiple studies (Napenas et al. 2007, Napenas et al. 2010, Ye et al. 2013), but 
no clear pattern could be observed so far due to the large variability among multiple studies in 
patient populations, sample types, and sample collection and analysis methods (Vanhoecke 
and Stringer 2015). Moreover, only a couple of studies compared the composition of the 
microbiota before and after chemotherapy, making it difficult to attribute microbiome shifts to 
chemotherapy or other disease- or therapy-associated factors (Vanhoecke et al. 2015b). The 
advent of next generation sequencing has however resulted in a more profound insight in how 
cancer therapy affects the human microbiome. The use of 16S rRNA gene clone libraries of 
oral buccal microbiota of 9 breast cancer patients before and after chemotherapy revealed 
species that had never been identified in patients before (Napenas et al. 2010). In pediatric 
cancer patients, 454-sequencing of oral mucosal bacterial samples showed a lower diversity 
and higher inter-individual variability for patients compared to healthy children. Furthermore, 
they found a higher microbial diversity before the start of chemotherapy and more pronounced 
shifts of the bacterial community by chemotherapy in patients who later developed oral 
mucositis (Ye et al. 2013). A recent study observed a large microbial variability over time in 
hospitalized cancer patients treated with chemotherapy (Galloway-Pena et al. 2017). 
Therefore, the importance of longitudinal follow-up to fully unravel the host-microbe 
interactions in oral mucositis during cancer treatment is emerging (Vasconcelos et al. 2016, 
Galloway-Pena et al. 2017). 
Despite the variability in microbial shifts following chemotherapy, different 
microorganisms have been linked with mucositis or oral ulcerations. A study with immune-
compromised patients showed a correlation between oral lesions and the presence of 
Staphylococcus spp., Enterococcus spp., and Candida spp. (Olczak-Kowalczyk et al. 2012). 
In patients undergoing HSCT, Porphyromonas gingivalis in particular, but also Parvimonas 
micra, Treponema denticola, Fusobacterium nucleatum,  and Candida spp. were associated 
with oral ulcerations (Laheij et al. 2012). Also viruses such as Herpes simplex virus (HSV)-1 
have been shown to be linked with the severity of mucositis (de Mendonca et al. 2012, de 
Mendonca et al. 2015). Microorganisms colonizing this ulcers might easily penetrate into the 
submucosa and cause bacteremia and sepsis (Sonis 2007). In the past, Gram-negative 
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bacteria were the main cause of invasive infections in neutropenic cancer patients. However, 
a shift towards Gram-positive infections has been shown since the 1990s (Zinner 1999) 
(Panghal et al. 2012). This can be explained by the prophylactic use of fluoroquinolones, the 
use of high-dose chemotherapy causing oral mucosal barrier disruption and the use of central 
venous lines increasing the risk of infections with skin bacteria, which are usually Gram-
positive (Zinner 1999, Panghal et al. 2012). Viridans streptococci are an important group of 
Gram-positive pathogens causing infections (Shenep 2000, Tunkel and Sepkowitz 2002) and 
increased abundance of Streptococcus oralis group of viridians streptococci has been shown 
in saliva samples following chemotherapy and total body irradiation for allogeneic bone marrow 
transplantation in pediatric patients (Lucas et al. 1997). 
In this study, we investigated the oral microbial composition of 5 pediatric patients treated 
with chemotherapy for hematological malignancies, as they highly suffer from oral mucositis. 
The first aim was to perform a longitudinal analysis of the oral microbial community by 
monitoring saliva, buccal and lesion microbiota once or twice a week for a 2-2.5 month period 
with 16S rRNA gene-based Illumina sequencing. The second aim was to link the oral microbial 
changes during this long-term period with potential confounding factors. Factors of interest 
were sample type, sampling period, mucositis, chemotherapy, concurrent antibiotic treatment, 
neutropenia, inflammation, pain, LLLT and the use of antimicrobial and antimycotic mouth 
rinses. The third aim was to measure the extent of recovery of the microbiome and therefore 
the oral microbial community was studied at least 4 weeks after finishing chemotherapy. 
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2. Materials and methods 
2.1 Subjects 
Five patients, aged 8-15 years and treated for hematological malignancies, were 
included in this study after informed consent was obtained from their parents (Ethical approval 
from Ghent University hospital, Belgian Registration number B670201112526). Patient details 
and their chemotherapeutic courses during this study period are summarized in Table 5.1. All 
patients received alkylating agents (cyclophosphamide, etoposide) and anthracyclines 
(doxorubicin, mitoxantrone, liposomal daunorubicin) known to induce bone marrow aplasia 
and mucositis. Moreover, some patients (patients 2,3,4) were treated with high dose 
methotrexate (3 g/m² or 8 g/m²) and cytarabine was administered to patient 5. Prior to 
chemotherapy, a first sampling was conducted (= Pre-treatment). Next, oral samples were 
collected once or twice a week over a 2-2.5 month period. In this period patients received two 
or three chemotherapeutic courses as depicted in Table 5.1. Samples were linked to treatment 
periods, each starting at the first day of a chemotherapy course and ending when the next 
chemotherapy course started (= Treatment period 1, 2, 3). Finally, a follow-up sample was 
collected 1 to 3 months after the last chemotherapeutic treatment. Age and gender-matched 
children (n=4), without any know systemic disorder were recruited as reference individuals.  
2.2 Oral samples 
 At each sampling point, three sample types were collected: saliva, a buccal swab and a 
tongue swab. When the patients suffered from mucositis, an extra swab at the lesion was 
collected. All samples were collected at least 2 hours after eating or brushing teeth and before 
sampling the oral cavity of the individuals was flushed with drinking water. For the buccal and 
tongue samples, a sterile cotton swab was gently wiped ten times along the inner cheek or on 
the dorsal side of the tongue. For the lesion samples, a sterile cotton swab was gently wiped 






Table 5.1 - Patient details and chemotherapeutic courses.  
COPAD: Vincristine 2 mg/m²x2; Prednisolone 60 mg/m²/day for 5 days; Cyclophosphamide 250 mg/m²/12 hour x 3 days; Doxorubicin 60 mg/m². COP: 
Cyclophosphamide 300 mg/m²; Vincristine 1 mg/m²; Prednisolone 60 mg/m²/day for 7 days. COPADM: COPAD + High Dose Methotrexate (HD MTX) 3g/m²; intrathecal 
injection of chemotherapy (IT). CYM: HD MTX 3g/m² + Cytarabine 100 mg/m²/day for 5 days + IT. Ritux: Rituximab 375 mg/m². COPADM for group C1 contains HD MTX 
8 g/m² instead of 3 g/m²; Maint 1=2: Etoposide 150 mg/m²/day for 3 days; Cytarabine 50 mg/m²/12 hours for 5 days; Maint 3=4: Prednisolone 30 mg/m²/12 hours for 5 
days orally; Cyclophosphamide 500 mg/m²/day for 2 days; Doxorubicin 60 mg/m² on Day1. MEC: Mitoxantrone 5 mg/m²/day for 5 days; Etoposide 150 mg/m²/day for 
5 days; Cytarabine 200 mg/m²/day for 7 days; IT. ADxE: Cytarabine 2x 100 mg/m²/day and 6 x 200 mg/m²/day; liposomal daunorubicin 60 mg/m²/day for 3 days; 














Treatments after treatment 
period 3 and before follow-up 
# sampling 
points 
Patient 1 8 year Male 
Burkitt lymphoma, 
stage 2 
LMB 2001, group A COPAD COPAD / / 11 
Patient 2 10 year Male 
Burkitt lymphoma, 
stage 3, high risk 
Inter-B-NHL Ritux 
2010, group B 
COP - COPADM COPADM CYM CYM + Ritux 13 
Patient 3 15 year Male 
Diffuse Large B-cell 
lymphoma (DLBCL) 
LMB 2001, group B COP - COPADM COPADM CYM CYM 14 
Patient 4 15 year Female Burkitt leukemia 
Inter-B-NHL Ritux 




Ritux – Maint1 – Ritux – Maint2 – 
Maint3 – Maint4 
14 





MEC ADxE / / 14 
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2.3 Clinical records 
Several parameters were registered during the time of the collection of the samples. 
First, the World Health Organization (WHO) grading scale for oral mucositis was used to 
estimate the severity of mucositis (WHO 1979). The value of chemotherapy load was 
determined by increasing the load with one value for each day of subsequent treatment, 
followed by decreasing the load with one value on each subsequent day without treatment till 
it reached zero. The same system was used to calculate an antibiotic load, although here the 
value depended on the category of the antibiotic, based on the antimicrobial spectrum. Patients 
2, 3, 4 and 5 were treated with sulfamethoxazole and trimethoprim in the weekend, as 
prophylaxis against Pneumocystis jiroveci infection. On these days, the antimicrobial load 
increased with a value of 1. The patient with AML (patient 5) got prophylactic treatment with 
oral ciprofloxacin after each course. Due to its broader antimicrobial spectrum, this was set as 
category 2. If the patient developed neutropenic fever, broad-spectrum antibiotics were started 
for empirical treatment of Gram-negative, Gram-positive +/- anaerobic bacteria: either 
amikacin and ceftriaxone in case of low-risk infection or amikacin and piperacillin/tazobactam 
in case of profound neutropenia and high risk infection. Amikacin and ceftriaxone were 
considered as category 2 (value of 2 for each day of administration), and the combination of 
amikacin and piperacillin/tazobactam had a value of 3. If the fever persisted despite the 
antibiotics mentioned before or in case of a poor general condition, vancomycin or teicoplanin 
was added and/or antibiotics were switched to meropenem and ciprofloxacin, which is a 
combination with a very broad spectrum and therefore all categorized with a value of 4. 
Patient 5 was treated at the end of the sampling period with amoxicillin with clavulanic acid 
due to appendicitis. In combination with the prophylactic ciprofloxacin, this was classified in 
category 3. The use of antibacterial mouth rinses with chlorhexidine (0.05 % or 0.12 %), 
antimycotic mouth rinses with nystatin (100 000 IE/mL) and treatment with LLLT was 
monitored. Neutropenia was categorized as mild when neutrophils were between 
1000-2500/µL, as moderate when neutrophils were between 500-1000/µL and as severe 
neutropenia in case of less than 500 neutrophils per µL (National Cancer Institute 2009). The 
C-reactive protein (CRP) levels were monitored as an inflammatory marker, with mild 
inflammation between 5-40 mg/L, an active inflammation and bacterial infection (=’moderate’) 
between 40-200 mg/L and a severe bacterial infection when > 200 mg/L (Clyne and Olshaker 
1999). Oral pain was measured using the Visual Analogue Scale (VAS).  
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2.4 Microbial community analysis 
Total DNA was extracted from the buccal or tongue swab or the pellet of 100 µL of saliva 
sample, as described in Chapter 3, section 2.4. On all samples, DGGE was performed using 
the 338F-GC and 518R primers targeting the V3 region of the 16S rRNA gene as described in 
Chapter 3, section 2.5.1. Illumina sequencing of the V3-V4 region of the 16S rRNA gene was 
performed on saliva, buccal and lesion samples by LGC Genomics (Berlin, Germany) on the 
MiSeq platform as described in Chapter 3, section 3.5.2.  
2.5 Statistical analysis 
All statistical analyses were performed in R (version 3.3.2). The packages phyloseq 
(McMurdie and Holmes 2013) and vegan (Oksanen 2016) were used for microbial community 
analysis. Heatmaps were generated with the pheatmap package and order-based Hill’s 
numbers (Hill 1973) were calculated. NMDS plots of the bacterial community data were created 
based on the Bray-Curtis distance measures. Significant differences were identified by means 
of Permutational ANOVA (PERMANOVA) using the adonis function (vegan). Multivariate 
homogeneity of dispersion (variance) was calculated with the betadisper function (vegan), a 
multivariate analogue of the Levene's test for homogeneity of variances, and significant 
differences were identified with the Kruskall-Wallis Rank Sum test.  
For all other basic statistics, differences between three or more groups were defined via 
ANOVA and Tukey as post-hoc test, if the data were normally distributed (tested with 
Shapiro-Wilk test) and homoscedastic (tested with Levene test), if not, Kruskall Wallis Rank 
Sum test with Tukey post-hoc testing was used as a non-parametric alternative. For the 
comparison between two groups, a t-test was used for normally distributed and homoscedastic 
data and the Wilcoxon Rank Sum test as a non-parametric alternative. Differences were 
considered significant at p<0.05. 
3. Results 
3.1 Oral mucositis 
All 5 patients included in this study developed oral mucositis over time, however not all 
to the same extent. Patient 1 developed only grade 1 mucositis; patient 2 and 3 developed 
grade 1 and 2; whereas patient 4 and 5 had episodes of grade 1, 2 and 3 mucositis. This is 
not surprising since the latter patients got the most intensive treatment with 8 g/m² 
methotrexate and cytarabine on top of anthracyclines, respectively (Table 5.1). Mucositis 
started between the last days of the course up to 6 days following the chemotherapy, and the 
duration of mucositis was 2-16 days. Except for patient 1 (the least intensively treated patient), 
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mucositis always occurred during a period of neutropenia and also often co-occurred with 
increased C-reactive protein (CRP) levels.  
3.2 Oral microbial composition changes over time, but recovers to its initial 
composition at the follow-up 
Oral microbial community analysis of 5 pediatric patients treated for hematological 
malignancies was assessed by Illumina sequencing of the 16S rRNA gene. Saliva, buccal 
swabs and lesion samples were analyzed on 11-14 time points over a 2-2.5 month period. 
Altogether, the seven most abundant phyla (in decreasing order of importance) Firmicutes, 
Fusobacteria, Proteobacteria, Bacteroidetes, Actinobacteria, Candidatus Saccharibacteria 
and Tenericutes, comprise at least 97.7 % of abundance in each sample. The most abundant 
genera were Streptococcus, Veillonella, Haemophilus, Fusobacterium, Prevotella and 
Neisseria. As expected, inter-individual variability was large and it was the most important 
factor explaining the variance in the data (17.1 %, based on Bray-Curtis dissimilarities) (Figure 
5.1A). A higher degree of community variation in function of time was observed for patients 4 
and 5 (p=0.0024) (Figure 5.1B). Similarly, samples during treatment showed an increased 
community variation compared to both follow-up samples (p=0.02) and samples before start 
of chemotherapy (p=0.0039) (Supplementary Figure 5.1). The variation of the community was 
also significantly larger for samples taken in a period with an antibiotic load (p=0.0002), during 
antibiotic treatment (p=0.00098), inflammation (p=0.0012), neutropenia (p=0.0057) and 
mucositis (p=0.0007) and when using a chlorhexidine mouth rinse (p=0.0062), antimycotic 
mouth rinse (p=0.0046) and LLLT (p=0.017) (Supplementary Figure 5.1). This indicates that 
all these factors were related to the increased variation in the microbial composition during 
treatment.  
For each patient, the salivary and buccal composition was followed over time using 
NMDS based on the Bray-Curtis dissimilarities (Figure 5.2). For patient 1, the salivary microbial 
composition only changed in treatment period 2, but returned to the initial composition at the 
follow-up. The buccal samples were more variable over time but the composition of the 
follow-up samples were also similar to that at the beginning of treatment 1. Similar trends were 
seen for patient 2, with a salivary microbial community that was stable at the start, changed 
just before the start of the second chemotherapeutic treatment, but recovered to the initial 
composition in the end. The buccal and salivary samples from patient 3, were variable during 
treatment 1 and 2, more constant following treatment 3 and also returned to the initial 
composition at the follow-up. For patient 4, the buccal and salivary microbial communities were 
variable during both treatment 1 and 2, but also recovered to the initial microbial composition 
at the follow-up. However, the buccal microbial community at the follow-up was more similar 
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to that of the salivary initial composition. For patient 5, the buccal and salivary microbial 
community were similar at the start and displayed similar changes over time. As no follow-up 
sample was available for patients 5, no conclusion could be made about recovery. 
 
Figure 5.1 - A) NMDS plot of all samples based on Bray-Curtis dissimilarities with 95 % confidence ellipsoids 
of the mean; B) Distance to the centroid, based on Bray-Curtis dissimilarities. Significant differences 
between groups are indicated by the asterisks (p<0.05). 
3.3 Diversity decreased following chemotherapeutic and antibiotic treatment 
and partially recovered at the follow-up 
The α-diversity of the samples was assessed with the inverse Simpson index, also known 
as the second Hill number (Hill 1973). Overall, no significant differences were observed 
between diversity of saliva versus buccal samples (p=0.26). For both saliva and buccal 
samples, diversity changed over time showing similar profiles. Minor decreases could be 
observed after a chemotherapy course, whereas diversity largely decreased during or following 
antibiotic treatment (Figure 5.3). Similar trends were observed for the Hill numbers 
representing richness and evenness (data not shown). At the follow-up (at least 1 month 
following the last chemotherapeutic treatment) only a partial recovery of both buccal and 
salivary bacterial diversity was observed (Figure 5.3).  
Diversity was also measured based on the DGGE microbial profiles of saliva, buccal, 
tongue and lesion samples (Supplementary Figure 5.2; DGGE profiles see Supplementary 
Figure 5.3 and Supplementary Figure 5.4). Diversity profiles showed similar trends as 
compared to Illumina sequencing results i.e. decreases in diversity following chemotherapeutic 
and antibiotic treatments. The DGGE profiles of four healthy children (Supplementary Figure 
5.5) showed that salivary diversity of pre-treatment and follow-up samples of the patients 
(19.5 ± 7.1) was similar to that of healthy children (18.2 ±7.5). 
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Figure 5.2 - NMDS plots based on Bray-Curtis dissimilarities indicating the shifts in microbial community 
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Figure 5.3 - Buccal and salivary diversity (Hill number 2 = inverse Simpson coefficient) based on Illumina 
amplicon sequencing data. Data with less than 1000 reads per sample are indicated with a ‘X’. 
 
3.4 Multiple confounding factors determine the oral microbial composition 
Metadata such as chemotherapeutic treatment, mucositis, pain, antibiotic treatment, use 
of antimicrobial or antimycotic mouth rinses, LLLT, neutropenia, and inflammation were 
monitored during the sampling period (Supplementary Table 5.1). All factors correlated 
significantly with the overall microbial community variation based on Bray-Curtis dissimilarities, 
with the individual (17.1 %), sample type (9.0 %), antibiotic grade (7.7 %), inflammation grade 
(6.9 %) and sampling period (6.3 %) as five most important factors (Table 5.2). As large 
inter-individual variability was observed, the most important confounding factors were also 
determined for each patient separately. Some variability is reported among the five most 
important confounding factors for each patient, but some general trends can be noticed (Table 
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5.2). Similar to the analysis of the entire dataset, the sample type (saliva vs. buccal vs. lesion) 
and the period of sampling (pre-treatment vs. treatment period 1 vs. 2 vs. 3 vs. follow-up) 
explained a high percentage of the variation for each of the five patients (respectively 10.8-
28.5 % and 17.2-31.1 %). Next to the antibiotic grade, also the antibiotic load was an important 
confounding factor. They each had a significant contribution in 2 and 4 of the patients 
respectively. In those cases, they explained respectively 12.2-15.8 % and 9.2-13.5 % of the 
variation. The grade of inflammation was highly important for patient 4 and 5 (17.7 % and 
26.1 %), whereas also the grade of neutropenia was an important cofactor for 4 out of 5 
patients (13.4-22.7 %). Although the use of an antibacterial mouth rinse with chlorhexidine only 
explained 3.7 % of the variation of the entire dataset, it significantly explained 11-20.1 % of the 
variation in the microbial community for all 4 patients who used it. This may indicate patient-
specific changes due to oral mouth rinse. Mucositis, chemotherapy and chemotherapy load 
were ranked in the top-five confounding factors for only 1 patient each. Pain and the use of 
LLLT and antimycotic rinse were less important confounding factors as they were not ranked 
in the top-five for any patient. 
 
Table 5.2 - R² (%) based on the Bray-Curtis dissimilarities for the entire dataset (ALL) and for each patient 
(P1-P5). Significant differences are indicated in red. The five largest values per column are indicated with 
a grey background. 
(%) ALL P1 P2 P3 P4 P5 
Patient 17.1 NA NA NA NA NA 
Sample type 9.0 28.5 23.9 22.7 10.8 14.4 
Sampling period 6.3 31.1 20.7 20.3 17.2 27.7 
Chemotherapy 1.7 3.8 2.8 6.8 14.9 13.3 
Chemotherapy load 1.9 3.8 2.8 6.0 5.7 20.9 
Antibiotic grade 7.7 9.0 3.3 NA 12.2 15.8 
Antibiotic load 4.7 12.8 11.7 7.7 9.2 13.5 
Antibacterial mouth rinse 3.7 17.2 15.0 11.0 NA 20.1 
Antimycotic mouth rinse 2.7 9.2 4.9 8.0 11.8 8.0 
Low level laser therapy 2.6 NA 4.5 8.0 12.5 12.2 
Mucositis grade 4.5 11.3 4.2 7.1 9.0 17.0 
Neutropenia grade 5.2 15.5 22.7 13.4 17.0 7.2 
Inflammation grade 6.9 8.5 8.3 5.3 17.7 26.1 
Pain 2.5 11.3 10.3 4.3 4.8 16.1 
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3.5 Patient-specific shifts at genus level and increases in opportunistic 
pathogens 
Heatmaps of the most abundant genera (average abundance > 1 % or present in one 
sample with an abundance > 5 %) indicated that the shifts occurring over time were patient-
specific (Figure 5.4). For patient 1, both buccal (50-76 %) and saliva (35-41 %) samples started 
with high abundances of Streptococcus, which decreased (to minimum 5 %) following the first 
and second chemotherapeutic course. Relative abundances increased again in the follow-up 
samples to initial levels. An inverse trend was observed for Veillonella in saliva samples, with 
an initial increase in abundance (till maximum 70 %), followed by a decrease in the follow-up 
samples. The buccal sample at day 38 was dominated by Gemella (51 %). The lesion sample 
had a large Streptococcus abundance (62 %), similar to the buccal sample of that day.  
The microbial community of patient 2 showed no clear shifts during the first three weeks. 
At day 24 however, a significant change occurred in both the saliva and buccal community, 
with Streptococcus almost completely dominating the community (90-99 %). In the buccal 
community, Streptococcus dominated for even longer, although in the saliva the abundance 
largely decreased at the next sampling point. Lesions were dominated by Aggregatibacter 
(50 %, day 14) or Streptococcus (81 %, day 24).  
The oral microbial profile of patient 3 was similar to patient 2, with Streptococcus 
dominating the buccal samples (34-91 %) from the start of the second treatment period. In 
saliva samples, high abundances of Veillonella were observed both in the pre-chemotherapy 
sample as during and following the second chemotherapeutic course. Both in saliva and buccal 
samples, Haemophilus was present in the initial samples, but completely disappeared after the 
first chemotherapeutic treatment, yet re-occurred at the follow-up at high abundances 
(22-44 %). Capnocytophaga was present at day 20 at higher abundances (33-35 %), whereas 
Lautropia was highly present at day 51 (21-33 %). Lesions were dominated by Streptococcus 
(57-93 %).  
For patient 4, each sample was dominated by a different genus. Starting with 
Haemophilus at day 13 (35-68 %), Lautropia at day 16 (49-57 %), Abiotrophia at day 20 (90 %), 
Rothia at day 30 (67 %), Enterococcus at day 44 (buccal 85 %) and day 47 (lesion 99 %), 
Streptococcus at day 47, 51 and 53 (54-91 %), and Veillonella at day 72 (saliva 62 %). Lesions 
were dominated by Enterococcus (day 47, 99 %) or Enterococcus and Streptococcus (day 44, 
26 % and 37 % respectively).  
A similar shifting dominance was observed for the samples from patient 5. The first 
sampling points were characterized by a high diversity, but Veillonella dominated at day 9 and 
15 (saliva 62-65 %), Leptotrichia at day 19 (59-89 %), Porphyromonas at day 26 in saliva 
(41 %), Actinomyces at day 26 in buccal swab (52 %) Fusobacterium at day 34 and 58 in saliva 
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(63 and 52 %) and day 56 and 58 in buccal samples (57 and 75 %) and Neisseria at day 47 
and 86 in saliva (89 and 50 %). In contrast to the other donors, Streptococcus almost 
disappeared from day 19 till day 62. Samples derived from lesions were dominated by 
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4. Discussion 
Longitudinal monitoring of five pediatric cancer patients revealed a large degree of 
inter-individual variability in microbial community composition and dynamics. Although Wang 
et al. (2014) showed that disease-related shifts in the oral microbiome occur prior to 
chemotherapy in AML patients, we did not find a deviating oral microbiome structure of the five 
patients prior to chemotherapy as opposed to that of healthy children. However, profound 
microbiome shifts occurred for all patients during and following the chemotherapy courses over 
this long-term period. This was particularly noticed for two study patients (patient 4 and 5) who 
displayed the highest degree in community variation over time. These two patients were also 
subjected to the most toxic chemotherapy courses and highest antibiotic loads and they 
experienced the most severe mucositis grade. Independent of sample type (saliva vs. buccal) 
major shifts in dominant oral genera, such as Fusobacterium, Neisseria, Rothia, Actinomyces, 
Lautropia, Leptotrichia, Enterococcus and Abiotrophia were noted for these two patients, 
primarily after antibiotic treatment. Yet, we were unable to reveal consistent shifts in 
microbiome composition across the different individuals, indicating interindividual microbiome 
differences to be a predominant factor in explaining dataset variability.  
Although profound shifts were observed over time, the microbial community recovered 
to its initial composition in the follow-up samples, 1 to 3 months after the last chemotherapeutic 
treatment. Despite this recovery in microbial community composition, ecosystem diversity only 
partially recovered at the follow-up. As microbial diversity closely correlates with functional 
diversity (Huttenhower et al. 2012), a lower diversity may indicate an ecosystem to be less 
homeostatic and closer to an ecological tipping point (Scheffer et al. 2009, Wittebolle et al. 
2009). Low diversity in combination with disrupted community composition may predispose for 
outgrowth of one species dominating the entire oral microbiota. This may eventually result in 
increased infection risks, as has also been reported for AML patients (Galloway-Pena et al. 
2017). These data underline the importance of maintaining a homeostatic microbiome and 
limiting microbiome shifts during treatment. This could be obtained through long-term proper 
oral hygiene practices and regular oral health care, also after finishing chemotherapeutic 
treatment.  
With respect to the nature of the treatment it was expected that chemotherapy would 
create clear shifts in the oral microbiome composition. However, chemotherapy only caused 
limited shifts in community composition in the five patients. In contrast, community diversity 
did decrease upon chemotherapy, paralleling previous findings of a decreased microbial 
diversity in fecal samples of AML patients (van Vliet et al. 2009). In addition, the toxic nature 
of the chemotherapy clearly correlated with the grade of mucositis: yet, despite its profound 
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impact on the quality of life for the patient, the grade of mucositis was not the most important 
confounding factor to explain oral microbial shifts for the five patients.  
In sharp contrast to chemotherapy and mucositis, antibiotic use was found a major 
confounding factor as it significantly affected both microbiome composition and diversity. This 
was also reflected in the high number of samples with low read counts (<1000) that originated 
from antimicrobial treatment periods. Although most scientific research primarily targets the 
effect of antibiotics on the gut microbiome, several antibiotics also have been shown to be 
present in saliva (Troeltzsch et al. 2014) and to impact the oral microbiome (de Vries-Hospers 
et al. 1991, Brismar et al. 1993, Sullivan et al. 2001, Zaura et al. 2015, Abeles et al. 2016). 
These include for example amoxicillin, ceftriaxone and ciprofloxacin, which were also used in 
our longitudinal study. In correspondence with our findings, Galloway-Pena et al. (2017) 
demonstrated that the duration of antibiotic treatment was significantly associated with an 
increased temporal variability of oral microbiome diversity and composition of hospitalized 
cancer patients. Following the above-mentioned lower microbiome diversity upon 
chemotherapy, we demonstrate that antibiotic use further impacts the already disturbed oral 
microbial community. This may be considered a risk factor for developing infections and for 
more severe mucositis episodes. Interestingly, the prophylactic use of antibiotics for the 
treatment of pediatric AML patients is currently under debate (Gamis 2015). As clinical 
evidence is lacking or even inadequate (McGuire et al. 2013), MASCC/ISOO guidelines do not 
support the prophylactic use of chlorhexidine mouth rinse to prevent oral mucositis (Lalla et al. 
2014). Our findings seem to support this view: not only systemic antibiotics, but also 
chlorhexidine-based mouth rinses were major contributors to microbiome disturbances at an 
individual level. Yet, clinicians could still opt for the use of antimicrobial mouth rinse if a clear 
association or even causation of specific microorganisms with mucositis would be 
demonstrated.  
We therefore also characterized the microbiome of lesions to reveal specific genera that 
could possibly associate with mucositis. Confirming previous reports (Ye et al., 2013), 
Streptococcus was the most prominent genus in lesion samples. While this finding may just be 
indicative of its status as common oral microbe, we also found Aggregatibacter, Enterococcus 
and Fusobacterium to be highly enriched in lesion samples from some patients. Several of 
these genera have been associated with pathogenicity (Teles et al. 2013). Yet we could not 
detect a common mucositis phylotype across the 5 patients. Our data are similar to previous 
sequencing data of mucositis lesions where high intersample variability was described with 
Actinomyces, Rothia, Prevotella, Staphylococcus, Abiotrophia and Lactobacillus spp. being 
abundant next to Streptococcus (Ye et al. 2013). Likewise, culture-based techniques did not 
reveal one common pathogen but rather an association of Enterococcus, Porphyromonas, 
Staphylococcus or Fusobacterium with mucositis and oral ulcers (Laheij et al. 2012, Olczak-
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Kowalczyk et al. 2012). Based on our observations we concur with Ye et al. (2013) that 
mucositis risk and severity is determined by the entire community, rather than an association 
with one specific pathogen. 
Similar to previous studies, buccal samples were characterized by a higher 
Streptococcus abundance (Segata et al. 2012). Dominance of Streptococcus was observed in 
samples from patient 1, 2 and 3. In contrast, Streptococcus almost disappeared from the oral 
cavity of patients 5 from day 15 till day 58. This co-occurred with the use of vancomycin mouth 
spray, targeting Gram-positive species. Despite this very low oral Streptococcus abundance, 
a positive Streptococcus viridans hemoculture (day 54) was observed during this period. For 
none of the other patients a Streptococcus sepsis was reported, although they had high 
abundances of streptococci in the oral cavity during mucositis periods. This indicates that the 
use of vancomycin as an oral mouth rinse eradicates streptococci, but does not prevent 
Streptococcus sepsis, which contradicts previous research (Brunet et al. 2006).  
In conclusion, longitudinal follow-up of pediatric patients with hematological 
malignancies revealed chemotherapy and mucositis to have a minor contribution to oral 
microbiome shifts. Yet, we hypothesize that the observed decrease in microbiome diversity 
may bring the oral microbiome closer to an ecological tipping point, resulting in a higher 
susceptibility to severe community disruption, once antibiotic treatment and/or antibacterial 
mouth rinses are given. The resulting dysbiosis could increase the risk of infection and bacterial 
sepsis, further aggravating mucositis episodes to which these patients are highly vulnerable. 
Our findings therefore support current MASCC/ISOO guidelines which do not support the 
prophylactic use of antimicrobial mouth rinses to prevent chemotherapy-induced oral 
mucositis. 
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6. Supplementary information 
 
Supplementary Figure 5.1 - Distance to the centroid, based on Bray-Curtis dissimilarities. Significant 
differences between groups are indicated by the asterisks (p<0.05). 
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Supplementary Figure 5.3 - DGGE profiles of saliva, tongue and buccal samples of patient 1, 2 and 3.  
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Supplementary Figure 5.4 – DGGE profiles of saliva, tongue and buccal samples of patient 4 and 5.  
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Supplementary Figure 5.5 - DGGE profiles of saliva samples of 4 healthy children.
 
 



























































































































































































































Patient 1 Day 12 Saliva Pre-treatment Yes 1 Yes AB Category 2 Yes 0 No No No No Grade 0 No No No No No 0 No 
Patient 1 Day 16 Saliva Treatment 1 Yes 1 Yes AB Category 0 No 0 No No Yes No Grade 1 Yes No No No No 4 Yes 
Patient 1 Day 22 Saliva Treatment 1 No 0 No AB Category 0 No 0 No No Yes No Grade 0 No Severe Yes No No 0 No 
Patient 1 Day 33 Saliva Treatment 2 Yes 1 Yes AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 1 Day 38 Saliva Treatment 2 Yes 2 Yes AB Category 0 No 0 No Yes No No Grade 0 No No No No No 0 No 
Patient 1 Day 44 Saliva Treatment 2 No 0 No AB Category 3 Yes 8 Yes Yes No No Grade 0 No Moderate Yes Mild Yes 0 No 
Patient 1 Day 47 Saliva Treatment 2 No 0 No AB Category 3 Yes 14 Yes Yes No No Grade 0 No Moderate Yes No No 0 No 
Patient 1 Day 54 Saliva Treatment 2 No 0 No AB Category 0 No 12 Yes Yes No No Grade 0 No Moderate Yes Mild Yes 0 No 
Patient 1 Day 61 Saliva Treatment 2 No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 1 Day 68 Saliva Follow-up No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 1 Day 79 Saliva Follow-up No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 1 Day 12 Buccal Pre-treatment Yes 1 Yes AB Category 2 Yes 0 No No No No Grade 0 No No No No No 0 No 
Patient 1 Day 16 Buccal Treatment 1 Yes 1 Yes AB Category 0 No 0 No No Yes No Grade 1 Yes No No No No 4 Yes 
Patient 1 Day 22 Buccal Treatment 1 No 0 No AB Category 0 No 0 No No Yes No Grade 0 No Severe Yes No No 0 No 
Patient 1 Day 33 Buccal Treatment 2 Yes 1 Yes AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 1 Day 38 Buccal Treatment 2 Yes 2 Yes AB Category 0 No 0 No Yes No No Grade 0 No No No No No 0 No 
Patient 1 Day 44 Buccal Treatment 2 No 0 No AB Category 3 Yes 8 Yes Yes No No Grade 0 No Moderate Yes Mild Yes 0 No 
Patient 1 Day 47 Buccal Treatment 2 No 0 No AB Category 3 Yes 14 Yes Yes No No Grade 0 No Moderate Yes No No 0 No 
Patient 1 Day 54 Buccal Treatment 2 No 0 No AB Category 0 No 12 Yes Yes No No Grade 0 No Moderate Yes Mild Yes 0 No 
Patient 1 Day 61 Buccal Treatment 2 No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 1 Day 68 Buccal Follow-up No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 1 Day 79 Buccal Follow-up No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 1 Day 16 Lesion Treatment 1 Yes 1 Yes AB Category 0 No 0 No No Yes No Grade 1 Yes No No No No 4 Yes 
Patient 2 Day 3 Saliva Treatment 1 No 0 No AB Category 0 No 0 No No No No Grade 0 No No No Mild Yes 5 Yes 





























































































































































































































Patient 2 Day 11 Saliva Treatment 1 Yes 4 Yes AB Category 0 No 0 No No No No Grade 0 No Severe Yes No No 0 No 
Patient 2 Day 14 Saliva Treatment 1 Yes 3 Yes AB Category 0 No 0 No No No Yes Grade 1 Yes Severe Yes No No 5 Yes 
Patient 2 Day 17 Saliva Treatment 1 No 0 No AB Category 3 Yes 6 Yes No Yes Yes Grade 2 Yes Severe Yes Severe Yes 0 No 
Patient 2 Day 24 Saliva Treatment 1 No 0 No AB Category 0 No 26 Yes Yes No Yes Grade 1 Yes Moderate Yes No No 0 No 
Patient 2 Day 28 Saliva Treatment 2 Yes 1 Yes AB Category 0 No 10 Yes No No No Grade 0 No Mild Yes No No 0 No 
Patient 2 Day 32 Saliva Treatment 2 Yes 3 Yes AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 2 Day 39 Saliva Treatment 2 No 0 No AB Category 2 Yes 2 Yes Yes No No Grade 0 No Severe Yes Mild Yes 0 No 
Patient 2 Day 50 Saliva Treatment 3 Yes 2 Yes AB Category 0 No 0 No Yes No No Grade 0 No Mild Yes No No 0 No 
Patient 2 Day 56 Saliva Treatment 3 Yes 8 Yes AB Category 0 No 1 Yes Yes No No Grade 0 No Mild Yes Mild Yes 0 No 
Patient 2 Day 198 Saliva Follow-up No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 2 Day 1 Buccal Pre-treatment Yes 1 Yes AB Category 0 No 0 No No No No Grade 0 No No No Mild Yes 0 No 
Patient 2 Day 3 Buccal Treatment 1 No 0 No AB Category 0 No 0 No No No No Grade 0 No No No Mild Yes 5 Yes 
Patient 2 Day 8 Buccal Treatment 1 Yes 1 Yes AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 2 Day 11 Buccal Treatment 1 Yes 4 Yes AB Category 0 No 0 No No No No Grade 0 No Severe Yes No No 0 No 
Patient 2 Day 14 Buccal Treatment 1 Yes 3 Yes AB Category 0 No 0 No No No Yes Grade 1 Yes Severe Yes No No 5 Yes 
Patient 2 Day 17 Buccal Treatment 1 No 0 No AB Category 3 Yes 6 Yes No Yes Yes Grade 2 Yes Severe Yes Severe Yes 0 No 
Patient 2 Day 24 Buccal Treatment 1 No 0 No AB Category 0 No 26 Yes Yes No Yes Grade 1 Yes Moderate Yes No No 0 No 
Patient 2 Day 28 Buccal Treatment 2 Yes 1 Yes AB Category 0 No 10 Yes No No No Grade 0 No Mild Yes No No 0 No 
Patient 2 Day 32 Buccal Treatment 2 Yes 3 Yes AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 2 Day 39 Buccal Treatment 2 No 0 No AB Category 2 Yes 2 Yes Yes No No Grade 0 No Severe Yes Mild Yes 0 No 
Patient 2 Day 50 Buccal Treatment 3 Yes 2 Yes AB Category 0 No 0 No Yes No No Grade 0 No Mild Yes No No 0 No 
Patient 2 Day 56 Buccal Treatment 3 Yes 8 Yes AB Category 0 No 1 Yes Yes No No Grade 0 No Mild Yes Mild Yes 0 No 
Patient 2 Day 198 Buccal Follow-up No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 2 Day 14 Lesion Treatment 1 Yes 3 Yes AB Category 0 No 0 No No No Yes Grade 1 Yes Severe Yes No No 5 Yes 
Patient 2 Day 17 Lesion Treatment 1 No 0 No AB Category 3 Yes 6 Yes No Yes Yes Grade 2 Yes Severe Yes Severe Yes 0 No 





























































































































































































































Patient 2 Day 28 Lesion Treatment 2 Yes 1 Yes AB Category 0 No 10 Yes No No No Grade 0 No Mild Yes No No 0 No 
Patient 3 Day 5 Saliva Treatment 1 No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 3 Day 9 Saliva Treatment 1 Yes 2 Yes AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 3 Day 16 Saliva Treatment 1 No 0 No AB Category 0 No 0 No No No No Grade 0 No Mild Yes No No 0 No 
Patient 3 Day 20 Saliva Treatment 1 No 0 No AB Category 0 No 0 No Yes Yes Yes Grade 2 Yes Severe Yes No No 0 No 
Patient 3 Day 23 Saliva Treatment 1 No 0 No AB Category 3 Yes 9 Yes Yes Yes Yes Grade 1 Yes Severe Yes Mild Yes 0 No 
Patient 3 Day 29 Saliva Treatment 2 Yes 1 Yes AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 3 Day 34 Saliva Treatment 2 Yes 4 Yes AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 3 Day 40 Saliva Treatment 2 No 0 No AB Category 0 No 1 Yes Yes No No Grade 2 Yes Severe Yes Mild Yes 4 Yes 
Patient 3 Day 47 Saliva Treatment 2 No 0 No AB Category 0 No 1 Yes Yes No No Grade 1 Yes No No Mild Yes 0 No 
Patient 3 Day 51 Saliva Treatment 3 Yes 2 Yes AB Category 0 No 0 No No No No Grade 2 Yes Mild Yes No No 0 No 
Patient 3 Day 55 Saliva Treatment 3 Yes 6 Yes AB Category 0 No 0 No No No No Grade 1 Yes Mild Yes No No 0 No 
Patient 3 Day 61 Saliva Treatment 3 No 2 Yes AB Category 0 No 1 Yes Yes No No Grade 0 No Severe Yes No No 0 No 
Patient 3 Day 75 Saliva Treatment 3 No 0 No AB Category 0 No 1 Yes Yes No No Grade 0 No Mild Yes No No 0 No 
Patient 3 Day 146 Saliva Follow-up No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 3 Day 5 Buccal Treatment 1 No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 3 Day 9 Buccal Treatment 1 Yes 2 Yes AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 3 Day 16 Buccal Treatment 1 No 0 No AB Category 0 No 0 No No No No Grade 0 No Mild Yes No No 0 No 
Patient 3 Day 20 Buccal Treatment 1 No 0 No AB Category 0 No 0 No Yes Yes Yes Grade 2 Yes Severe Yes No No 0 No 
Patient 3 Day 23 Buccal Treatment 1 No 0 No AB Category 3 Yes 9 Yes Yes Yes Yes Grade 1 Yes Severe Yes Mild Yes 0 No 
Patient 3 Day 29 Buccal Treatment 2 Yes 1 Yes AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 3 Day 34 Buccal Treatment 2 Yes 4 Yes AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 3 Day 40 Buccal Treatment 2 No 0 No AB Category 0 No 1 Yes Yes No No Grade 2 Yes Severe Yes Mild Yes 4 Yes 
Patient 3 Day 47 Buccal Treatment 2 No 0 No AB Category 0 No 1 Yes Yes No No Grade 1 Yes No No Mild Yes 0 No 
Patient 3 Day 51 Buccal Treatment 3 Yes 2 Yes AB Category 0 No 0 No No No No Grade 2 Yes Mild Yes No No 0 No 





























































































































































































































Patient 3 Day 61 Buccal Treatment 3 No 2 Yes AB Category 0 No 1 Yes Yes No No Grade 0 No Severe Yes No No 0 No 
Patient 3 Day 75 Buccal Treatment 3 No 0 No AB Category 0 No 1 Yes Yes No No Grade 0 No Mild Yes No No 0 No 
Patient 3 Day 146 Buccal Follow-up No 0 No AB Category 0 No 0 No No No No Grade 0 No No No No No 0 No 
Patient 3 Day 20 Lesion Treatment 1 No 0 No AB Category 0 No 0 No Yes Yes Yes Grade 2 Yes Severe Yes No No 0 No 
Patient 3 Day 23 Lesion Treatment 1 No 0 No AB Category 3 Yes 9 Yes Yes Yes Yes Grade 1 Yes Severe Yes Mild Yes 0 No 
Patient 3 Day 40 Lesion Treatment 2 No 0 No AB Category 0 No 1 Yes Yes No No Grade 2 Yes Severe Yes Mild Yes 4 Yes 
Patient 3 Day 47 Lesion Treatment 2 No 0 No AB Category 0 No 1 Yes Yes No No Grade 1 Yes No No Mild Yes 0 No 
Patient 3 Day 55 Lesion Treatment 3 Yes 6 Yes AB Category 0 No 0 No No No No Grade 1 Yes Mild Yes No No 0 No 
Patient 4 Day 13 Saliva Treatment 1 Yes 9 Yes AB Category 0 No 0 No No Yes No Grade 1 Yes Severe Yes No No 1 Yes 
Patient 4 Day 16 Saliva Treatment 1 No 6 Yes AB Category 3 Yes 9 Yes No Yes Yes Grade 2 Yes Severe Yes Mild Yes 2 Yes 
Patient 4 Day 20 Saliva Treatment 1 No 2 Yes AB Category 4 Yes 23 Yes No Yes Yes Grade 3 Yes Severe Yes Moderate Yes 2 Yes 
Patient 4 Day 27 Saliva Treatment 1 No 0 No AB Category 4 Yes 51 Yes No Yes Yes Grade 2 Yes No No Mild Yes 1 Yes 
Patient 4 Day 30 Saliva Treatment 2 Yes 1 Yes AB Category 0 No 39 Yes No No No Grade 0 No No No Mild Yes 0 No 
Patient 4 Day 34 Saliva Treatment 2 Yes 3 Yes AB Category 0 No 23 Yes No No No Grade 0 No No No Mild Yes 0 No 
Patient 4 Day 37 Saliva Treatment 2 Yes 6 Yes AB Category 0 No 11 Yes No No No Grade 0 No No No No No 2 Yes 
Patient 4 Day 41 Saliva Treatment 2 No 4 Yes AB Category 2 Yes 19 Yes No No Yes Grade 1 Yes Severe Yes No No 2 Yes 
Patient 4 Day 44 Saliva Treatment 2 No 1 Yes AB Category 2 Yes 25 Yes No No Yes Grade 3 Yes Severe Yes Moderate Yes 4 Yes 
Patient 4 Day 47 Saliva Treatment 2 No 0 No AB Category 4 Yes 35 Yes No No Yes Grade 2 Yes Severe Yes Moderate Yes 3 Yes 
Patient 4 Day 51 Saliva Treatment 2 No 0 No AB Category 4 Yes 51 Yes No No Yes Grade 1 Yes Severe Yes Moderate Yes 2 Yes 
Patient 4 Day 63 Saliva Treatment 2 No 0 No AB Category 0 No 61 Yes No No No Grade 0 No Mild Yes No No 0 No 
Patient 4 Day 72 Saliva Treatment 2 No 0 No AB Category 0 No 27 Yes No No No Grade 0 No Mild Yes No No 0 No 
Patient 4 Day 226 Saliva Follow-up No 0 No AB Category 0 No 0 No No No No Grade 0 No Mild Yes No No 0 No 
Patient 4 Day 13 Buccal Treatment 1 Yes 9 Yes AB Category 0 No 0 No No Yes No Grade 1 Yes Severe Yes No No 1 Yes 
Patient 4 Day 16 Buccal Treatment 1 No 6 Yes AB Category 3 Yes 9 Yes No Yes Yes Grade 2 Yes Severe Yes Mild Yes 2 Yes 
Patient 4 Day 20 Buccal Treatment 1 No 2 Yes AB Category 4 Yes 23 Yes No Yes Yes Grade 3 Yes Severe Yes Moderate Yes 2 Yes 





























































































































































































































Patient 4 Day 30 Buccal Treatment 2 Yes 1 Yes AB Category 0 No 39 Yes No No No Grade 0 No No No Mild Yes 0 No 
Patient 4 Day 34 Buccal Treatment 2 Yes 3 Yes AB Category 0 No 23 Yes No No No Grade 0 No No No Mild Yes 0 No 
Patient 4 Day 37 Buccal Treatment 2 Yes 6 Yes AB Category 0 No 11 Yes No No No Grade 0 No No No No No 2 Yes 
Patient 4 Day 41 Buccal Treatment 2 No 4 Yes AB Category 2 Yes 19 Yes No No Yes Grade 1 Yes Severe Yes No No 2 Yes 
Patient 4 Day 44 Buccal Treatment 2 No 1 Yes AB Category 2 Yes 25 Yes No No Yes Grade 3 Yes Severe Yes Moderate Yes 4 Yes 
Patient 4 Day 47 Buccal Treatment 2 No 0 No AB Category 4 Yes 35 Yes No No Yes Grade 2 Yes Severe Yes Moderate Yes 3 Yes 
Patient 4 Day 51 Buccal Treatment 2 No 0 No AB Category 4 Yes 51 Yes No No Yes Grade 1 Yes Severe Yes Moderate Yes 2 Yes 
Patient 4 Day 63 Buccal Treatment 2 No 0 No AB Category 0 No 61 Yes No No No Grade 0 No Mild Yes No No 0 No 
Patient 4 Day 72 Buccal Treatment 2 No 0 No AB Category 0 No 27 Yes No No No Grade 0 No Mild Yes No No 0 No 
Patient 4 Day 226 Buccal Follow-up No 0 No AB Category 0 No 0 No No No No Grade 0 No Mild Yes No No 0 No 
Patient 4 Day 16 Lesion Treatment 1 No 6 Yes AB Category 3 Yes 9 Yes No Yes Yes Grade 2 Yes Severe Yes Mild Yes 2 Yes 
Patient 4 Day 20 Lesion Treatment 1 No 2 Yes AB Category 4 Yes 23 Yes No Yes Yes Grade 3 Yes Severe Yes Moderate Yes 2 Yes 
Patient 4 Day 27 Lesion Treatment 1 No 0 No AB Category 4 Yes 51 Yes No Yes Yes Grade 2 Yes No No Mild Yes 1 Yes 
Patient 4 Day 41 Lesion Treatment 2 No 4 Yes AB Category 2 Yes 19 Yes No No Yes Grade 1 Yes Severe Yes No No 2 Yes 
Patient 4 Day 44 Lesion Treatment 2 No 1 Yes AB Category 2 Yes 25 Yes No No Yes Grade 3 Yes Severe Yes Moderate Yes 4 Yes 
Patient 4 Day 47 Lesion Treatment 2 No 0 No AB Category 4 Yes 35 Yes No No Yes Grade 2 Yes Severe Yes Moderate Yes 3 Yes 
Patient 4 Day 51 Lesion Treatment 2 No 0 No AB Category 4 Yes 51 Yes No No Yes Grade 1 Yes Severe Yes Moderate Yes 2 Yes 
Patient 5 Day 2 Saliva Pre-treatment Yes 2 Yes AB Category 0 No 0 No No No No Grade 0 No Severe Yes No No  No 
Patient 5 Day 6 Saliva Treatment 1 Yes 6 Yes AB Category 0 No 0 No No No No Grade 0 No Severe Yes No No 0 No 
Patient 5 Day 9 Saliva Treatment 1 Yes 9 Yes AB Category 3 Yes 6 Yes No Yes Yes Grade 0 No Severe Yes Moderate Yes 5 Yes 
Patient 5 Day 15 Saliva Treatment 1 No 9 Yes AB Category 3 Yes 24 Yes No Yes No Grade 1 Yes Severe Yes Mild Yes 0 No 
Patient 5 Day 19 Saliva Treatment 1 No 5 Yes AB Category 2 Yes 32 Yes Yes No No Grade 1 Yes Severe Yes Mild Yes 0 No 
Patient 5 Day 26 Saliva Treatment 1 No 0 No AB Category 4 Yes 54 Yes Yes No No Grade 2 Yes Severe Yes Mild Yes 0 No 
Patient 5 Day 34 Saliva Treatment 1 No 0 No AB Category 2 Yes 84 Yes Yes No No Grade 0 No Severe Yes No No 0 No 
Patient 5 Day 42 Saliva Treatment 2 Yes 2 Yes AB Category 2 Yes 100 Yes Yes No No Grade 0 No Mild Yes No No 0 No 





























































































































































































































Patient 5 Day 56 Saliva Treatment 2 No 0 No AB Category 4 Yes 133 Yes Yes Yes Yes Grade 2 Yes Severe Yes Moderate Yes 6 Yes 
Patient 5 Day 58 Saliva Treatment 2 No 0 No AB Category 4 Yes 141 Yes Yes Yes Yes Grade 3 Yes Severe Yes Moderate Yes 5 Yes 
Patient 5 Day 62 Saliva Treatment 2 No 0 No AB Category 4 Yes 157 Yes Yes No No Grade 3 Yes Severe Yes Moderate Yes 2 Yes 
Patient 5 Day 68 Saliva Treatment 2 No 0 No AB Category 4 Yes 181 Yes Yes No No Grade 2 Yes Severe Yes Severe Yes 0 No 
Patient 5 Day 86 Saliva Treatment 2 No 0 No AB Category 3 Yes 253 Yes Yes No No Grade 0 No Mild Yes No No 0 No 
Patient 5 Day 2 Buccal Pre-treatment Yes 2 Yes AB Category 0 No 0 No No No No Grade 0 No Severe Yes No No  No 
Patient 5 Day 6 Buccal Treatment 1 Yes 6 Yes AB Category 0 No 0 No No No No Grade 0 No Severe Yes No No 0 No 
Patient 5 Day 9 Buccal Treatment 1 Yes 9 Yes AB Category 3 Yes 6 Yes No Yes Yes Grade 0 No Severe Yes Moderate Yes 5 Yes 
Patient 5 Day 15 Buccal Treatment 1 No 9 Yes AB Category 3 Yes 24 Yes No Yes No Grade 1 Yes Severe Yes Mild Yes 0 No 
Patient 5 Day 19 Buccal Treatment 1 No 5 Yes AB Category 2 Yes 32 Yes Yes No No Grade 1 Yes Severe Yes Mild Yes 0 No 
Patient 5 Day 26 Buccal Treatment 1 No 0 No AB Category 4 Yes 54 Yes Yes No No Grade 2 Yes Severe Yes Mild Yes 0 No 
Patient 5 Day 34 Buccal Treatment 1 No 0 No AB Category 2 Yes 84 Yes Yes No No Grade 0 No Severe Yes No No 0 No 
Patient 5 Day 42 Buccal Treatment 2 Yes 2 Yes AB Category 2 Yes 100 Yes Yes No No Grade 0 No Mild Yes No No 0 No 
Patient 5 Day 47 Buccal Treatment 2 Yes 7 Yes AB Category 2 Yes 110 Yes Yes No No Grade 0 No Mild Yes No No 0 No 
Patient 5 Day 56 Buccal Treatment 2 No 0 No AB Category 4 Yes 133 Yes Yes Yes Yes Grade 2 Yes Severe Yes Moderate Yes 6 Yes 
Patient 5 Day 58 Buccal Treatment 2 No 0 No AB Category 4 Yes 141 Yes Yes Yes Yes Grade 3 Yes Severe Yes Moderate Yes 5 Yes 
Patient 5 Day 62 Buccal Treatment 2 No 0 No AB Category 4 Yes 157 Yes Yes No No Grade 3 Yes Severe Yes Moderate Yes 2 Yes 
Patient 5 Day 68 Buccal Treatment 2 No 0 No AB Category 4 Yes 181 Yes Yes No No Grade 2 Yes Severe Yes Severe Yes 0 No 
Patient 5 Day 86 Buccal Treatment 2 No 0 No AB Category 3 Yes 253 Yes Yes No No Grade 0 No Mild Yes No No 0 No 
Patient 5 Day 56 Lesion Treatment 2 No 0 No AB Category 4 Yes 133 Yes Yes Yes Yes Grade 2 Yes Severe Yes Moderate Yes 6 Yes 
Patient 5 Day 58 Lesion Treatment 2 No 0 No AB Category 4 Yes 141 Yes Yes Yes Yes Grade 3 Yes Severe Yes Moderate Yes 5 Yes 
Patient 5 Day 62 Lesion Treatment 2 No 0 No AB Category 4 Yes 157 Yes Yes No No Grade 3 Yes Severe Yes Moderate Yes 2 Yes 

















1. Positioning of the research 
Although chemotherapeutic agents for cancer treatment already exist for more than 75 
years and supportive care is getting more and more attention, cancer patients still have to deal 
with many side effects of chemotherapy. One of the major side effects is mucositis, an 
inflammation and ulceration of the mucosa, which can occur along the entire alimentary tract. 
It has a large negative impact on the quality of life of patients and can cause delay of the cancer 
treatment. Unfortunately, treatment options are elusive. Many chemotherapeutic agents are 
known to induce mucositis. In this thesis, we chose to focus on 5-FU and irinotecan (SN-38), 
two commonly used chemotherapeutic agents with high incidences of mucositis.  
In line with the general increasing interest in host microbiome research, the microbiota 
are thought to play an essential role in the development of both oral and gastrointestinal 
mucositis. Host-microbe interaction processes during mucositis and the impact of 
chemotherapy on these interactions are however largely underexplored. Certain studies 
showed that chemotherapy induces clear shifts in the microbiome, yet shifts are inconsistent 
between studies. The basic research question that prevails concerns the etiology of mucositis: 
1) do chemotherapeutics directly cause microbial dysbiosis, thereby increasing mucositis risk 
or 2) does the chemotherapy subjected host environment disturb the microbiome thereby 
aggravating the disease.  
In higher grades of mucositis, ulcerations will increase the pain and discomfort for the 
patient. These ulcers are highly colonized by bacteria and the loss of mucosal barrier will 
increase the risk of infection. The dysbiotic state of the microbiome may further provide the 
opportunity to pathogens to cause both local and systemic infections. Healing of the wounds 
is therefore essential for the recovery from mucositis and usually occurs spontaneously. 
However, the impact of the bacteria during the healing of these wounds is largely unknown.  
To further unravel the role of the host microbiota in the development of chemotherapy-
induced mucositis, we investigated 1) the direct effect of chemotherapeutic agents on both oral 
and gastrointestinal microbiota in vitro, 2) the interactions between the host, its microbiota and 
chemotherapeutic treatment both in vitro and in vivo. 
.  




2. Main research outcomes 
To gain more knowledge about the impact of chemotherapy on the microbiota in the 
context of alimentary mucositis different experimental set-ups were applied: a monoculture 
study (Chapter 2), an in vitro colon simulation (Chapter 3), an in vitro oral mucosa model 
(Chapter 4), and an in vivo longitudinal observational study of the oral microbiome (Chapter 5). 
The main research outcomes are summarized in Figure 6.1. 
In Chapter 2 a monoculture study showed that 5-FU sensitivity varies among oral 
microorganisms at physiologically relevant concentrations. Some species were highly resistant 
to all tested concentrations (0.1-50 µM 5-FU), whereas others had a reduced growth and 
viability already at 0.4 µM 5-FU. Dihydropyrimidine dehydrogenase, an enzyme involved in 
5-FU resistance in humans, did not impact the resistance of the microorganisms.  
An ecosystemic approach was used in Chapter 3 to assess the effect of chemotherapy 
on the gut microbiome. Fecal samples of different healthy individuals were incubated in an 
M-SHIME® (Mucosal-Simulator of the Human Intestinal Ecosystem) and exposed to 5-FU or 
SN-38 (active metabolite of irinotecan). For both chemotherapeutic agents, no clear effect on 
metabolic activity or microbial composition was observed. As this in vitro model does not 
include a host compartment, we hypothesize that the host is crucial in the establishment of 
chemotherapy-induced microbial shifts in vivo.  
Based on these findings, the second part of this research focused on the interactions 
between microbiota, chemotherapy and the host. The research in Chapter 4 showed that oral 
microbiota reduce wound healing capacity of oral epithelial cells, an important process in 
recovering from mucositis. For healthy donors, wound healing capacity was inversely 
correlated with microbial load. However, this was not the case for patient samples, probably 
due to the higher abundance of pathogenic genera combined with a less diverse microbial 
community. Again, the direct impact of 5-FU on the microbiome was limited.  
Finally, an in vivo longitudinal study of the oral microbiome of pediatric patients treated 
for hematological malignancies and suffering from oral mucositis was performed in Chapter 5. 
Major patient-specific shifts in the oral microbial community were observed during and 
following chemotherapeutic treatments. Chemotherapy and mucositis only induced minor 
microbial shifts, whereas the use of antibiotics had a major impact. Also neutropenia, 
inflammation and the use of antibacterial mouth rinse with chlorhexidine correlated with 
microbial changes. Despite the major shifts, the microbial community partially recovered after 
therapy. 
Overall, this research provided unique and valuable information concerning the effect of 
chemotherapy on the host microbiota. However, inclusion of more individuals will be crucial in 




Figure 6.1 - Schematic overview of the research chapters and their main outcomes. 
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3. Crucial factors in chemotherapy-induced microbial shifts 
3.1 The importance of the host and its immune system in chemotherapy-
induced mucositis 
Pre-clinical models and clinical studies have already reported changes in the microbiome 
during both oral (reviewed by Vanhoecke et al. 2015b, Vasconcelos et al. 2016) and 
gastrointestinal (reviewed by Stringer 2013, Touchefeu et al. 2014) mucositis, which are 
described in detail in Chapter 1. Our in vitro research however, showed a limited direct effect 
of chemotherapeutic agents on the host microbiome (Chapter 3 and 4). As our models did not 
comprise a host (immune system) compartment, this indicates that the host and its immune 
system are crucial factors mediating the chemotherapy-induced microbial changes. Hence, 
we hypothesize that the chemotherapy-disturbed host environment and not the direct effect of 
the chemotherapy on the microbiome, is the primary trigger of microbial changes, thereby 
aggravating the mucositis process.  
Following chemotherapy, an inflammatory status with high levels of pro-inflammatory 
cytokines and NF-κB characterizes the mucosa during the first phases of mucositis (Sonis 
2004, Logan et al. 2008a). These host-related changes of the environment may impact the 
microbiome. Once the inflammatory state is established by the chemotherapeutic agent, 
microbiota can further aggravate or reduce the inflammation, depending on the microbial 
community composition. Some commensals can reduce active NF-κB levels (Kelly et al. 2004, 
O'hara et al. 2006), whereas pathogens can increase the inflammation by activation of 
TLR/NF-κB pathway via MAMPs (Vanhoecke and Stringer 2015, Vasconcelos et al. 2016). 
In Chapter 1, a triangular model was proposed to describe the interactions between 
chemotherapy, the host and its microbiota. However, our results show that the impact of 
chemotherapeutic agents on the microbiota is limited. Therefore, we propose a more linear 
model, in which the effect of chemotherapy to the microbiome is expressed via the host (Figure 
6.2). In this model, the host environment will first be disturbed by the chemotherapeutic agent 
which induces an inflammatory status. This will induce microbial changes, which may further 




Figure 6.2 – Interactions between host, microbiota and chemotherapy: from a triangular to a linear model. 
3.2 The importance of antibiotics in chemotherapy-induced mucositis  
Next to the host-mediated effects of the chemotherapeutic agents, other factors can 
impact the microbiome during cancer treatment and mucositis. An important factor, which has 
been largely discussed in literature, is the use of antibiotics. Different local antimicrobial 
agents were tested to reduce oral mucositis. However, none of them is recommended by the 
MASCC/ISOO guidelines (Lalla et al. 2014). Multiple studies showed that a local oral antibiotic 
treatment with polymyxin E, tobramycin and amphotericin B (PTA) did not impact the incidence 
or severity of oral mucositis, although it did change the microbial community composition by 
lowering the abundance of Gram-negative species (Wijers et al. 2001, Stokman et al. 2003, 
Stokman et al. 2006). The antibacterial agent chlorhexidine is still commonly used to prevent 
mucositis or to reduce its severity (Rodriguez-Caballero et al. 2012). As conflicting results were 
reported (Stokman et al. 2006, Stringer and Logan 2015), no guideline towards its use in 
patients treated with chemotherapy could be set (Lalla et al. 2014). For patients receiving 
radiotherapy however, the use of chlorhexidine is not recommended (Lalla et al. 2014). 
Recently, a meta-analysis further discouraged the use of chlorhexidine during mucositis as no 
positive effect on mucositis was reported (Cardona et al. 2017). Compared to brushing the 
teeth, chlorhexidine use did not have an inhibitory effect towards mucositis development, nor 
towards infection risk (Antunes et al. 2010a). The main goal of all these local antimicrobials is 
to selectively eliminate certain oral microbiota, such as aerobic Gram-negative bacteria (Wijers 
et al. 2001). Thereby, these antimicrobials all lead to shifts in the microbiome. In our in vivo 
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study, we indeed observed an impact of chlorhexidine mouth rinse on the oral microbial 
community composition (Chapter 5). Similarly, the use of chlorhexidine mouth rinse by healthy 
individuals, shifted their tongue and saliva microbial community composition (Exterkate et al. 
2015). In vitro, chlorhexidine has been shown to reduce the relative abundance of 
Streptococcus, Solobacterium and Megasphaera, the microbial diversity and the amount of 
viable cells of oral biofilms (Mostajo et al. 2017). This all indicates a shift to a disturbed 
microbial community and a lack of clinical evidence in favor of the use of chlorhexidine for 
mucositis. Therefore, we do not support the use of a chlorhexidine mouth rinse in mucositis 
patients, which is in line with the MASCC/ISOO guidelines (Lalla et al. 2014).  
Not only local antimicrobial agents, but also systemic antibiotics may have large effects 
on the host microbiome (Chapter 5). Both therapeutic and prophylactic antibiotics can impact 
all host microbiota with disturbances depending on the specific agent, the absorption, the route 
of elimination, and possible enzymatic inactivation and/or binding to fecal material (Sullivan et 
al. 2001). Most of the research concerning the impact of systemic antibiotics on the host 
microbiome is conducted focusing on the gastrointestinal microbiome in the context of 
antibiotic-associated diarrhea, a frequent side effect of antibiotic treatment (Sullivan et al. 
2001, Silverman et al. 2017). However, also the oral microbiome can be disturbed by systemic 
antibiotics (Sullivan et al. 2001), although more research is needed to get a better view on the 
impact of systemic antibiotics towards the oral microbiome. The use of antibiotics may not only 
shift the commensal microbiome, but also change the infection pattern. The use of prophylactic 
antibiotics for high risk cancer patients was previously reported to cause a prominent shift in 
infection cultures from Gram-negative to Gram-positive species in the nineties (Zinner 1999). 
This leads to large numbers of Streptococcus viridans infections in cancer patients (section 4).  
Thus, both local and systemic antibiotics may impact the oral and gut microbiome. The 
microbiota are however crucial in maintaining homeostasis in both the oral cavity (Marsh 2012) 
and the gastrointestinal tract (Sekirov et al. 2010). The establishment of colonization resistance 
by a normal healthy community, for example, will prevent the colonization of exogenous 
pathogens. However, long-term use of antibiotics will suppress the resident microbiota, leading 
to a dysbiotic ecosystem in which exogenous microbiota are able to colonize the oral cavity 
or the gastrointestinal tract (Marsh 2012, Silverman et al. 2017). Moreover, low abundant 
endogenous microbiota can become dominant and change the microbial composition and 
metabolic activity (Marsh 2003). The eradication of microbiota by use of prophylactic antibiotics 
resulted for example in an overgrowth of pathogens in the gut of AML patients (van Vliet et al. 
2009). The common infectious pathogen Clostridium difficile is the most important source of 
antibiotic-associated diarrhea (Wilcox 2003). An unbalanced microbial ecosystem with lower 
microbial diversity and higher abundances of pathogenic species will probably be more 
sensitive to stress factors (Wittebolle et al. 2009). For one patient, lower microbial diversity 
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was indeed linked with major changes in the microbial community composition after 
chemotherapeutic treatment (Chapter 4). The interindividual response to chemotherapy for 
samples with a low diversity is probably related with a different microbial composition in 
combination with differential sensitivity to chemotherapy among microorganisms (Chapter 2). 
In conclusion, chemotherapy will create a high inflammatory status which may induce 
changes in the microbiome. The use of systemic or local antibiotics may further disrupt the 
microbial community and thereby aggravate the mucositis process. Moreover, this unbalanced 
microbiome may be more susceptible to additional chemotherapeutic treatments, leading to 
an even more unbalanced microbiome. 
4. Oral streptococci: friends or foes? 
One of the most important bacterial genera in the oral cavity is Streptococcus. All oral 
communities (saliva, tongue, plaque…) are highly colonized with streptococci, with the highest 
abundances (around 50 %) in the buccal mucosa (Segata et al. 2012). Their ability in adhering 
to teeth or mucosal surfaces makes them one of the pioneering species in biofilm formation. 
Cell multiplication and integration of other bacteria will create a mature biofilm and prevent the 
bacteria from being excreted with the salivary flow (Nobbs et al. 2009, Kolenbrander et al. 
2010). Therefore, following each oral hygiene measure, streptococci are essential in rebuilding 
the oral biofilm (Kolenbrander et al. 2010). All our data confirmed that Streptococcus is a highly 
dominant genus in the oral cavity. In our in vitro co-culture model, biofilm formation based on 
oral samples was dominated with Streptococcus (Chapter 4). In the longitudinal patient study 
we observed high levels of Streptococcus in most of the samples and in general higher levels 
were seen in buccal samples, compared to saliva samples (Chapter 5). Moreover, all tested 
commensal Streptococcus strains were resistant to 5-FU in our study (Chapter 2). This 
indicates high resistance of streptococci against chemotherapeutic agents. 
Although streptococci belong to the resident commensal oral microbiota, they often 
cause infections in cancer patients. In particular the viridans streptococci are known to be 
a major source of infection during neutropenia (Shenep 2000). These viridans streptococci are 
non-hemolytic or α-hemolytic and contain multiple species such as S. mitis, S. oralis, 
S. sanguis, S. gordonii, S. crista, S. salivarius and the S. mutans group. (Tunkel and Sepkowitz 
2002). In the oral cavity, they are the first persistent colonizers after birth (Pearce et al. 1995). 
They not only reside in the oral cavity but also in the respiratory tract, the female genital tract 
and the entire gastrointestinal tract (Tunkel and Sepkowitz 2002). The attention for viridans 
streptococci infections has grown since the nineties, when the main strains causing blood 
stream infections in cancer patients with febrile neutropenia shifted from Gram-negative to 
Gram-positive species (Zinner 1999, Gustinetti and Mikulska 2016). However, today the 
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reverse trend is observed in many hospital care units with Gram-negative species taking over 
again (Gustinetti and Mikulska 2016). Still, viridans streptococci are one of the important 
Gram-positive blood cultures. This resulted in the experimental use of mouth rinses targeting 
Gram-positive species, for example containing vancomycin. The use of vancomycin mouth 
rinse was correlated with low viridans streptococci sepsis in a retrospective study of pediatric 
AML. However, the overall blood stream infections were not affected and infections with 
Staphylococcus species were high (Brunet et al. 2006). In our in vivo study, one patient used 
a vancomycin mouth spray and this was correlated with a reduced abundance of 
Streptococcus in the oral samples (Chapter 5). However, during this period, a positive blood 
culture for viridans streptococci was observed for this patient. Possible explanations are that 
the residing viridans streptococci became more pathogenic and virulent, or that the infection 
was coming from another source instead of the oral cavity. The stomach for example has been 
shown to be an important entry point for viridans streptococci following chemotherapeutic 
treatment (Tunkel and Sepkowitz 2002). Recent studies in our lab have shown that most of 
the oral microbiota (including multiple Streptococcus species) are much less sensitive to 
vancomycin, compared with chlorhexidine, at least for short incubation periods, mimicking the 
use of a mouth rinse (Beterams 2017). This all indicates that the use of vancomycin mouth 
spray is not advised to lower the infection risk, although more research is needed to confirm 
this.  
In conclusion, the use of antibiotics will always favor certain microbiota, as the niche of 
the targeted microbiota becomes available for others. This may lead to an unbalanced 
community with low diversity and outgrowth of specific endogenous or exogenous pathogens. 
Therefore, the use of preventive antibiotics should be limited as much as possible to give the 
commensal microbiota the opportunity to re-establish their normal community, which will create 
homeostasis. During this re-establishment, streptococci will be crucial as they are the first 
colonizers of the immature biofilm. To reduce infection risk, it is however important to keep the 
absolute number of microbiota low for instance by mechanical cleaning such as tooth brushing.  
5.  (Future) use of in vitro models in mucositis research 
5.1 In vitro versus in vivo studies in mucositis research  
The impact of chemotherapy on the microbiome and the impact of the microbiome on 
mucositis can be studied both in vitro and in vivo each with their own strengths and limitations. 
While in vitro technologies will never exactly mimic the in vivo situation, physiological 
conditions are more accessible to high-throughput research and mechanistic studies in 
particular (Papadimitriou et al. 2015). Multi-parametric control allows several confounding 
factors to be controlled. This includes the use of microbiota from actual human origin as 
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opposed to animal microbiota from in vivo models and the possibility of including different types 
of host cells to study host-microbe interactions more in depth. In our case, in vitro setups for 
studying chemotherapy-microbiota interactions (Chapter 2 and 3) were used and models with 
the inclusion of host cells (Chapter 4) were used to study a specific phase of the mucositis 
process, namely wound healing. While our research primarily targeted epithelial processes, 
the addition of immune cells as a fourth element would make it even more physiologically 
relevant (Fontana et al. 2013).  
In vivo research is always needed to confirm the mechanisms revealed by in vitro 
technologies. Both animal and clinical studies have the strength to be physiologically more 
relevant, but they are limited by higher costs and ethical constraints (Papadimitriou et al. 2015). 
Animal studies are largely used in mucositis research (Vanhoecke et al. 2015a). However, 
microbial shifts and host-microbe interactions might be different in animals in comparison to 
humans (Nguyen et al. 2015). Next to ethical constraints, clinical trials may have to deal with 
large numbers of confounding factors, that also impact the microbiome composition 
(Chapter 5). As our research revealed that the host and its immune system are crucial in 
chemotherapy-induced microbial shifts, the use of in vivo trials or in vitro technologies including 
host immune cells might be preferred in the future to get a better view on the host-microbiota-
chemotherapy interactions. 
5.2 (Future) opportunities for in vitro studies in mucositis research  
Both in the in vitro co-culture model (Chapter 4) and in the in vivo observational study 
(Chapter 5), Streptococcus and Veillonella were highly abundant genera. Streptococcus is 
one of the initial biofilm colonizers (Kolenbrander et al. 2010) and is highly abundant in the 
buccal mucosa (Segata et al. 2012). Moreover, Streptococcus is acid-resistant and therefore 
important in caries, as it can convert glucose into lactic acid (Marsh 2003). Veillonella on the 
other hand, can consume this lactic acid and in this way take advantage of the presence of the 
streptococci (Kolenbrander 2000). So for healthy individuals, Streptococcus and Veillonella 
were the main genera included in the biofilm formation in the in vitro co-culture model.  
In contrast, high interindividual differences in microbial composition were observed in the 
in vitro model when samples from patients suffering from mucositis were used. For each 
patient, one genus (Streptococcus, Enterococcus or Abiotrophia) was highly dominating the 
model, leading to a low diversity. As this mostly resembles in vivo mucositis lesion samples 
(Chapter 5) (Ye et al. 2013), this made us conclude that the oral in vitro co-culture model is 
primarily a pathological model, in which a certain genus/genera is/are dominating the 
community. The composition of the initial oral sample will determine the final composition in 
the model and has been shown to be more variable in patients suffering from mucositis 
compared to healthy individuals (Ye et al. 2013). Hence, by using saliva samples of patients, 
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a community more similar to the lesion microbiome is created in the model to investigate its 
interactions with the wound healing process. 
In conclusion, the use of in vitro models is encouraged to further investigate the impact 
of microbiota on wound healing and to unravel the mechanisms behind. A longitudinal 
follow-up of patients samples in the model before, during and after mucositis, could provide 
more details on the effect of the shifting microbiome on wound healing capacity. Moreover, our 
studies only checked for shifts in the microbial DNA, based on 16S rRNA gene DGGE or 
Illumina amplicon sequencing. Measuring activity of the microbiome (RNA level), proteomics 
or metabolomics, could reveal more details about changes in activity profiles and underling 
mechanisms. Our data further suggest that to study chemotherapy-induced microbial shifts, 
the incorporation of a host compartment, including immune cells is essential in in vitro setups. 
6. Treatment approaches for mucositis 
6.1 Do oral and gastrointestinal mucositis need a different treatment 
approach? 
Oral and gastrointestinal mucositis are both described by a 5-phases model comprising 
of an initiation, messenger amplification, proliferation, ulceration and healing phase (Sonis 
2004). However, the question rises if this also implies that a similar treatment approach should 
be used for both pathologies? Several factors crucial for mucositis will be described below, to 
conclude with a suggested treatment approach. 
Both oral and gastrointestinal mucositis are characterized by a disturbed mucosal 
barrier function. The combination of an increased epithelial permeability and the disruption of 
the mucus layer will enhance the ability of microbiota to reach the submucosa (Sonis 2004). 
This will make patients suffering from mucositis more prone to secondary infections, 
bacteremia and sepsis (Vasconcelos et al. 2016). In healthy conditions, the epithelial integrity 
is established by tight junction proteins, intercellular complexes providing a primary barrier. 
Alteration of tight junction proteins following chemotherapy can lead to ulcer development or 
reduced tissue integrity in both the gastrointestinal tract and in the oral cavity (Wardill et al. 
2012, Wardill et al. 2016). Moreover, chemotherapy-induced diarrhea is linked with an 
increased intestinal permeability (Russo et al. 2013). Next to epithelial integrity, the mucosal 
barrier function is established by the mucus layer. Also here, chemotherapy can reduce this 
barrier compartment as it may impact mucus secretion (Stringer et al. 2009c). 
An important feature in recovering from mucositis and in restoring the mucosal barrier is 
wound healing. A high microbial load is linked with a reduced wound healing capacity and 
increases the risk of infection (Chapter 4; Edwards and Harding 2004). The importance of 
microbial density in the wound healing process has previously been shown by De Ryck et al. 
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(2015). In other oral diseases such as gingivitis and periodontitis, a high microbial biomass is 
also linked with disease development (Meyle and Chapple 2015, Kilian et al. 2016). To reduce 
this microbial load in the oral cavity, good oral hygiene is essential, both in healthy and 
diseased state (McGuire et al. 2013). The use of oral care protocols, including regular basic 
oral hygiene (tooth brushing and flossing), professional examinations, education of patients 
and family and an interdisciplinary approach are advised by MASCC/ISOO guidelines in the 
management of oral mucositis (Keefe et al. 2007, McGuire et al. 2013, Lalla et al. 2014). 
Moreover, normal saline and sodium bicarbonate mouth washes may help maintaining oral 
hygiene, as they are harmless and improve patient comfort (McGuire et al. 2013). However, 
we and others have shown that the use of antimicrobial mouth rinses for oral mucositis are not 
recommended, as they do not significantly prevent mucositis or reduce infection risk. On the 
contrary, they can negatively impact the oral microbial community, which may in turn lead to 
an unbalanced microbiome (section 3.2)  
Not only the microbiota themselves, but also their secretion products can enhance or 
reduce wound healing capacity (Wilson and Gibson 1997, Laheij et al. 2013). Short chain 
fatty acids (SCFA) are able to enhance wound healing of colonic epithelial cells (Wilson and 
Gibson 1997) and to reduce intestinal permeability and gastrointestinal mucositis in mice 
(Ferreira et al. 2012). In contrast, De Ryck et al. (2015) showed that accumulation of (a) 
microbial metabolite(s) is responsible for a reduction in wound healing and quorum sensing 
molecules were thought to be involved in this process. Microbiota use quorum sensing 
molecules (autoinducers) to regulate gene expression of cell-density dependent processes 
such as biofilm formation, antibiotic production and virulence. Gram-negative bacteria use 
acetylated homoserine lactones, whereas Gram-positive bacteria use processed oligopeptides 
(Miller and Bassler 2001). Moreover, quorum sensing molecules allow communication 
between bacteria and their host (Hughes and Sperandio 2008). As microbial load and quorum 
sensing seems important during the wound healing phase of mucositis, quorum sensing 
inhibitors (Antunes et al. 2010b, Defoirdt et al. 2013) could be an interesting lead to explore in 
the context of mucositis in the future. By targeting virulence instead of viability of microbial 
species, problems such as increasing antibiotic resistance could be solved (ten Cate and 
Zaura 2012). 
We suggested in this thesis that the host is a crucial intermediate in chemotherapy-
induced microbial shifts (section 3.1 and Chapter 3). Before the start of membrane disruptions, 
activation of the innate immune system and further production of pro-inflammatory cytokines 
are the first steps in the development of mucositis and are initiated by the cancer treatment 
(Sonis 2007, Vasconcelos et al. 2016). Following disruption of the epithelial barrier not only 
DAMPs, but also MAMPs may increase inflammation by NF-κB activation in a TLR-dependent 
manner (Vasconcelos et al. 2016). The changed host environment characterized by a high 
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inflammatory status may shift the microbiome both before and following barrier disruption. 
This disturbed microbiome might impact the recovery from mucositis, as the microbial 
community composition is another factor which may impact wound healing capacity for 
patients (Chapter 4). Our data confirmed previous research stating that wound healing is not 
only density dependent, but also species dependent (De Ryck et al. 2015). An unbalanced 
microbiome might therefore lead to a slow recovery from mucositis, but more research on 
which species will improve or delay wound healing is needed. The importance of the host and 
its immune system in creating these microbial shifts during mucositis is similar to other oral 
diseases. The shift from gingivitis to periodontitis with co-occurring microbial shifts only takes 
place when a high microbial load is combined with an increased inflammatory status, which 
creates a niche for anaerobes (Meyle and Chapple 2015, Kilian et al. 2016). Treatment 
approaches should therefore also focus on the re-establishment of a balanced microbiome. 
Different plaque hypotheses were described in the last centuries and every oral disease 
can be linked to multiple of these hypotheses (Rosier et al. 2014). Based the findings described 
above, mucositis can be linked to three of these hypotheses. First, the ‘updated non-specific 
plaque hypothesis’, in which the density of the microbiota is crucial in combination with the fact 
that resident oral microbiota can become virulent (Theilade 1986). Next, Marsh (1994) linked 
the overgrowth of pathogenic bacteria to an imbalance of the oral ecosystem caused by an 
ecological stress in the ‘ecological plaque hypothesis’. Additionally he stated the inverse, that 
bacteria can influence the environment (Marsh 1994). The most recent ‘Keystone-pathogen 
hypothesis’, added the importance of the host, its immune system and low-abundant microbial 
pathogens (Hajishengallis et al. 2012, Rosier et al. 2014). 
In conclusion, although the exact role of microbiota is still not clear, we hypothesize that 
chemotherapy damages the host by disrupting the mucosal barrier, which makes it in turn more 
susceptible to infections (Vasconcelos et al. 2016). Local infections can aggravate the 
mucositis process and as most of the cancer patients are immunocompromised, systemic 
infections could have major consequences. Therefore, we propose that improvement of the 
mucosal barrier has to be the first major goal of mucositis treatment, as it reduces the risk of 
infection. In the past, different strategies targeting specific microbial groups with antimicrobial 
agents were investigated for oral mucositis without any success. As also commensal bacteria 
(f.e. streptococci) can induce infections and multiple infectious pathogens are known, targeting 
the pathogenic microbiota does not seem a proper approach. A better option to speed up the 
wound healing process, is to keep the bacterial load low enough in oral mucositis by 
mechanical removal of bacteria. Although it is an old method, it is still today the most efficient 
way of preventing diseases in the oral cavity as it reduces the bacterial load, without disturbing 
the community composition (Rosier et al. 2014). For gastrointestinal mucositis, keeping the 
microbial load low, without disturbing the entire community, is practically less feasible. 
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Therefore, the use of anti-inflammatory or immune-suppressive agents, shown to establish 
mucosal healing in inflammatory bowel disease (De Cruz et al. 2013), could be a possible 
treatment option in restoring mucosal barrier in gastrointestinal mucositis. Probiotics should be 
used with extra care due to neutropenia periods in cancer patients, but the use of prebiotics to 
restore the barrier function might be of interest and will be further discussed in the next section. 
Once the mucosal barrier is restored, the second step should be to restore the 
microbiome as the cancer treatment indirectly also induces microbial shifts. In our in vivo 
study, we reported that the oral microbiome recovers spontaneously to its initial composition 
after finishing all chemotherapeutic treatments in the oral cavity of pediatric patients treated 
for hematological malignancies (Chapter 5). However, a sustained lower microbial diversity 
was observed in the follow-up samples, indicating that extra measures could help for a full and 
fast recovery. Possible new treatment approaches such as pre- and probiotics could be 
investigated in this perspective and will be further discussed in next section. Another approach 
might be a preventive treatment with pre- and probiotics targeting a balanced and diverse 
microbiome before the start of chemotherapy, in order to prevent disturbances of the 
microbiome during cancer treatment. Both for oral diseases (Bizzarro et al. 2016) and 
gastrointestinal diseases (Michail et al. 2012) higher microbial diversity has been linked with 
better clinical treatment outcomes. Further, a personalized approach is possibly required due 
to the large interindividual differences in the microbiome, the chemotherapeutic regimen, the 
catabolism of chemotherapeutic agents (for example DPD deficiency), the activity of the host 
immune system, etc.  
6.2 Future treatment options 
Probiotics are defined as ‘a live organism that, when ingested in adequate amounts, 
exerts a health benefit to the host’ and are promising treatment options for many gut diseases 
(Whelan and Quigley 2013). They exert many beneficial functions on pathways which are 
important in mucositis and thereby makes them an interesting treatment approach to study. 
Their mechanisms of action depend on the strain, but include 1) restoration the mucosal 
barrier, by increasing tight junctions, enhancing epithelial function or stimulating mucin 
secretion, 2) modulation of the inflammatory immune response by interaction with signaling 
pathways such as NF-κB and MAPK, thereby influencing cytokine profiles, and  
3) displacement of pathogenic bacteria (Lebeer et al. 2010, Thomas and Versalovic 2010, van 
Vliet et al. 2010, Whelan and Quigley 2013, Vasconcelos et al. 2016).  
Most of the research concerning the use of probiotics for mucositis has focused on 
gastrointestinal mucositis. Promising results with Lactobacillus and Streptococcus strains 
have been shown in pre-clinical models of chemotherapy-induced mucositis. However, varying 
effects are observed depending on the model, the strain, the dosing and the treatment plan 
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(Touchefeu et al. 2014). Clinical trials with probiotics in chemotherapy-induced mucositis are 
limited so far, although some studies showed that probiotics exerted positive effects on the gut 
and its microbiome (Osterlund et al. 2007, Wada et al. 2010). More studies have been 
performed for radiotherapy-induced mucositis, but inconsistent results point to the importance 
of finding the correct strain and dose for each clinical setting (Touchefeu et al. 2014, Ciorba et 
al. 2015). Although the effectiveness of probiotics is shown in other gastrointestinal disorders, 
like inflammatory bowel disease (IBD), also there, recommendations are needed for specific 
strains and specific symptoms (Whelan and Quigley 2013). 
For oral mucositis, clinical trials concerning the use of probiotics are even more limited. 
However, some promising results are shown with Lactobacillus brevis CD2 lozenges (Sharma 
et al. 2012) and AG013, an oral rinse containing recombinant Lactococcus lactis secreting 
mucosal protectant human trefoil factor 1 (hTFF1) (Limaye et al. 2013) as both reduced the 
severity of oral mucositis. In other oral diseases, the interest in probiotics has also grown the 
last decades and studies are supportive for the use of probiotics for periodontitis and gingivitis. 
However, more clinical studies are necessary (Haukioja 2010, Gruner et al. 2016). 
Some safety concerns must be noted towards the use of probiotics for both 
gastrointestinal and oral mucositis, as most of the patients are immunocompromised due to 
the disease and/or the treatment (Touchefeu et al. 2014). In combination with the increased 
permeability and lesions during mucositis, the risk of infection is very high. As also commensal 
microbiota, such as viridans streptococci can cause systemic infections, one should be very 
cautious with the use of probiotics in immunocompromised patients. Although the use of 
probiotics in immunocompromised patients is shown to be safe (Van den Nieuwboer et al. 
2014), translocation and infections by probiotics in immunocompromised patients have been 
reported (Liong 2008). Therefore, the use of probiotics is probably best advised as a preventive 
measure for mucositis, before the start of chemotherapy and co-occurring neutropenia, or as 
a post-treatment option to facilitate recovery to a balanced microbiome (Vasconcelos et al. 
2016). 
Alternative options without generating a risk for invasive infections could be considered, 
such as the use of bacterial parts or prebiotics. The use of bacterial parts (such as 
immunostimulatory DNA sequences) has been shown to be sufficient to reduce inflammation 
for colitis (Rachmilewitz et al. 2002, Borchers et al. 2009). However, no studies in the context 
of mucositis were conducted so far. The concept of prebiotics was first described in 1995 
(Gibson and Roberfroid 1995) and defined as ‘a selectively fermented ingredient that allows 
specific changes, both in the composition and/or activity in the gastrointestinal microbiota that 
confers benefits upon host well-being and health’ (Roberfroid 2007). Although largely 
investigated in gastrointestinal diseases, only a few studies were performed on their 
effectiveness in mucositis (Smith et al. 2008, Baffoni et al. 2012). However, prebiotics may 
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impact the microbiota, the mucus layer, the immune system and inflammatory status, without 
adding an extra bacterial load, and makes them therefore promising candidates for treatment 
of gastrointestinal mucositis (Wang et al. 2016). Also in the oral cavity, nutritional stimulation 
of beneficial microbiota by prebiotics could improve recovery of a balanced microbiome 
(Slomka et al. 2017). As the area of prebiotics is largely underexplored and preliminary 
research is promising, this might be an interesting way to go in the future for mucositis 
treatment.  
7. Conclusions 
The oral and gastrointestinal microbiota are gaining more and more importance in the 
development of mucositis. As treatment options are elusive and incidences of chemotherapy-
induced mucositis are still high, a better knowledge of the impact of chemotherapy on the host 
microbiome is eligible. By using in vitro technologies and a clinical study in pediatric patients 
suffering from mucositis, we have shown that:  
- 5-FU sensitivity varies among oral microorganisms at physiologically relevant 
concentrations and this is not mediated by dihydropyrimidine dehydrogenase; 
- both 5-FU and irinotecan (SN-38) have limited impact on the colon microbial activity 
and composition; 
- oral microbiota reduce wound healing of epithelial monolayers, irrespective of the 
presence of 5-FU;  
- wound healing is inversely correlated with bacterial load for healthy individuals, 
whereas this is not the case for patients suffering from mucositis probably due the 
higher abundance of pathogenic genera combined with a less diverse microbial 
community; 
- major patient-specific shifts in the oral microbial community of pediatric patients treated 
for hematological malignancies occur during and after chemotherapeutic treatment, but 
partial recovery is observed at the follow-up;  
- chemotherapy and mucositis are only correlated with microbial shifts to a minor extent, 
whereas the use of antibiotics has a major impact and also neutropenia, inflammation 
and the use of antibacterial mouth rinse with chlorhexidine are correlated with microbial 
changes. 
These findings do not directly translate to a new treatment approach, but they highly 
encourage good oral hygiene during cancer treatment. Furthermore, they indicate the 
importance of the host and its immune system in the establishment of chemotherapy-induced 













Although chemotherapy exists already for more than 75 years, it is still associated with 
multiple side effects. A predominant side effect is mucositis, an inflammation and ulceration of 
the mucosa that can occur along the entire alimentary tract. Both oral and gastrointestinal 
mucositis majorly impact the quality of life of cancer patients. Oral mucositis can cause 
problems with eating, speaking and drinking and is characterized by oral pain, erythema, 
edema and ulcerations causing a higher infection risk. Symptoms of gastrointestinal mucositis 
include abdominal pain, diarrhea, constipation, bleeding and infections. Both types of 
mucositis may lead to a reduction or delay of cancer treatment and unfortunately good 
treatment options are elusive. A mounting body of evidence suggests a key role for the 
microbiota in mucositis development. However, the underlying mechanisms remain unclear. 
Microbial shifts have been observed following chemotherapy in both clinical and animal 
studies. However, it is not clear whether chemotherapy directly induces microbial shifts or if 
chemotherapy causes a disturbed host environment inducing microbial changes. In this thesis, 
we focused on two commonly used chemotherapeutic agents with high incidence of mucositis: 
5-fluorouracil (5-FU) and irinotecan (SN-38). 
In the first part of this research, the direct effect of chemotherapy on microbiota was 
investigated. In Chapter 2, the effect of physiologically relevant concentrations of 5-FU on the 
viability and growth of oral bacterial monocultures was investigated. 5-FU sensitivity varied 
among the tested oral species. Klebsiella oxytoca, Streptococcus salivarius, Streptococcus 
mitis, Streptococcus oralis, Pseudomonas aeruginosa and Lactobacillus salivarius appeared 
to be highly resistant to all tested concentrations (0.1-50 µM). In contrast, Lactobacillus oris, 
Lactobacillus plantarum, Streptococcus pyogenes, Fusobacterium nucleatum and Neisseria 
mucosa showed a significant reduction in growth and viability starting from very low 
concentrations (0.2–3.1 µM). We also provided evidence that dihydropyrimidine 
dehydrogenase, an enzyme involved in 5-FU resistance in humans, is not involved in the 5-FU 
resistance of the selected species. 
To assess the direct impact of chemotherapeutic agents on a complex microbial 
ecosystem, we used the M-SHIME®, an in vitro mucosal simulator of the human intestinal 
microbial ecosystem (Chapter 3). The direct impact of 5-FU and SN-38 on the luminal and 
mucosal gut microbiota from several human donors was investigated. At a dose of 10 µM, 
5-FU impacted the functionality and composition of the colon microbiota to a minor extent. 
Similarly, a daily dose of 10 µM SN-38 did not cause significant changes in the functionality or 




therefore assume that the changed microbiome observed in vivo is primarily induced by an 
altered host environment upon chemotherapeutic treatment. 
In the second part of this research, the interactions between the host, the microbiome 
and chemotherapeutic treatments were investigated in more detail. In Chapter 4, the effect of 
5-FU was assessed in an in vitro co-culture model that consists of an epithelial cell layer and 
a biofilm derived from oral microbiota from different oral regions (saliva, buccal and tongue 
swabs) and donors (healthy individuals and patients suffering from mucositis). Oral microbiota 
reduced wound healing capacity of epithelial cells with higher bacterial cell counts linked to 
lower wound healing capacity in healthy individuals. However, for patients suffering from 
mucositis wound healing was more related to microbial composition, rather than microbial load. 
Indeed, these oral samples were characterized by a disturbed microbial community and higher 
abundances of pathogenic genera. However, no major impact of 5-FU on wound healing 
capacity or the composition of the microbiome was seen. These results emphasize the 
importance of controlling bacterial load by oral hygiene for proper oral wound healing in healthy 
individuals. However, extra measures besides oral hygiene might be necessary to assure a 
good wound healing during mucositis.  
To assess the impact of chemotherapy in vivo, a longitudinal study of the oral microbiota 
from five pediatric patients, treated with chemotherapy for hematological malignancies and 
suffering from oral mucositis, was performed in Chapter 5. Microbial community composition 
analysis showed that large microbial dynamics were present throughout therapy in all patients, 
however shifts were patient-specific. Mucositis lesions were highly dominated by 
Streptococcus, but also by more pathogenic genera as Aggregatibacter, Enterococcus and 
Fusobacterium. Surprisingly, chemotherapy and mucositis had only a minor effect on microbial 
community composition, whereas one of the major confounding factors of our study was the 
use of systemic antibiotics as it majorly affected both microbial composition and diversity. 
Other confounding factors were sample type and sampling period, but also the use of 
antibacterial mouth rinse with chlorhexidine, neutropenia and inflammation. While the overall 
community composition seemed to return to its initial composition at least 1 month after 
therapy, a sustained impact towards a lower diversity was noted. This indicates the importance 
of long-term follow-up of oral health and good oral hygiene for these patients. 
In conclusion, this PhD research demonstrated that the direct effect of chemotherapy on 
the oral and gut microbiome is limited, but that the chemotherapy-disturbed host environment 
may largely impact the host microbiota. A low bacterial load may improve wound healing 
capacity and reduce risk of infection. Mechanical removal of oral microbiota is preferred, as 
antimicrobial rinses may cause microbial shifts leading to dysbiosis. However, long-term 
follow-up and extra measures are needed to assess a fast and full recovery of both host 
mucosa and microbiota in chemotherapy-induced mucositis.  
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Chemotherapie bestaat al meer dan 75 jaar, maar gaat nog steeds gepaard met veel 
neveneffecten. Een van de belangrijkste bijwerkingen is mucositis, die wordt gekenmerkt door 
een ontsteking en aften ter hoogte van de slijmvliezen van het spijsverteringsstelsel. Zowel 
orale als gastro-intestinale mucositis kunnen de levenskwaliteit van de patiënt sterk 
beïnvloeden. Oral mucositis kan problemen veroorzaken met spraak en voedselopname en 
wordt typisch gekenmerkt door pijn, roodheid, zwelling en ontstekingen in de mond, wat kan 
leiden tot een verhoogd risico op lokale en systemische infecties. De belangrijkste symptomen 
van gastro-intestinale mucositis daarentegen omvatten buikpijn, diarree, constipatie, 
bloedingen en infecties. Beide types van mucositis kunnen leiden tot een dosisreductie of zelfs 
uitstel van de kankertherapie. Tot op heden bestaan er nog steeds geen afdoende 
behandelingen voor mucositis.  
Recent onderzoek duidt een belangrijke rol aan voor de bacteriën in de darm en de mond 
bij de ontwikkeling van mucositis, al blijven de onderliggende mechanismen onduidelijk. Zowel 
klinische studies als dierenproeven hebben aangetoond dat zich veranderingen in de 
microbiële gemeenschap voordoen tijdens/na een behandeling met chemotherapie. Het is 
echter niet duidelijk of de chemotherapie zelf de microbiële veranderingen teweeg brengt of 
de chemotherapie de gastheeromgeving verstoort waardoor veranderingen in de microbiële 
samenstelling ontstaan. In deze thesis hebben we gefocust op twee courante 
chemotherapeutica waarvan de behandeling vaak gepaard gaat met het optreden van 
mucositis, namelijk 5-fluorouracil (5-FU) en irinotecan (SN-38). 
In het eerste deel van dit onderzoek werd het direct effect van chemotherapie op 
bacteriën onderzocht. Het effect van fysiologisch relevante concentraties 5-FU op de viabiliteit 
en groei van orale bacteriële monoculturen werd onderzocht in Hoofdstuk 2. Er werd 
aangetoond dat de gevoeligheid voor 5-FU varieert tussen de geteste orale species. Klebsiella 
oxytoca, Streptococcus salivarius, Streptococcus mitis, Streptococcus oralis, Pseudomonas 
aeruginosa en Lactobacillus salivarius bleken resistent bij alle geteste concentraties 
(0.1-50 µM). Lactobacillus oris, Lactobacillus plantarum, Streptococcus pyogenes, 
Fusobacterium nucleatum en Neisseria mucosa daarentegen vertoonden een significante 
reductie in groei en viabiliteit al vanaf zeer lage concentraties 5-FU (0.2-3.1 µM). Daarnaast 
werd aangetoond dat het dihydropyrimidine dehydrogenase enzym dat belangrijk is bij 5-FU 
resistentie in patiënten, geen rol speelt bij de resistentie bij de geteste bacteriële species.  
In Hoofdstuk 3 maakten we gebruik van de M-SHIME®, een in vitro model voor de 
humane colon bacteriën, om de directe impact van chemotherapeutica na te gaan op een 




darmbacteriën werd onderzocht voor verschillende donoren. Daaruit bleek dat een dosis van 
10 µM 5-FU slechts een beperkte invloed had op de functionaliteit en de samenstelling van de 
colon bacteriën. Ook een dagelijkste dosering van 10 µM SN-38 had geen significante impact 
op de microbiële functionaliteit of samenstelling. Aangezien het in vitro model geen gastheer 
compartiment omvat, veronderstellen we dat in vivo, het de verstoring van de 
gastheeromgeving is die zal leiden tot veranderingen in het microbioom. 
In een tweede deel van dit onderzoek, werden de interacties tussen de gastheer, de 
bacteriën en chemotherapie meer in detail bestudeerd. In Hoofdstuk 4 werd het effect van 
5-FU onderzocht in een in vitro co-cultuur model bestaande uit een epitheliale cellaag en een 
biofilm afkomstig van orale bacteriën van verschillende orale regio’s (speeksel, wang- en 
tongswabs) en verschillende donoren (gezonde individuen en patiënten met orale mucositis). 
Onze resultaten toonden aan dat orale bacteriën de wondhelingscapaciteit van de epitheliale 
cellen reduceren en dat hogere bacteriële celaantallen zorgen voor een lagere 
wondhelingscapaciteit in gezonde individuen. Voor patiënten met orale mucositis daarentegen 
zijn niet alleen de celaantallen belangrijk, maar de ook de microbiële samenstelling, aangezien 
pathogene genera in hogere relatieve hoeveelheden aanwezig waren. Verrassend, 5-FU 
vertoonde geen significant effect op wondheling noch op de microbiële samenstelling. Deze 
resultaten benadrukken het belang van orale hygiëne voor een goede wondheling bij gezonde 
individuen, maar wijzen er ook op dat extra maatregelen nodig kunnen zijn bij patiënten met 
mucositis.  
Verder werd een opvolgingsstudie uitgevoerd, waarbij gekeken werd naar de 
samenstelling van de orale bacteriën afkomstig van vijf pediatrische kankerpatiënten om de 
impact van chemotherapie in vivo na te gaan (Hoofdstuk 5). De patiënten werden behandeld 
met chemotherapie voor een hematologische aandoeding en ontwikkelden allemaal orale 
mucositis. Voor alle patiënten werden verschuivingen waargenomen in de orale microbiële 
samenstelling tijdens de therapie, al bleken deze patiënt-specifiek. Mucositis letsels werden 
vooral gedomineerd door streptococci, maar ook door meer pathogene genera zoals 
Aggregatibacter, Enterococcus en Fusobacterium. Chemotherapie en mucositis hadden 
verrassend genoeg slechts een kleine impact op de samenstelling van de orale bacteriën. 
Daarentegen was het gebruik van systemische antibiotica een van de belangrijkste factoren in 
onze studie, aangezien het een grote impact had op zowel de samenstelling als de diversiteit 
van de orale bacteriën. Daarnaast werden ook het staaltype, de periode van staalname, het 
gebruik van antibacteriële mondspoelingen met chloorhexidine, neutropenie en inflammatie 
gelinkt met verschuivingen in de microbiële samenstelling. Minstens 1 maand na de therapie, 
herstelde de microbiële samenstelling zich terug naar de initiële samenstelling, al was de 
diversiteit beduidend lager. Dit duidt opnieuw op het belang van een goede opvolging van de 
patiënt en van een goede orale hygiëne. 
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In dit doctoraatsonderzoek werd aangetoond dat het direct effect van chemotherapie op 
de orale en gastro-intestinale bacteriën beperkt is. Daarentegen zal chemotherapie vooral het 
volledige gastheerweefsel verstoren wat vervolgens aanleiding kan geven tot grote 
verschuivingen in het microbioom. Het beperken van de microbiële belasting kan wondheling 
stimuleren en het risico op infecties verlagen. Bij orale mucositis is hierbij een mechanische 
verwijdering van orale bacteriën aangeraden, aangezien antibacteriële mondspoelingen 
verschuivingen in het microbioom kunnen teweeg brengen en aanleiding kunnen geven tot 
dysbiose. Echter, een langdurige opvolging met eventuele extra maatregelen zijn aan te raden 
om een volledig herstel van zowel de slijmvliezen als de bacteriën te bewerkstelligen na 
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